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introDuction
neuroblastoma
Neuroblastoma (NBL) is an embryonic tumor that arises from neural crest 
derived sympathetic nervous cells. It is the most common extracranial solid 
tumor in childhood, accounting for 6-8% of all pediatric cancers and caus-
ing over 15% of pediatric cancer related deaths1. Both clinical presentation 
and prognosis of children with NBL vary considerably: from spontaneous 
regression in a specifi c subtype 4S with a favorable prognosis, to dissemi-
nated disease with a very poor prognosis. To stratify therapy, patients are 
categorized into low, intermediate and high risk groups2 (Figure 1). Current 
treatment protocols for high risk patients consist of chemotherapy, surgery, 
autologous bone marrow transplantation, radiation therapy, followed by im-
munotherapy and retinoic acid treatment3. Despite initial responsiveness to 
chemotherapy, high risk NBL is associated with a survival of 30-50%4. Most 
of these survivors suffer from long-term side effects from the treatment, 
the most common being impaired renal function, endocrine disturbances 
and deafness5. Therefore, there is a clear and urgent need to improve the 
survival of NBL patients, preferably without increasing toxicity.
figure 1: (adapted from Maris et al, Lancet, 2007) Patients treated between 1986 and 
2001 in Children’s Cancer Group, Pediatric Oncology Group and Children’s Oncology 
Group studies were classifi ed as low-risk, intermediate-risk and high-risk at diagnosis, 
based on clinical and biological features. Kaplan-Meier survival analysis shows marked 
differences in event-free survival for these groups of patients. Data courtesy of W. Lon-
don, Children’s Oncology Group statistical offi ce.
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immunotherapy and nbl
Fundamental and translational studies are essential to increase our knowl-
edge of the pathogenesis of NBL6, 7. This knowledge could eventually lead to 
improved treatment regimens for NBL, as it can provide a strong rational ba-
sis for the selection therapies that can be tested in the limited number of NBL 
patients eligible for clinical trials8. One potential therapy for the treatment of 
cancer in general is immunotherapy, which makes use of the patient’s own 
immune system. Immunotherapy holds the promise of more selective target-
ing of tumor cells over normal cells, thereby having less side-effects than, 
for example, chemotherapy9. In NBL, recent evidence has suggested that 
immunotherapy has the potential to improve the survival of NBL patients in 
a recent phase III clinical trial, showing immunotherapy also holds promise 
to improve the outcome of NBL patients3. In this thesis, we wanted to better 
understand the interactions of the immune system with NBL using a relevant 
NBL mouse model. These novel insights in the immunobiology of NBL could 
lead to improved immunotherapy regimens for NBL patients.
the immune system
The main function of the immune system is to distinguish between harm-
less self and harmful non-self structures and to neutralize the latter ones10. 
Harmful micro-organisms, but also cancer cells, can invade/arise in the host 
virtually everywhere in the body. Therefore, the effector cells and molecules 
of the immune system are widely dispersed and highly motile. The immune 
system can be roughly divided into an innate and an adaptive arm, although 
these arms interact to a large extend. Innate immune cells, like macro-
phages and dendritic cells (DCs), but also ‘non-immune’ cells, like epithelial 
or endothelial cells, are the first cells to recognize potential harmful events. 
These innate immune cells then start to produce factors and cytokines that 
leads to the initiation of an immune response.
Specialized innate immune cells called antigen presenting cells (APCs) 
bridge the innate and adaptive arms of the immune system. DCs are by 
far the most professional APCs in the human body11, 12. DCs are equipped 
with two different major histocompatibility (MHC) molecules, namely MHC 
class I (MHCI) and MHC class II (MHCII). These different MHC molecules 
direct two different groups of T cells, CD8+ and CD4+ T cells, respectively. 
Somatic cells, including cancer cells, can be eliminated by CD8+ cytotoxic T 
lymphocytes (CTLs). Naïve CD8 T cells become CTLs after specific recogni-
tion of an antigen presented in the context of MHCI by a DC, together with 
other activation signals13. These CTLs expand and home to the site of infec-
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tion or tumor, where they induce cell death upon recognition of the same 
MHCI-peptide combination on the cell surface of somatic (malignant) cells. 
As a safeguard mechanism for cells that lack MHCI expression due to viral 
infection or malignant transformation, NK cells survey for MHCI expression 
and induce cell death in somatic cells lacking MHCI molecules on the cell 
surface14.
CD4+ cells or T helper (Th) cells become activated by an APC presenting 
antigen in the context of MHCII13. B cells become activated following recogni-
tion of antigen through the B-cell receptor in combination with CD4+ T cell 
help via CD40 – CD40 ligand interactions15. Upon activation, B cells become 
plasma cells and start to produce large amounts of specifi c antibodies16. 
The produced antibodies then circulate the body and bind to the previously 
recognized antigen on the cell surface of the pathogen or malignant cell. 
Upon binding of the antibody to its target (malignant) cell, specialized innate 
immune cells like NK cells, macrophages and granulocytes can recognize 
the bound antibodies and eliminate the pathogen or malignant cell. These 
phagocytic immune cells express high levels of Fc-receptors that can bind 
the Fc-tail of the antibody. Subsequently, these innate effector cells can ex-
ert antibody dependent cellular cytotoxicity (ADCC) or phagocytosis (ADCP), 
resulting in the elimination of the opsonized target (malignant) cell17.
the immune system and cancer immunotherapy
Tumor cells differ from normal cells in their genetic alterations, which are at 
the same time the main cause of their malignant transformation18. These ge-
netic alterations may result in the expression of so-called tumor associated 
antigens (TAAs) that can be recognized by the immune system as being non-
self19, 20. In patients with tumors where such an immune response occurs, as 
indicated by the presence of tumor infi ltrating lymphocytes, this correlates 
with a favorable prognosis21. In immune compromised individuals, increased 
rates of malignancies are observed22. These observations suggest that the 
immune system plays a role in the protection against cancer development. 
On the other hand, chronic infl ammation is also known to promote tumor 
growth23. These two opposite observations demonstrate the ‘janus-face’ of 
the immune system in tumor development and tumor growth, respectively. 
The potential of a tumor to evoke an anti-tumor immune response is called 
the intrinsic immunogenicity of a tumor and differs among different types 
of malignancies. The classical example of a tumor having an intrinsic high 
immunogenicity is melanoma24. Indeed, recently, immunotherapy using im-
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chapter 1 | General introduction
12
mune stimulatory monoclonal antibodies (mAb) increased the survival of 
stage 4 melanoma patients25, 26.
the immunobiology of nbl
In NBL, early studies reported that lymphocyte infiltrations in resected NBL 
tumors correlated with a favorable prognosis27, 28. This lymphocyte infiltration 
was most abundant in a small number of patients who present with the 
opsoclonus-myoclonus syndrome, a neurological disorder suggested to be 
immunologically mediated29. Children with NBL and this syndrome have a 
favorable oncologic prognosis, suggesting immune involvement30. Tumors 
in these children, however, are generally of low stage and well differenti-
ated histology, which are also favorable prognostic markers. NBL in high-risk 
patients is generally regarded as a low immunogenic tumor31. These NBL 
cells were shown to express low levels of MHCI and lack the expression 
of co-stimulatory molecules, suggesting that T cells cannot recognize and 
eliminate these NBL cells32. Although a number of TAA’s expressed by NBL 
have been identified33, NBL specific T cells were largely absent in these NBL 
tumors. Because of low expression levels of MHCI, however, NBL cells are 
well-recognized and eliminated by NK cells. Also, NK cells are suggested 
to exert anti-NBL effects in patients34-36. A more extensive overview of the 
immunobiology of high-risk NBL is provided in chapter 2.
immunotherapy as treatment for nbl
Only two phase I trials using DC vaccination, to induce T cell mediated im-
munity, have been performed in NBL patients. The results of these trials were 
disappointing thus far37, 38. This could be due to the low expression of MHCI 
on NBL cells or due to a suboptimal DC vaccine, as immature DC instead of 
the more potent mature DC were used in these trials. NBL tumors, however, 
seem to be more effectively treated with tumor directed antibodies3, 17, 39, 40. 
MAb directed to the NBL cell surface antigen disialoganglioside (GD2) were 
developed and showed anti-NBL effects in mouse models41-43. Recently, use 
of the chimeric anti-GD2 mAb ch14.18, in combination with systemic cyto-
kines IL-2 and GM-CSF, increased the survival of high-risk NBL patients by 
20% in a phase III clinical trial3. FcR expressing immune cells, like NK cells, 
granulocytes and recently also myeloid cells, have been implicated as effec-
tor cells in the clinical response following anti-GD2 mAb17, 34, 44 (Figure 2). 
These immune effector cells recognize NBL cells that are opsonized by anti-
GD2 mAb and can subsequently exert ADCC or ADCP, leading to tumor cell 
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death. A more extensive overview of the preclinical and clinical studies using 
immunotherapy in the treatment of NBL is provided in chapter 2.
the immune suppressive tumor microenvironment of nbl 
tumors
NBL tumors were shown to avoid the immune system by downregulating 
MHCI molecules on the cell surface, thereby avoiding T cell recognition32, 45. 
An increasing body of literature indeed suggests that manifest cancers have 
evolved to evade destruction by the immune system18, 23. Tumors evade im-
mune mediated destruction, amongst others, by circumventing immune rec-
ognition and suppressing ongoing immune responses46, 47. One of the major 
mechanisms by which tumor cells suppress the immune system is to attract 
and induce immune suppressive cells in the tumor microenvironment (TME) 
as reviewed in48. To what extend and by which mechanisms NBL tumors 
induce local immune suppression is still largely unknown. Studies performed 
in other tumors have shown, however, that the tumor induced immune sup-
NBL cell
NK cell
Myeloid
cell
Fc-receptor
Anti-GD2
GD2
figure 2: Fc-receptor expressing immune cells like NK cells and myeloid cells recognize 
the mAb that has bound to GD2, which is specifi cally expressed on the cell surface of 
NBL cells. Following recognition these immune cells can exert ADCC, resulting in death 
of the NBL cell.
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pression can hamper the efficacy of immunotherapy to a large extend49, 50. 
Therefore, a better understanding of the potential mechanisms of immune 
suppression in NBL tumors could aid to improve current immunotherapy of 
NBL. The few already known immune evasive and suppressive mechanisms 
of NBL tumors are more extensively discussed in chapter 2.
immunocombination therapy for nbl
In the experiments described in this thesis, we investigated whether com-
binations of so-called tumor targeted therapies with immunotherapy could 
lead to more effective immunotherapy for NBL, by amongst others reducing 
local immune suppression in NBL tumors (chapters 2 + 3). Nowadays, more 
and more genetic aberrations and their functional consequences are known 
for many tumors, also for NBL tumors7. Tumor targeted drugs have been 
developed that can inhibit or reverse these specific genetic aberrations that 
are crucial for the survival of these tumor cells51. By targeting the tumor 
specific defects, these small molecule inhibitors are able to induce specific 
tumor cell death, while leaving normal cells more or less unaffected. A group 
of tumor targeted drugs, called the histone deacetylase (HDAC) inhibitors, 
were shown to highly induce NBL specific cell death and are therefore prom-
ising tumor targeted drugs in the treatment of NBL52-54. Although the effects 
of these drugs on NBL cells are well-studied, their effects on immune cells 
are only starting to become unraveled. Therefore, before combining these 
drugs with immunotherapy in a novel preclinical mouse model of NBL, we 
first reviewed the current literature concerning the effects of HDAC inhibitors 
on immune cells in chapter 3.
aim of the thesis
The aim of this thesis was to develop and understand (more) effective im-
munotherapy for NBL patients using a preclinical mouse model.
In chapter 2, we review the current knowledge on the immunobiology of 
NBL and discuss preclinical and clinical studies using immunotherapy to treat 
NBL. The known mechanisms of immune avoidance and suppression in NBL 
tumors are discussed. The term immunocombination therapy is defined and 
postulated as a hypothesis to improve immunotherapy for high risk NBL 
patients. Finally, we discuss the available mouse models that are suitable to 
study the immunobiology of NBL and test novel immunotherapies.
Michel Kroesen - Binnenwerk V7.indd   14 05-08-15   10:36
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In chapter 3, we review the current knowledge on the effects of HDAC 
inhibitors on tumor cells and immune cells and discuss the role of HDAC in-
hibitors in immunocombination therapy. We concluded that the type of HDAC 
inhibitor used and the timing of HDAC inhibitor administration are emerging 
as critical factors for the effi cacy of HDAC inhibitors in immunocombination 
therapy.
In chapter 4, we report on a novel autologous mouse model of NBL, called 
the transplantable TH-MYCN model, and describe its immunological charac-
teristics. We found the immunobiology of this model to be highly similar to 
the immunobiology of human NBL.
In chapter 5, we expanded the transplantable TH-MYCN model to an or-
thotopic model by injecting 9464D NBL cells in the adrenal gland. We found 
this orthotopic transplantable TH-MYCN model to be a highly relevant and 
stringent model to develop immunotherapy for NBL.
In chapter 6, we investigated the interaction between anti-GD2 mAb and 
the HDAC inhibitor Vorinostat in the transplantable TH-MYCN model of NBL. 
We found a synergistic interaction between these treatment modalities, 
which could be correlated to novel effects of Vorinostat on NBL cells and 
immune cells in vivo.
In chapter 7, the results presented in this thesis are discussed and related 
to the fi ndings of others. Finally, we also provide directions for future re-
search in immunotherapy for the treatment of NBL.
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abstract
Neuroblastoma (NBL) is an aggressive malignancy of the sympathetic ner-
vous system (NS). Advanced stage neuroblastomas prove fatal in around 50 
% of the patients within 5 years1. Therefore, new treatment modalities are 
urgently needed. Immunotherapy is a treatment modality that can be com-
bined with already established forms of treatment. Administration of mono-
clonal antibodies (mAbs) or dendritic cell (DC)-based therapies alone can 
lead to favorable clinical outcomes in individual cancer patients, e.g. patients 
with melanoma, lymphoma and neuroblastoma. However, clinical benefit is 
still limited to a minority of patients and further improvements are clearly 
needed. In this article, we review the most commonly used approaches to 
treat patients with NBL and highlight the prerequisites and opportunities 
of cell-based immunotherapy, involving both innate and adaptive immune 
effector cells. Furthermore, we discuss the potential of the combined applica-
tion of immunotherapy and novel tumor targeted therapies for the treatment 
of cancer in general and NBL in particular.
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neuroblastoma; general information
NBL is the most common extracranial solid tumor in children and the most 
frequently diagnosed solid neoplasm during infancy. Characterized as a 
neuroendocrine malignancy, arising from neural crest cells, NBL can develop 
anywhere in the sympathetic NS. It is most frequently found in the adrenal 
glands and further also in the nerve network throughout thoracic, abdominal 
or pelvic regions2. Although relatively rare, accounting for 6-8 % of all child-
hood cancers, NBL is the cause of 15 % of all pediatric cancer deaths3. It 
has a wide range of both clinical presentation and prognosis, ranging from 
spontaneous regression in a specifi c subtype 4S, to widespread disease with 
poor prognosis in high-risk stage 4 disease. At diagnosis, around 50 % of 
NBL tumors are disseminated to distant organs, predominantly to the bone 
marrow (BM) and bone. To survive in this niche, Ara et al showed that NBL 
cells induce the production of interleukin (IL)-6 by BM stromal cells. This in 
turn leads to the activation of signal transducer and activator of transcription 
3 (STAT-3) in tumor cells thereby enhancing their survival in the BM4. Fur-
thermore, STAT-3 is an important factor in inducing an immune suppressive 
tumor microenvironment (TME)5. The immune suppressive properties of the 
TME will be discussed in more detail further on.
Genomic amplifi cation of the proto-oncogene MYCN is consistently associ-
ated with poor prognosis and occurs in around 20 % of primary NBL tu-
mors6-8. Current treatment protocols for high-risk disease consist of surgery, 
chemotherapy, radiation therapy and autologous hematopoietic stem cell 
transplantation (ASCT) followed by retinoic acid (RA) treatment9. Despite a 
high initial responsiveness to chemotherapy, high risk NBL remains associ-
ated with around only 50 % 5-year survival1. Most of these survivors will 
suffer from long-term side effects from treatment and it is estimated that 
2 out of 3 survivors of this childhood cancer will develop at least 1 chronic 
or life-threatening, treatment related health problem, including secondary 
malignancies10.
The most recent proof that the immune system of these young patients 
is capable of clinically relevant responses comes from studies using mAb 
directed to a tumor specifi c antigen (Ag) disialoganglioside GD211, 12. The 
following sections will discuss current experimental immunotherapeutic 
treatment modalities in NBL.
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immunotherapy of neuroblastoma
t cell mediated therapy
Mutations that alter the function of only a few key genes may contribute to 
malignant transformation of normal cells13. The subsequent genetic instability 
of developing tumor tissue further contributes to the accumulation of addi-
tional genomic changes, and may deregulate the expression of other normal 
cellular components14. Genetic mutations have the potential to create novel 
epitopes for recognition by cells of the adaptive immune system and provide 
targets for targeted therapies using small molecules. Indeed, the discovery 
of (mutated) tumor-associated Ag (TAA) specifically recognized by T cells 
provided proof of concept and opened up the possibility to perform cancer 
immunotherapy by adoptive T cell transfer15. A number of non-mutated TAA 
expressed by NBL cells have also been identified16-18. These are mostly self-
Ag that normally are expressed transiently during fetal development. NBL 
cells have been reported to express low levels of MHC class I molecules, 
limiting their recognition by TAA specific CTL. However, NBL cells were shown 
to upregulate MHC class I molecules upon inflammation, especially exposure 
to interferon–γ produced by activated natural killer (NK) cells in the TME19. 
Cytotoxic T cells specific for the tumor specific protein Survivin have been 
reported in NBL patients, showing potent killing of human NBL cell lines in 
vitro. However, the Ag-specific T cells failed to control and eradicate the 
tumor in vivo, suggesting they were rendered ineffective within the tumor 
microenvironment 20. Interestingly, CTL lines specific for two different pep-
tides from the N-Myc protein were generated and were shown to be capable 
of killing N-Myc over-expressing NBL cells in vitro21, 22. In vitro generated or 
expanded CTLs could be used for adoptive transfer studies as pioneered in 
melanoma and renal cell carcinoma23, 24. Alternatively, a high avidity T cell 
receptor (TCR) alpha and B chain combination could be cloned and rein-
troduced into patients T cells25. This gene therapy approach has recently 
been proven feasible and effective in the treatment of melanoma and other 
malignancies26. For NBL, studies have been reported with chimeric antigen 
receptors (CARs) expressing T cells. CARs combine TCR signaling and func-
tion with the specificity of a mAb. Modified T cells bearing a transgenic CAR 
specific for L1-cell adhesion molecule, a NBL-associated Ag, were generated 
in high numbers and were safely given back to NBL patients27. CTLs bearing 
a CAR specific for GD2, co-expressing the endogenous Epstein-Barr virus-
specific TCR, had long lifetimes in vivo. Moreover, their infusion resulted in 
promising clinical results in half of the patients tested in this small cohort28.
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These clinical and preclinical data collectively suggest that T cells have the 
potential of killing NBL cells in vitro and in vivo. However, clinical benefi t has 
still to be proven in clinical trials and will most likely depend on the homing 
effi ciency and the killing effi cacy of the T cells at the tumor site27.
nK cell mediated therapy
NK cells are innate cytotoxic lymphocytes that play an important role in the 
defense against infection, stress and malignant transformation29. A variety of 
activating and inhibitory receptors are involved in the detection of abnormal 
or stressed cells30. The balance between activating and inhibitory signals 
regulates NK cell activation and the acquisition of cytotoxic effector func-
tions. Inhibitory signals are generated by the binding of major histocompat-
ibility complex (MHC) class I or human leukocyte antigen (HLA) molecules 
to killer-cell immunoglobulin-like receptors (KIR) and to immunoglobulin-like 
transcript in humans, to Ly49 in mice, and to the CD94/NKG2A heterodimer 
in both species31. Activating receptors such as NKp46, NKp30, NKp44 and 
NKG2D, collectively termed natural cytotoxicity receptors, recognize stress-
inducible molecules on the tumor cells. These stress-induced molecules 
include the MHC class-I chain-related protein (MIC) A and B and the UL16-
binding proteins 1-4 in humans and Rae1, H60 and Mult1 in mice. Another 
activating ligand for NK cells is the poliovirus receptor (PVR). The interaction 
of PVR on NBL cells with DNAX accessory molecule-1 (DNAM-1) on NK cells 
was shown to be important for the killing of freshly isolated NBL cells in 
vitro32. In addition, NBL cells are generally characterized by low to absent 
levels of MHC class I33, 34. They have been shown to be good targets cells for 
NK cells both in vitro and in vivo in mouse studies35, 36. In preclinical studies 
using anti-GD2 directed mAb therapy, the anti-tumor effect is at least partly 
dependent on the presence of NK cells37-39. Recent data also provide evidence 
that NK cells are an important anti-tumor effector cell in NBL patients shortly 
after ASCT and during anti-GD2 therapy11, 40. The lack of inhibitory HLA-
ligands for autologous KIR was shown to be an independent prognosis factor 
following ASCT41. The proposed mechanism is that the newly arisen NKcells 
from the graft more readily kill NBL cells in the absence of an inhibitory 
signal. Similarly, patients having a KIR-HLA mismatch uniquely benefi ted 
from the treatment in a phase II trial using the humanized version of the 
anti-GD2 mAb ch14.18 fused to IL-2 (hu14.18-IL2). Patients that did not 
have a KIR-HLA mismatch did not show a signifi cant benefi t of the treatment. 
These observations show that the absence of an inhibitory signal for NK cells 
can be a prognostic factor40. Adoptive transfer of activated NK cells has the 
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potential to further increase the pool of effector cells after ASCT42. These 
studies collectively suggest that NK cells play an important role in the anti-
tumor immune response in NBL patients in the setting following ASCT. The 
recent clinical success of the anti-GD2 mAb therapy in NBL shows the proof 
of principle that boosting this innate response can lead to improved disease 
outcome in this setting12.
mab therapy mediated by immune cells
MAb bind specific molecules on the surface of tumor cells and thereby medi-
ate their destruction43. The resulting tumor cell death can either be a direct 
or an indirect effect of the mAb. Direct effects on tumor cells involve for 
example blocking of receptor signaling or transmission of signals in tumor 
cells that lead to apoptosis44. Indirect effects involve the concerted action 
of various Fc-receptor (FcR) bearing immune cells. These are neutrophils, 
macrophages, NK cells, but also professional antigen presenting cells (APC) 
like dendritic cells (DCs). These innate effector cells can kill opsonized tumor 
cells via the mechanism of antibody-dependent cell-mediated cytotoxicity 
(ADCC) and APC can take up opsonized antigen and present it to T cells43. In 
a trial using the anti-GD2 mAb 3F8 combined with granulocyte macrophage 
colony-stimulating factor (GM-CSF), indirect evidence was provided that NBL 
cells were killed by FcR-bearing innate immune cells11. In line with this, 
important progress in the treatment of NBL has recently been made in a 
phase III trial using the chimeric anti-GD2 mAb ch14.1812. Using a combi-
national approach, a 20 % increase in the 2 year event free survival was 
observed. Following ASCT, RA was given in blocks and alternated with blocks 
of systemic administration of the cytokines IL-2 and GM-CSF and concurrent 
anti-GD2 mAb therapy. This study is a prime example that a combination of 
a tumor-targeted mAb in combination with systemic activation of immune 
cells can have an impact on clinical outcome. The proposed mechanisms 
of the anti-GD2 mAb treatment in this study were complement activation 
and ADCC by NK cells, neutrophils and monocytes. Although this study and 
others have provided evidence that innate immune cells can contribute to an 
anti-NBL immune response, the contribution of the adaptive immune system 
to anti-GD2 mAb therapy in NBL to date is still elusive.
Dendritic cell therapeutic vaccines
The discovery of TAAs also has led to the development of therapeutic vaccines 
for the treatment of cancer45. Multiple vaccine modalities have been applied 
against NBL in mice, including whole tumor cell vaccination, DNA vaccines 
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and DC vaccination46-48. Studies utilizing DCs in active immunotherapy indi-
cate that these cells are particularly effi cient in inducing adaptive immune 
responses against the tumor, with only limited toxicity for the patient49. DCs 
are the professional APCs that sample the environment and express high 
levels of HLA and co-stimulatory molecules (CD40, CD80 and CD86) fol-
lowing their activation/maturation50. These mature DCs are highly effi cient 
in initiating T-cell-mediated immune responses51. They can be loaded with 
tumor lysate, peptides eluded from autologous tumor cells, defi ned TAA, 
mRNA-encoding TAA or whole TAA proteins52. So far two phase I trials using 
DC vaccination in NBL patients have been performed.
Geiger et al.53 performed a phase I study in end-stage solid tumor pediatric 
patients, including NBL patients. DCs generated from patients’ peripheral 
blood monocytes were pulsed with tumor lysate and used for autologous 
vaccination. TAA-specifi c CTLs were shown to be induced after vaccination 
and signifi cant regression of multiple metastatic sites was observed in one 
patient. In a study by Caruso et al, monocyte-derived DCs were generated by 
culturing monocytes with GM-CSF and IL-454. Tumor-derived RNA was pulsed 
onto the DCs and vaccinations were given to 11 end-stage NBL patients 
after standard treatment. No clinical responses were observed, however, and 
only 3 out of 11 patients showed an anti-tumor humoral response. No auto-
immune symptoms were recorded in both trials. A possible explanation as to 
why effective clinical responses were generally lacking in the latter trial, was 
the relatively lower CD4+ to CD8 + population after intensive chemotherapy. 
Alternatively, both studies made use of immature DCs, while recent data 
show that mature DCs, preferably following pattern recognition receptor 
stimulation, are far better stimulators of adaptive immune responses. Indeed, 
recent studies in melanoma show that effective DC migration, induction of 
anti-tumor immune responses, and clinical benefi t are highly dependent on 
DC maturation state55, 56. Therefore, it will be interesting to explore the ef-
fi cacy of mature DC-based vaccines in NBL patients.
Most immunotherapy protocols used so far primarily involve the activation 
of a single arm of the immune system. To reach an optimal immune re-
sponse, however, activation of multiple effector arms of the immune system 
is highly preferable. For example, vaccination against tumor antigens using 
DCs to induce CD4 cells and CD8 T cell responses50, 57 could be combined 
with NK cell activation and antibody administration. DCs have the ability to 
sustain the survival and activation status of NK cells and the same holds true 
vice versa58. In this setting, multiple effector cells, like NK cells, CTLs and 
FcR-bearing innate immune cells could become recruited to the site of the 
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tumor. In the presence of support by T-helper cells producing interferon-γ 
and other inflammatory cytokines, a strong inflammatory environment could 
be created that allows for the eradication of the tumor. Indeed, adoptive 
T-cell transfer or donor lymphocyte infusion therapies were shown to be 
enhanced by concurrent DC vaccination59, 60. Furthermore, it has been re-
ported that apoptotic antibody coated tumor cells were efficiently taken up 
by DCs, which resulted in enhanced adaptive immune responses and higher 
protection from experimental tumor challenge in mice61.
the immunosuppressive tumor microenvironment
Potent multi-effector immune responses are only one prerequisite for effec-
tive immunotherapy, because tumors induce an immune suppressive TME 
that can counteract these responses62, 63. A growing body of evidence shows 
the detrimental effects of the suppressive TME on tumor immunity, of which 
the most important mechanisms are listed below.
Studies have shown that T cells at the site of the tumor may fail to eradicate 
the tumor cells due to the presence of this suppressive TME. The TME con-
tains myeloid derived suppressor cells (MDSC) and regulatory T cells (Treg) 
that specifically inhibit the anti-tumor T cells. Data from Gabrilovich and 
colleagues have demonstrated that the differentiation and function of APCs is 
severely affected in cancer patients. These defects in differentiation of APCs 
are associated with accumulation of immature myeloid cells in tumor-bearing 
animals64, 65. Under normal conditions, these cells represent an intermedi-
ate stage of myeloid cell differentiation. In cancer patients, however, they 
apparently have lost the ability to further differentiate into mature cells like 
granulocytes, DCs, and macrophages66. These MDSC become functionally 
defective and acquire the ability to suppress immune responses67. Although 
MDSC have been documented in many cancer types, their role in NBL is still 
elusive.
Treg are a subset of T cells that can suppress other T cells in an antigen 
specific manner. They express the transcription factor Forkhead box P3 and 
have an essential role in immune homeostasis68. One of the first reports on 
the prognostic significance of the CD8/Treg ratio in tumors was in epithelial 
ovarian cancer69. But infiltration of Treg in the TME is also observed in many 
other tumors and results in the suppression of tumor specific CD8 T-cells70, 71. 
Depletion of Treg results in enhanced anti-tumor immunity following vaccina-
tion in NBL mouse models as well as in other animal models72-74. A clinical 
trial in melanoma patients showed effective depletion of Treg prior to DC 
vaccination using an anti-CD25 mAb75. Unfortunately, the anti-CD25 mAb 
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also inhibited other T cells from acquiring effector functions and no signifi -
cant effect on progression-free survival was observed. It needs to be tested 
if human NBL actively attract Treg, which could result in the suppression of 
CD8 T cells in the TME.
In NBL, several other mechanisms of immune suppression have been re-
ported. The expression of Macrophage inhibitory factor by NBL cells has an 
immunosuppressive effect on tumor infi ltrating T cells in a mouse model of 
NBL76. Glycolipids can be shed into the TME and can have immunosuppressive 
properties on many immune cells77. GD2 is the ganglioside most abundantly 
expressed by virtually all NBL cells. Shedding of GD2 by NBL cells inhibits DC 
maturation in vitro78. It is tempting to speculate that anti-GD2 specifi c mAb 
in vivo mediate their effect partly by blocking this inhibitory effect of GD2 
on DCs or other immune cells. This mechanism could add up to the already 
established effect NK cells have in the anti-GD2 mAb therapies. MICA is a 
MHC I-like surface molecule, which is induced in cells upon viral infection 
or malignant transformation. It acts as an activating ligand for the NKG2D 
receptor on the cell surface of NK cells, which in this way can sense stressed 
or transformed cells. Shed MICA molecules were found in the sera of NBL 
patients, but not in healthy controls79. In another study similar elevated 
levels of soluble MICA were observed in NBL patients. Soluble MICA in sera 
of patients was shown to have an inhibitory effect on NK cells in vitro. This 
was mediated through downregulation of the cognate NKG2D receptor on 
the cell surface of the NK cells80. Another interesting way of NBL immune 
evasion might be the interaction of NBL cells with tumor stromal cells, since 
the stromal cells derived from patients’ tumors were shown to inhibit NK cell 
functioning in vitro81.
In summary, NBL and other tumors have many ways to induce immune 
suppression. Therefore more detailed insight in the mechanisms underlying 
tumor induced immune suppression is needed. This knowledge would pos-
sibly allow for the development of targeted therapeutic interventions that 
can relief the immune suppression.
immunocombination therapy
Immunocombination therapy: deﬁ nition
Robust anti-tumor immune responses alone are often ineffective at control-
ling tumor growth due to the suppressive TME. Future immunotherapeutic 
strategies therefore might need to be combinations of treatment modalities 
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that complement each other in order to reach two specific goals. This is 
the concept of immunocombination therapy, which we herein define as a 
specific combination of immuno- and tumor targeted therapies. Applied in 
the right timing and in the right dosage, this combination has to achieve two 
complementary goals: (a) an optimal activation of innate and additive im-
munity and (b) the elimination of tumor cells and their immune suppressive 
microenvironment. When these goals are both met, the anti-tumor immune 
effectors generated can exert their function in a more immune permissive 
TME (Fig 1).
potential candidates for immunocombination therapy and 
experimental examples
A potential candidate to combine with immunotherapy in NBL might be the 
histone deacetylase inhibitors (HDACi). Histone deacetylases are epigenetic 
regulators that catalyze the removal of acetyl moieties from histones and 
non-histone proteins. Aberrant histone deacetylation often correlates with 
pathological gene repression and neoplastic transformation82. Over the re-
cent years, HDACi have become an emerging group of anti-cancer drugs 
that preferentially target tumor cells over normal cells83. NBL cells have 
been shown to be highly sensitive to HDAC inhibition, resulting in tumor cell 
apoptosis or differentiation84, 85. Besides induction of tumor cell death, HDACi 
can also sensitize malignant cells to other extracellular signals of cell death. 
E.g., NBL cells were shown to become sensitized to TRAIL-induced apoptosis 
following HDAC inhibition86. In Hodgkin lymphoma, HDAC inhibition results 
in direct tumor cell death, but also in lowered cytokine production of the 
present Reed-Sternberg cells87. These data indicate that HDACi can (1) di-
rectly kill NBL cells by activating apoptosis pathways or lead to tumor cell 
differentiation, (2) sensitize NBL cells to TRAIL mediated apoptosis and (3) 
result in immune favorable cytokine secretion by tumor cells. Collectively, 
these data imply that HDACi can contribute to sensitization of tumor cells 
to immunotherapy and the reversal of tumor induced immune suppression. 
In support of this hypothesis, HDAC inhibition in combination with adoptive 
CTL transfer resulted in synergistic anti-tumor effects in a mouse melanoma 
model88. A potential drawback of the use of HDACi in immunocombination 
therapy is their described suppressive effect on cytokine secretion by im-
mune cells89. Using short pulses of HDACi might circumvent this negative 
effect. In conclusion, further studies are needed to establish the precise role 
and application of HDACi in immunocombination therapy.
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figure 1: The concept of immunocombination therapy. The combined action of immu-
notherapy and tumor targeted therapy has to achieve two goals as stated below. Tumor 
directed mAbs may contribute to these goals by (a.) direct killing of tumor cells, (b.) 
immune cell mediated killing of tumor cells and activation of innate immune cells (c.) 
targeted delivery of anti-cancer compounds. Tumor targeted therapy such as small mol-
ecules and chemotherapy may contribute to these goals by (d.) direct killing of tumor 
cells, possibly resulting in immunogenic cell death (e.) sensitizing tumor cells to immune 
cell mediated cell death (f.) targeted elimination or reversal of immune suppressive 
cells, for example tumor stromal cells (TSC). Immunotherapy can induce robust T-cell 
(g.) and natural killer (NK) cell (h.) responses towards NBL cells. Dendritic cells (DC) 
play a central role in the induction of these responses. Immunomodulatory mAbs may 
contribute to immuno-combination therapy by (i.) boosting immune responses leading 
to increased T-cell and NK cell responses and (j.) the reversal of the immune suppres-
sive phenotype of tumor infi ltrating macrophages (TAM).
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Genetic analyses have resulted in specific targeted anti-cancer therapies, 
one of the first examples being inhibitors targeting the BCR-ABL transloca-
tion in chronic myelogenous leukemia90. Because these therapies specifically 
target the cells that bear the genetic defect, normal cells, including immune 
cells, might not be affected by them. In addition, the selective killing of 
tumor cells will likely result in reduction in the suppressive nature of the 
TME. Small molecule drugs in some instances can also specifically target 
immunosuppressive cells in the tumor. An illustrative example of this is the 
tyrosine kinase inhibitor Sorafenib, which is used in the treatment of renal 
cell carcinoma. It targets tyrosine kinase signaling in tumor cells, causing 
selective apoptosis of tumor cells over normal cells. Strikingly, Sorafenib 
treatment also resulted in lower number of intratumoral Treg and an increase 
of the CD8:CD4 ratio in the tumor91. This example illustrates that one treat-
ment modality simultaneously can target both tumor cells and have a benefi-
cial or reversing effect on immune suppression in the TME. Specific genetic 
defects in NBL, like MYCN amplification, have been found to render NBL cells 
dependent on the activity of genes like MDM2 or CDK2. The protein products 
of these genes can be targeted via the small molecule drugs Nutlin-3a and 
Roscovitine, respectively92-94. It might be interesting to explore the effects 
of the combination of these tumor targeted therapies with immunotherapy 
in NBL.
Tumor Ag specific mAbs can also act as vehicles in tumor targeted therapy, 
inducing direct killing of tumor cells. As an example, mAbs specific for the 
epidermal growth factor receptor (EFGR) inhibit its signaling resulting in tu-
mor cell apoptosis in for example colorectal cancer or kidney cancer44. MAbs 
can also act as targeted therapy by delivering other anti-cancer compounds 
specifically to the tumor site. These compounds can include cytokines, radio-
active isotopes or chemotherapeutics95-97. In NBL, the anti-GD2 mAb 14.g2a, 
which is the mouse version of ch14.18, was shown to induce direct NBL 
cell death in vitro98. However the main contribution of NBL cell death by 
anti-GD2 mAb seems to be the indirect killing via CDC and ADCC99, 100. As 
an example of delivering cytokines to the TME in NBL a humanized version 
of the anti-GD2 mAb ch14.18 fused to IL-2 (hu14.18-IL2) was engineered. 
This mAb was shown to have potent effects in mouse models and is now in 
clinical trials96, 101. Brignole et al. target liposomes to GD2 in a NBL xenograft 
tumor model. They engineered liposomes coated with Fab’ fragment of the 
anti-GD2 mAb 14.g2a. These liposomes contained c-myb antisense nucleo-
tides bearing CpG motifs102. Only the GD2 targeted liposomes containing the 
(immuno)combination therapy resulted in long-term survival of the mice. 
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In contrast, c-myb antisense nucleotide or CpG motifs alone did not result 
in long-term survival of the NBL tumor challenge. The authors argued that 
the CpG mediated immune stimulation had enhanced the specifi c antisense 
activity of the c-myb nucleotides. However, it is tempting to speculate that 
antisense oligonucleotide therapy might have resulted in the elimination of 
tumor cells and their suppressive mechanisms and that this allowed for the 
CpG motif induced immune effector cells to exert their anti-tumor effects.
Another group of biologicals with potential use in immuno-combination 
treatment for NBL are the immunomodulatory mAbs. These mAbs specifi cally 
target modulator receptors of the immune system such as co-stimulatory 
molecules (OX40, 4-1BB) or inhibitory receptors (CTLA-4, PD1, PD-L1). 
They can enhance active vaccination strategies and have been shown to 
improve anti-tumor immunity in combination regimens in several preclinical 
models103-105. An interesting immunomodulatory target is the CD40 pathway. 
Using CD40 agonists in combination with chemotherapy, Beatty et al found 
that CD40-activated macrophages in mice and humans rapidly infi ltrated tu-
mors. The macrophages became tumoricidal and facilitated the depletion of 
tumor stroma, which was independent from therapy-induced T-cells106. This 
combination therapy resulted in reversal of immune suppression by targeting 
tumor-infi ltrating myeloid cells involved in cancer progression. Of note, NBL 
cells have been reported to express low levels of CD40, triggering of which 
may result in tumor cell apoptosis in vitro107. These observations add up to 
the versatile effects of CD40-CD40L interaction, which was originally identi-
fi ed as a major switch in the induction of adaptive immune responses by 
providing help in the priming of CD8 T-cells towards tumoricidal CTLs108-110.
Chemotherapy is well-known for its general immunosuppressive effects111. 
However, studies performed by Zitvogel et al have shown that tumor cell death 
induced by certain chemotherapeutic agents can be highly immunogenic and 
result in Ag-specifi c immune responses112. Tumor cell death induced by the 
anthracyclin doxorubicin results in enhanced uptake of dying tumor cells by 
DCs and elicits strong anti-tumor immune responses in mice113, 114. Using a 
different mechanism, platinum-based chemotherapeutics result in enhanced 
T-cell priming by DCs and abrogate T-cell inhibition by tumor cells. This 
immunostimulatory effect is mediated by downregulation of the programmed 
death receptor ligand-2 on DCs and tumor cells, respectively115. These stud-
ies suggest that exploiting both the cytotoxic and the immunostimulatory 
effects of certain chemotherapeutics in immuno-combination therapy has 
a rational basis. In NBL, chemotherapy is used in high doses in the induc-
tion phase of the treatment before ASCT. The addition of immunotherapy 
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in this phase of the treatment potentially might result in higher efficacy of 
the treatment compared to chemotherapy alone. In an illustrative study, 
Buhtoiarov et al combined anti-CD40 and CPG-ODN immunotherapy with 
vincristine, doxorubicin and cyclophosphamide in preclinical models of NBL 
and melanoma. This combination treatment of immuno- and chemotherapy 
had a synergistic anti-tumor effect116. In the melanoma mouse model they 
recorded the repolarization of tumor resident macrophages from an immune 
suppressive to an immune stimulatory phenotype. This study, as well as 
the one from Beatty et al106, illustrates that immuno-combination therapy 
can lead to the reversal of immune suppression through repolarization of 
suppressive cells in the TME.
Development of immunocombination therapy
To find optimal complementary effects of immunotherapy with targeted anti-
tumor therapies, well defined preclinical models that recapitulate the human 
disease are needed. One reason to use these models is that synergistic 
therapeutic effects often depend on the timing and dosage of the different 
treatment modalities. For example, in a mouse melanoma model, the timing 
between tumor cell destruction via cryo-ablation and immune stimulation via 
cytosine-phosphate-guanosine (CpG) is essential to prevent relapse of the 
tumors117. Another important reason is that in order to translate effective 
immunocombination therapy to the clinic, the involved mechanisms must be 
well understood. Knowing these mechanisms allows for the development of 
strategies to induce similar synergistic effects in patients.
Many immunotherapeutic studies with respect to NBL models have been 
performed in the murine C1300 model, which arose spontaneously on the 
mice with A/J background118, 119. However, this murine model does not seem 
to recapitulate the human disease with respect to genetic aberrations and 
expression of GD2. The GD2 positive cell line NXS2, obtained by fusion of 
C1300 tumor cells with primary GD2+ ganglion cells from C57BL/6 mice, 
is not fully autologous in both A/J and C57BL/6 mice and can therefore be 
highly immunogenic120. Importantly, many of the immunological tools -the 
MHC tetramers, knock-out mice- to dissect and monitor immune responses 
are not available on the A/J background (Table 1).
More recently, a new, so-called TH-MYCN transgenic mouse model was 
developed. In this model, expression of the human MYCN coding sequence 
is driven by the rat tyrosine hydroxylase (TH) promoter. Neural crest lineage 
cells in these mice over-express N-Myc specifically. After a latent period of 1-4 
months homozygous transgenic mice spontaneously develop NBL tumors121. 
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This murine TH-MYCN model is highly similar to high-risk MYCN amplifi ed hu-
man NBL with respect to histology and molecular aberrations122-124. E.g., the 
microRNA (miRNA) miR-380-5p was shown to repress p53 expression and 
is highly expressed in NBL tumors. High expression is correlated with poor 
prognosis in MYCN amplifi ed NBL tumors. Interestingly, targeting this miRNA 
using a miR-380-5p antagonist in the TH-MYCN model leads to reduced 
tumor growth125. In conclusion, the TH-MYCN model seems to recapitulate 
human NBL in many aspects.
Some drawbacks of the TH-MYCN model are the relatively slow rate of 
tumor formation and variability in tumor penetrance on different genetic 
backgrounds. To overcome these drawbacks, cell lines have been derived 
from spontaneous tumors in these transgenic mice. These cell lines have 
been shown to exhibit the same characteristics as the original tumors, in-
cluding MYCN amplifi cation126. So far, only few immunotherapeutic studies 
have been performed using these cell lines in immunocompetent C57Bl/6 
mice116. Therefore, scant information about the immunobiology of the TH-
MYCN model is available. We and others are currently exploiting this NBL 
model to study novel immunocombination therapies for NBL.
future perspective
The treatment for high-risk NBL patients has reached maximal tolerable 
limits. Current cytotoxic therapies can lead to minimal residual disease, but 
table 1. Comparison of mouse models for immunotherapy in NBL
characteristics
c1300 derived
(a/J)
nXs2
(a/J)
th-mycn derived
(c57bl/6)
genetic aberrations 
similar to human
Unknown Unknown Yes [123, 126]
fully autologous model Yes No [120] Yes
immunological tools 
available on genetic 
background
Limited Limited Excellent
expression gD2 No Yes [120] Yes*
possibility to test in 
spontaneous model
No No Yes [121]
Table 1: Comparison of available mouse models to study novel immunotherapy for NBL. 
*Expression of GD2 on TH-MYCN derived cell lines personal observation MK & GA.
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relapses are common. Future therapies will therefore need to be designed 
and tested in preclinical models and in clinical trials. These therapies should 
aim at also killing the persistent tumor cells. Immunotherapy and targeted 
therapies, combined in immunocombination therapy, might result in better 
outcomes. The ultimate goal of immunocombination therapy is the complete 
eradication of all transformed cells.
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abstract
Epigenetic modifications, like histone acetylation, are essential for regulating 
gene expression within cells. Cancer cells acquire pathological epigenetic 
modifications resulting in gene expression patterns that facilitate and sustain 
tumorigenesis. Epigenetic manipulation therefore is emerging as a novel 
targeted therapy for cancer. Histone Acetylases and Histone Deacetylases 
regulate histone acetylation and hence gene expression. Histone deacetylase 
(HDAC) inhibitors are well known to affect cancer cell viability and biology 
and are already in use for the treatment of cancer patients. Immunotherapy 
can lead to clinical benefit in selected cancer patients, especially in patients 
with limited disease after tumor debulking. HDAC inhibitors can potentially 
synergize with immunotherapy by elimination of tumor cells. The direct ef-
fects of HDAC inhibitors on immune cell function, however, remain largely 
unexplored. Initial data have suggested HDAC inhibitors to be predominantly 
immunosuppressive, but more recent reports have challenged this view. In 
this review we will discuss the effects of HDAC inhibitors on tumor cells and 
different immune cell subsets, synergistic interactions and possible mecha-
nisms. Finally, we will address future challenges and potential application of 
HDAC inhibitors in immunocombination therapy of cancer.
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introDuction
Recent reports have demonstrated synergistic effects of HDAC inhibitors 
with cancer immunotherapy. Whereas the direct cytotoxic effects of HDAC 
inhibitors on cancer cells are well known, the effects of HDAC inhibitors on 
the immune system are less well understood. Here, we review the effects of 
HDAC inhibitors on immune cell function in relation to anti-tumor immunity. 
Furthermore, we discuss the mechanisms of HDAC inhibitors in combination 
with immunotherapy in the treatment of patients with cancer and provide 
future directions for research.
Only a few gene mutations may lead to the change of a healthy normal cell 
into a malignant cancer cell. The genetic instability of a developing tumor 
leads to further accumulation of genomic mutations/alterations but also to 
changes in the epigenetic code, the epigenome1. The epigenome regulates 
the heritable patterns of gene expression without changing the sequence of 
the genome2. In cancer, alterations to the epigenome may lead to gene ex-
pression profi les that support tumorigenesis and thereby play an important 
role in cancer initiation and progression3-6. Epigenetic changes can occur 
at multiple levels including direct modifi cations of the DNA itself as well as 
modifi cations of the DNA associated histone proteins7. Histone proteins can 
be chemically modifi ed by acetylation, methylation, phosphorylation, and 
ubiquitination8. Hyperacetylation of histone proteins results in increased 
transcriptional activity, whilst histone hypoacetylation is associated with 
repression of gene transcription9. Hypoacetylation of histones was shown to 
occur specifi cally in a variety of human cancer cell lines as well as in primary 
lymphoma and colon carcinoma tissue samples10.
Immunotherapy is a promising novel cancer therapy for multiple cancer 
types, including melanoma and neuroblastoma11, 12. Immunotherapy can lead 
to clinical benefi t and active anti-tumor immune responses have been ob-
served in selected patients13. However, in most patients, the clinical response 
is still limited or even absent following immunotherapy14. Accumulating evi-
dence indicates that tumors evade immune responses by down regulation of 
MHC molecules and tumor antigens or active suppression of anti-tumor im-
mune responses at the site of the tumor by creating an immune suppressive 
tumor microenvironment (TME)15-18. Therefore, immunotherapy should best 
be combined with other therapies in so-called immunocombination therapy 
to overcome these tumor induced immune escape mechanisms19.
One potential type of therapies that could be combined with immunother-
apy are therapies that target the epigenetic code. Epigenetic alterations are 
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dynamic and generally reversible and for this reason epigenetic manipula-
tion has emerged as an attractive novel treatment for cancer20. Small mol-
ecule inhibitors were identified that target the enzymes responsible for the 
deacetylation of histones, the histone deacetylases (HDACs). These so-called 
HDAC inhibitors, are now regarded as a group of anti-cancer drugs with high 
clinical potential9, 21, 22. Inhibition of HDACs leads to genomic effects through 
accumulation of acetylated histone proteins, resulting in altered gene tran-
scription23. Specifically in cancer cells, the altered gene transcription leads 
to, amongst others, the activation of and/or sensitization to intrinsic and 
extrinsic apoptosis pathways24, 25. Besides blocking the function of HDACs 
leading to genomic effects, HDAC inhibitors also modulate the function of 
many other proteins resulting in non-genomic effects. For example, p53 
becomes hyper acetylated upon HDAC inhibitor treatment, resulting in tumor 
cell apoptosis26, 27. Interestingly, tumor cells appear much more sensitive to 
the induction of apoptosis by HDAC inhibitors than normal cells, although 
the responsible mechanisms are still not fully understood. Besides changes 
in gene transcription other possible mechanisms for the tumor specificity of 
HDAC inhibitors have been suggested, e.g. induction of double-strand DNA 
breaks28. Other reports link the selective sensitivity of cancer cells to HDAC 
inhibitors relative to normal cells to the disturbed chromatin structure in 
cancer cells29.
The classical HDAC inhibitors inhibit the function of one or more of the 11 
known zinc-containing HDAC enzymes. The zinc-containing HDAC enzymes 
can be classified into several Classes: Class I HDAC (HDAC 1,2,3,8), Class 
IIA (HDAC 4,5,7,9) and Class IIB (HDAC 6,10). Class III HDACs or Sirtuins, 
have a different catalytic mechanism and are not a target for the classical 
HDAC inhibitors. The most recently discovered HDAC11 is the only Class IV 
HDAC9. PanHDAC inhibitors inhibit HDACs from Class I, II and IV, while Class 
specific HDAC inhibitors only inhibit HDACs from either Class I or Class II. 
More recently, HDAC inhibitors preferentially targeting a single HDAC have 
been developed30, 31. Because each individual HDAC inhibitor has a unique 
chemical structure and HDAC inhibitory profile, different HDAC inhibitors can 
cause a large variety of biological effects in cancer cells and in normal cells32, 
33.
Although the effects of HDAC inhibitors on tumor cells have been studied 
extensively, the exact role of HDAC inhibitors on immune cells and in anti-
tumor immunity is just emerging. HDAC inhibitors were previously reported 
to exhibit strong anti-inflammatory effects34-36. Rapamycin, however, previ-
ously viewed as a pure immune suppressant drug, was more recently also 
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shown to mediate strong immune stimulating effects as reviewed in37, 38. 
Similarly, a recent study showed that the Class I HDAC inhibitor Entinostat 
markedly enhanced anti-tumor vaccination39. In this review we will discuss 
the effects of classical pan-, Class I and Class II HDAC inhibitors on tumor 
cells and immune cells in relation to immunotherapy. Furthermore, we will 
discuss the potential of combining HDAC inhibitors with immunotherapy as 
immunocombination therapy for cancer.
effects of hDac inhibitors on tumor cells; 
immunological conseQuences
HDAC inhibitors can induce tumor cell death in a specifi c manner through 
various mechanisms and with different half maximum inhibitory concentra-
tions (IC50s) as reviewed elsewhere9, 22, 40. However, HDAC inhibitors also 
have profound effects on the remaining viable tumor cells. Here we will 
discuss the effects of HDAC inhibitors on the cell biology of these surviving 
tumor cells with a focus on the immunological consequences.
effects of hDac inhibitors on tumor cell recognition by t cells 
and nK cells
Tumor cell recognition and elimination by tumor specifi c T cells is, amongst 
others, dependent on the expression levels of both tumor associated anti-
gens (TAAs) and MHC class I (MHCI) molecules by the tumor cells. HDAC 
inhibitors can increase TAA expression by tumor cells. The Class I HDAC 
inhibitor Depsipeptide enhanced the expression of the tumor antigen gp100 
in murine melanoma cells41. Combination treatment of Depsipeptide and 
adoptive transfer of gp100-specifi c cytotoxic T cells resulted in increased 
tumor killing by transferred tumor specifi c CD8 T cells. However, sometimes 
TAA-expression is downregulated after HDAC inhibitor treatment. The panH-
DAC inhibitor Valproic acid (VPA) downregulated the expression of the tumor 
antigen Muc1. Remarkably, it upregulated another tumor antigen NY-ESO-1 
in mesothelioma cells in vitro42.
Other reports have shown that HDAC inhibitors upregulate genes involved 
in the antigen presentation machinery or co-stimulatory molecule expression 
by tumor cells43, 44. The panHDAC inhibitor Trichostatin A (TSA) up-regulated 
MHCI surface expression in a murine cervical cell line with an impaired anti-
gen-processing machinery45. TSA pre-treatment of these tumor cells resulted 
in more effective lysis of these tumor cells by CD8 T cells in vitro. Similarly, 
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TSA was able to increase or induce expression of TAP-1, TAP-2, LMP-2, and 
Tapasin in TAP-expressing and TAP–deficient murine tumor cell lines46. TSA 
treatment of mice bearing TAP-deficient tumors delayed tumor growth due to 
enhanced tumor cell killing by adaptive immune effector cells. More recently, 
the panHDAC inhibitor Panobinostat was shown not only to enhance the 
expression of several TAAs, MHCI and MHCII, but also the expression of 
co-stimulatory molecules in several human and a murine melanoma cell lines 
in vitro47. In addition, effective therapy of B16F10 melanoma bearing mice 
using Panobinostat was dependent on the presence of the adaptive immune 
system. In another study, TSA induced MHC class II expression in murine 
plasmacytoma cells through activation of the pIII-CIITA promoter, result-
ing in enhanced proliferation of CD4 T cells in vitro48. In summary, HDAC 
inhibitors can modulate TAA expression and many components of the tumor 
antigen processing and MHC presentation pathway in surviving tumor cells, 
overall resulting in enhanced tumor cell recognition and killing by tumor 
specific T cells (Table 1).
Natural killer (NK) cells are innate immune cells that exert important 
anti-tumor effector functions in cancer immunotherapy49. The outcome of an 
interaction between a tumor cell and a NK cell is balanced by the expression 
of activating and inhibitory ligands by the tumor cell. Several stress-induced 
activating ligands, like MHC class I-related chain A (MICA) and B molecules 
(MICB), and UL16-binding proteins (ULBPs), expressed by tumor cells are 
recognized by the activating NKG2D receptor on NK cells50. HDAC inhibitors 
were shown to increase the expression of activating ligands for this NK cell 
receptor by tumor cells. The Class I HDAC inhibitor VPA induced the ex-
pression of MICA, MICB and ULBPs in human hepatocellular carcinoma cells 
resulting in enhanced recognition and killing by NK cells in vitro51. Impor-
tantly, in non-malignant primary human hepatocytes, VPA treatment did not 
induce the expression of these NKG2D ligands. Although the mechanisms for 
the tumor specific induction of NKG2D ligands remained unclear, this study 
confirms the selective effect of this panHDAC inhibitor on the expression of 
NK cell activating ligands by malignant cells. Lopez-Soto et al. showed that 
TSA increased the expression of ULBPs in epithelial tumor cells by releasing 
HDAC3 mediated repression on ULBP promotors52. Similar effects have been 
reported for other panHDAC inhibitors when added to osteosarcoma, leuke-
mia and Ewing sarcoma cell lines in vitro and to primary myeloid leukemia 
cells ex vivo53-56. These studies collectively show that panHDAC inhibitors can 
increase the expression of activating NKG2D ligands resulting in enhanced 
tumor cell recognition and elimination by NK cells.
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table 1 : Overview of the observed effects of HDAC inhibitors on tumor cells and im-
mune cells
hDac inhibitor 
(class) observations references
tumor cells
Depsipeptide (Class I)
Valproic Acid 
(panHDAC)
Trichostatin A 
(panHDAC)
LAQ824 (panHDAC)
Panobinostat 
(panHDAC)
TAA↑ MHCI↑ MHCII↑
Co-stimulatory molecules↑
Recognition by T cells↑
[41-43, 45-48, 126]
Valproic Acid 
(panHDAC)
Trichostatin A 
(panHDAC)
Expression NKG2D ligands↑
Recognition by NK cells↑
[51-56]
Vorinostat (panHDAC) Immunogenic cell death↑ [60, 61, 63]
effector lymphocytes
CD4 T cells Trichostatin A 
(panHDAC)
N-butyrate(panHDAC)
Scriptaid (panHDAC)
Vorinostat (panHDAC)
Romidepsin (Class I)
Viability↓
Proliferation↓
Pro-infl ammatory cytokines↓
[39, 91-93, 98, 99, 
126]
Vorinostat (panHDAC) Viability= [94]
Activated
CD4 T cells
Vorinostat (panHDAC) Viability=
Cytotoxicity=
[99]
CD8 T cells Panobinostat 
(panHDAC)
Trichostatin A 
(panHDAC)
Pro-infl ammatory cytokines↑
Cytotoxicity↑
Memory function↑
[39, 100, 101, 126]
NK cells Valproic Acid 
(panHDAC)
Proliferation↓
Cytotoxicity↓
[104]
Entinostat (Class I) Cytotoxicity↑ [105]
Activated
NK cells
Vorinostat (panHDAC) Cytotoxicity = [99]
apc / cytokine production
Macrophages 
/DC
Trichostatin A 
(panHDAC)
Vorinostat (panHDAC)
LAQ824 (panHDAC)
Panobinostat 
(panHDAC)
Valproic Acid 
(panHDAC)
Entinostat (Class I)
Co-stimulatory molecules↓
Pro-infl ammatory cytokines↓
APC function↓
[68, 69, 76, 78-83, 
85]
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HDAC inhibitors, however, do not always increase tumor cell recognition by 
immune cells. Fiegler et al. showed that the panHDAC inhibitor Vorinostat 
and other panHDAC inhibitors down regulated the B7 family member B7-H6, 
a ligand for the activating NKp30 receptor on NK cells, in multiple human 
cancer cell lines, both at the mRNA and protein level57. The decreased sur-
face expression of B7-H6 resulted in decreased degranulation of primary 
NK cells in an NKp30 dependent manner. Thus, HDAC inhibitors can also 
mediate the downregulation of activating ligands for NK cells by tumor cells. 
Furthermore, HDAC inhibitor induced increased MHCI expression, leading to 
increased tumor cell recognition by T cells, at the same time will negatively 
affect NK cell recognition. Besides lymphocytic NK and T cells, macrophages 
and other myeloid cells are also able to recognize and kill tumor cells di-
table 1 : Overview of the observed effects of HDAC inhibitors on tumor cells and im-
mune cells (continued)
hDac inhibitor 
(class) observations references
Cytokines / 
inflammation
Vorinostat (panHDAC)
Givinostat (panHDAC)
Pro-inflammatory cytokine 
production↓
Inflammation ↓
[34, 35, 74, 76, 77, 
84]
Macrophages
Tumor cells
Vorinostat (panHDAC)
Trichostatin A 
(panHDAC)
Valproic Acid 
(panHDAC)
Tumorigenic sol. factors / 
cytokines↓
[86, 87]
regulatory immune cells
Treg Trichostatin A 
(panHDAC)
Vorinostat (panHDAC)
Valproic Acid 
(panHDAC)
Tubacin (Class II)
Entinostat (Class I)
Cell numbers↑ FoxP3 
expression↑
Immune suppressive 
capacity↑
[107-113, 116, 
117]
Entinostat (Class I) Numbers =/↓ FoxP3 
expression↓
Immune suppressive 
capacity↓
[39, 118]
Bone marrow 
cells
Trichostatin A 
(panHDAC)
Vorinostat (panHDAC)
Differentiation↓ MDSC↑
Macrophages/DC ↓
[120]
MDSC Valproic Acid 
(panHDAC)
Differentiation↑ MDSC↓ 
Macrophages/DC↑
[121]
TAM Trichostatin A 
(panHDAC)
Valproic Acid 
(panHDAC)
MHCII expression↑ [123, 124]
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rectly58. However, the effects of HDAC inhibitors on tumor cell recognition by 
myeloid cells have not been reported to date. We conclude that, in general, 
HDAC inhibitors lead to enhanced recognition and elimination of tumor cells 
by effector lymphocytes, but this effect may vary between tumor types and 
HDAC inhibitors used.
hDac inhibitors and immunogenic cell death
Selected chemotherapeutics can induce so-called “immunogenic cell death”, 
a process in which dying tumor cells can stimulate cellular uptake, activation 
and cross-presentation by antigen presenting cells (APCs), thereby inducing 
antitumor T cell responses59. Christiansen et al. showed that MC38 colon car-
cinoma cells, treated with the panHDAC inhibitor Vorinostat, were effi ciently 
taken up by dendritic cells (DCs) in vitro60. In addition, in other studies, 
Vorinostat stimulated the release of important mediators of immunogenic 
cell death, like HMGB1 and ATP, as well as the expression of cell surface Cal-
reticulin, an important ‘eat-me’ signal, by dying tumor cells61, 62. However, the 
precise role of immunogenic cell death upon Vorinostat therapy in vivo was 
not investigated in these studies. AK7 pancreatic carcinoma cells, pretreated 
with Vorinostat or other cytotoxic drugs, have also been used together with 
the adjuvant BCG as a vaccine. Only the vaccine consisting of the Vorinostat 
treated tumor cells was able to inhibit tumor growth upon tumor challenge 
and resulted in increased CD8 T cell infi ltration in this experimental set-
ting63. These studies imply that Vorinostat, like a subset of chemotherapeutic 
compounds, induces a form of cell death with immunogenic properties. It 
remains to be determined whether other panHDAC or Class specifi c HDAC 
inhibitors also induce immunogenic cell death. Furthermore, it will be inter-
esting to compare the potency of Vorinostat and other HDAC inhibitors to 
induce immunogenic cell death with that of chemotherapeutic agents previ-
ously demonstrated to induce immunogenic cell death64.
effect of hDac inhibitors on immune cells
So far, we discussed the effects of HDAC inhibitors on tumor cell biology and 
the immunological consequences. In the next paragraphs we will review the 
effects of HDAC inhibitors on immune cell viability and function and address 
the mechanisms and critical factors of successful combinations of HDAC 
inhibitors and immunotherapy in vivo. Immune cells can have both pro- and 
anti-tumor effects, depending on cell lineage and environmental cues. For 
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example, in a recent study by West et al, successful treatment of MC38 colon 
carcinoma tumors using the panHDAC inhibitors Vorinostat and Panobinostat 
was fully dependent on the presence of an intact immune system61.
effect of hDac inhibitors on antigen presenting cells and 
cytokine production
In order to generate effective and long-lasting immune responses, activation 
of both the innate and adaptive arms of the immune system is required. 
APCs, like monocytes, macrophages and DCs are the first innate immune 
cells to sense danger signals coming from foreign or damaged self65. Upon 
encounter of these signals, APCs become activated and start to recruit and 
activate other immune cells and thereby initiate antigen specific immunity66. 
DCs are professional APCs and are therefore especially capable of induc-
ing adaptive immunity. Besides signal 1 coming from specific recognition 
of antigens presented in MHCI and MHCII molecules, co-stimulatory and 
cytokine signals (signals 2 and 3, respectively) are required to initiate and 
direct adaptive immune responses67.
HDAC inhibitors were repeatedly shown to down regulate both co-stimula-
tory and cytokine signals coming from APCs. The panHDAC inhibitors Vori-
nostat and TSA profoundly down-regulated genes involved in co-stimulation 
and the production of cytokines in murine bone marrow derived macrophages 
(BMDM) and dendritic cells (BMDC)68, 69. Upon treatment with TSA, surface 
expression of CD40, CD80, CD86 and CCR7 as well as the production of 
pro-inflammatory cytokines IL-6, IL-12 and TNF-α was down regulated in 
BMDC69. In contrast, TSA and the panHDAC inhibitor Panobinostat increased 
IL-12 production in peritoneal elicitated macrophages, which was associ-
ated with a downregulation of the anti-inflammatory cytokine IL-1070. One 
explanation for these different findings could be that the timing of HDAC in-
hibitor exposure differed between these studies: in the first studies the APCs 
were exposed to the HDAC inhibitor one hour before the immune stimulus, 
whereas in the latter study the HDAC inhibitor and the immune stimulus were 
administered together. These observations suggest that the pre-activation 
of these APCs leads to differential effects upon HDAC inhibitor treatment. 
Also, in contrast to the panHDAC inhibitor TSA, the Class I specific HDAC 
inhibitor Entinostat did not down regulate IL-12 mRNA in BMDM, suggesting 
Entinostat may prevent the reduced production of IL-12 in these APCs71. In 
addition, HDAC6 was required for the production of IL-10 in murine APCs, 
suggesting panHDAC and Class II HDAC inhibitors may downregulate IL-10 
production by APCs72.
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Support for a role of individual HDACs in the initiation of infl ammatory cy-
tokine production by APCs comes from studies using HDAC3-/- murine BMDM. 
These cells were shown to be incapable of a pro-infl ammatory gene response 
when stimulated with LPS73. The lack of expression of pro-infl ammatory 
genes could be largely explained by a lack of IFN-β expression in the HDAC3-
/- macrophages. This was most probably due to the constitutive over expres-
sion of Cox-1 in these macrophages, which interfered with pro-infl ammatory 
signaling cascades. In addition, other studies have reported on panHDAC 
inhibitor mediated downregulation of systemic infl ammation by reducing 
pro-infl ammatory cytokine production in mice34, 35, 74-77. Similar suppressive 
effects of HDAC inhibitors on pro-infl ammatory cytokine production were 
also reported for human macrophages and DCs76, 78-81. In human monocyte 
derived DCs, the reduced cytokine production upon HDAC inhibitor exposure 
was suggested to be mediated through decreased NF-kB and type I interferon 
signaling as suggested by the reduced nuclear translocation of NF-kB RelB, 
IRF-3 and IRF-882. Similarly, upon exposure to Panobinostat, RelB was down-
regulated in a dose-dependent manner in human monocyte derived DCs83. 
Cytokine production by immune cells was also reduced upon administration 
of the panHDAC inhibitor Givinostat to healthy human subjects84. Givinostat 
treatment reduced the pro-infl ammatory cytokine production by endotoxin 
stimulated PBMC, four hours after Givinostat administration ex vivo. Twelve 
hours after Givinostat administration, however, cytokine production by the 
PBMC had already returned to baseline levels, suggesting a transient re-
duction in cytokine production. This observation was in agreement with the 
half-life of Givinostat of around 6 hours as determined in the same study. 
This transient reduction of pro-infl ammatory cytokine production following 
Givinostat treatment, could imply that the timing of HDAC inhibitor treat-
ment may be crucial when combining HDAC inhibitors with immunotherapy 
(Figure 1). In this respect, short pulses of Givinostat might circumvent 
prolonged immune suppression in immunocombination therapy regimens. 
Overall, these data suggest that HDAC inhibitors suppress macrophage and 
DC functions in terms of reduced expression of co-stimulatory molecules and 
reduced production of pro-infl ammatory cytokines.
The effect of HDAC inhibitors on the (cross-)presentation of antigens by 
APCs has not been studied extensively. TSA reduced the capacity of murine 
BMDC to induce T cell proliferation in mixed-lymphocyte-reactions, but the 
contribution of antigen (cross-)presentation was not investigated85.
Besides down-regulating pro-infl ammatory cytokines, HDAC inhibitors can 
also reduce the production of pro-tumorigenic soluble factors or cytokines. 
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Vorinostat reduced the production of the tumorigenic factors Nitric Oxide 
(NO) and M-CSF & MMP-9 by murine peritoneal macrophages and primary 
mammary tumor cells, respectively86. Administration of Vorinostat delayed 
tumor onset in a spontaneous mammary tumor model, which was associated 
with reduced numbers of tumor infiltrating macrophages. Similarly, several 
panHDAC inhibitors reduced the production of the tumorigenic cytokine Mac-
rophage migration inhibitory factor in several human cancer cell lines as well 
as in mouse blood87. These studies suggest that the production of tumori-
genic cytokines or other soluble factors by myeloid cells and tumor cells are 
also reduced upon panHDAC inhibitor treatment. The net outcome of HDAC 
inhibitor treatment on anti-tumor immune responses will likely be a delicate 
balance in the production of pro- and anti-inflammatory cytokines and other 
soluble factors in the blood, lymphoid organs and, more importantly, locally 
in the tumor.
effect of hDac inhibitors on effector lymphocytes
CD4 T cells are essential in the induction of adaptive anti-tumor immunity 
by maintaining and skewing immune responses88-90. HDAC inhibitors were 
reported to have inhibitory effects on CD4 T cell viability and function. The 
panHDAC inhibitor TSA inhibited PMA/Ionomycin induced NF-kB nuclear 
translocation in murine CD4 T cells after 8 hours and impaired their viability 
after 20 hours in vitro91. TSA also potently decreased the antigen specific 
proliferation of murine CD4 T cells, which was associated with upregulation 
of the cyclin-dependent kinase inhibitor 1 p21Cip192, 93. In human CD4 T cells, 
Vorinostat had limited to no effect on viability and the expression of genes 
involved in proliferation, differentiation, and apoptosis after a 24 hour expo-
sure period94. These opposite observations may be species related or due to 
intrinsic differences between the panHDAC inhibitors used in these studies. 
Indeed, the panHDAC inhibitor TSA has a higher inhibitory potency for most 
of the individual HDACs compared to Vorinostat, which could explain the 
more pronounced effects of TSA in the murine CD4 T cells95-97. In patients 
treated with the Class I HDAC inhibitor Romidepsin, the percentages of CD4 
and CD8 T cells in patient’s blood were decreased by around 50%98. In a 
study by Schmudde et al, Vorinostat affected the proliferation and function 
of naïve human PBMC and T cells, but not of IL-2 pre-activated PBMC or 
previously primed T cells99. These studies suggest that pan- and Class I 
HDAC inhibitors reduce the viability and function of naive CD4 T cells, thus 
hampering the induction of anti-tumor T cell responses. The inhibitory effect 
of HDAC inhibitors, however, seems less severe or absent following activa-
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tion of these CD4+ lymphocytes. Therefore, the timing of HDAC inhibitor 
administration in combination with immunotherapy could critically determine 
the outcome of immunocombination therapy, combining HDAC inhibitors with 
immunotherapy (Figure 1).
For effective anti-tumor immunity the function of cytotoxic CD8 T cells is 
of crucial importance13. Several studies suggest HDAC inhibitors enhance 
the function of this CD8+ T cell subset. Treatment of mice with the panH-
DAC inhibitor Panobinostat resulted in increased serum levels of IFN-γ and 
TNF-α and an accelerated graft-versus-host disease, which was associated 
figure 1: Emerging factors for effective HDAC inhibitor immunocombination therapy. 
Timing of HDAC inhibitor administration and the type of HDAC inhibitor used, determine 
the effect on the various types of immune cells and their interactions. Therefore, these 
are emerging factors determining the outcome of combinations of HDAC inhibitors with 
immunotherapy in the treatment of cancer.
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with higher numbers of CD8 T cells in the affected organs100. Strikingly, 
in murine CD8 T cells, the panHDAC inhibitor TSA mimicked the effect of 
the pro-inflammatory cytokines IL-12 and IFN-α at the level of gene ex-
pression101. TSA up-regulated genes involved in CD8 T cell activation and 
memory similar to those induced by these pro-inflammatory cytokines. This 
finding suggests that part of the immune inhibitory effect of HDAC inhibitors 
on pro-inflammatory cytokine production by APC may be compensated by 
the direct induction of a set of genes in these effector lymphocytes. Murine 
memory CD8 T cells were capable of producing IFN-γ only when CD4 T cell 
help was present during priming102. Interestingly, only in these CD8 T cell 
memory cells, the IFN-γ locus was hyper acetylated, allowing for the rapid 
production of IFN-γ. More recently, the function of exhausted CD8 T cells 
in chronic viral infection was shown to be restored upon treatment with 
panHDAC inhibitors103. The effect of Class II HDAC inhibitors on CD4 and CD8 
T cells have not been reported to date. These studies collectively suggest 
that panHDAC inhibitors have the ability to stimulate CD8 T cell activation 
and function.
Although HDAC inhibitor treated tumor cells are more efficiently recog-
nized by effector NK cells, not much is known regarding the effects of HDAC 
inhibitors on NK cell function itself. Ogbomo et al. first showed that the Class 
I HDAC inhibitor VPA and the panHDAC inhibitor Vorinostat inhibited the 
proliferation and cytotoxic capacity of human NK cells, treated with IL-2 and 
the HDAC inhibitor simultaneously104. The NK cells down regulated the ex-
pression of activating receptors on the cell surface upon Vorinostat exposure. 
In another study, upon exposure to similar concentrations of Vorinostat, NK 
cells were still able to degranulate upon co-culture with tumor cells99. The 
NK cells from the latter study, however, had received the activating cytokine 
three days prior to the addition of the HDAC inhibitor and were thus pre-
activated. These studies imply that IL-2 pre-activated NK cells retain their 
functionality whereas NK cells receiving IL-2 simultaneous with the HDAC 
inhibitor show reduced functionality. In a more recent study, the Class I 
HDAC inhibitor Entinostat increased the expression of the activating receptor 
NKG2D in IL-2 and IL-21 activated as well as in freshly isolated human NK 
cells. Entinostat also increased the expression of NKG2D ligands on human 
tumor cell lines, but not on normal cells, in this study105. Furthermore, Enti-
nostat treated NK cells showed increased cytotoxicity upon co-culture with 
tumor cells and the combination of Entinostat treatment and adoptive NK 
cell transfer resulted in synergistic inhibition of tumor growth in vivo. Thus, 
the Class I HDAC inhibitor Entinostat increased activating ligand expression 
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by tumor cells as well as NK cell cytotoxicity. The effects of Class II HDAC 
inhibitors on NK cells have not been reported to date. These studies suggest 
that panHDAC inhibitors have distinct effects on NK cells, at least partially 
depending on their activation status, whereas Class I HDAC inhibition seems 
to enhance NK cell function.
In conclusion, HDAC inhibitors can either inhibit or promote effector lym-
phocyte function depending on the cell type, activation status and the type 
of HDAC inhibitor used.
effect of hDac inhibitors on regulatory immune cells
After induction of effective immunity through activation of both innate and 
adaptive arms of the immune system, feedback loops are in place to control 
the ongoing infl ammation. Specialized immune cells like CD4+ regulatory 
T cells (Treg) and specifi c subsets of regulatory myeloid cells can actively 
dampen immune responses. Tumors actively recruit Treg, myeloid derived 
suppressor cells (MDSC) and tumor associated macrophages (TAM)106. These 
immune cells all contribute to an immune suppressive tumor microenviron-
ment (TME), abrogating anti-tumor immune responses.
Several panHDAC inhibitors were shown to promote the expansion and 
function of CD4+ Treg in multiple mouse studies, often after prolonged daily 
administrations of panHDAC inhibitors107-111. HDAC 6 and HDAC9, both Class 
II HDAC enzymes, were shown to be expressed by murine CD4+FoxP3+ 
Treg and acted as inhibitors of the suppressive function of these regulatory 
immune cells107, 112, 113. HDAC9-/- mice showed increased numbers of Treg with 
increased suppressive capacity112. In line with these observations, exposure 
to Class II HDAC inhibitors was repeatedly shown to directly enhance the 
suppressive function of murine Treg113-115. These studies demonstrate that 
Class II HDAC enzymes are important regulators of Treg function and that 
Class II HDAC inhibition results in increased Treg functionality. The effect 
of Class I HDAC inhibition on Treg proliferation and function is less clear. 
The Class I HDAC inhibitor Entinostat enhanced Treg numbers and FoxP3 
expression by Treg116, 117. In another study, however, the numbers of Treg 
were equal and FoxP3 expression by the Treg was down-regulated following 
Entinostat treatment, leading to improved anti-tumor vaccination in vivo118. 
In addition, Bridle et al. showed both reduced Treg numbers as well as re-
duced FoxP3 expression in Treg upon Entinostat treatment39. These studies 
collectively indicate that pan- and Class II HDAC inhibitors enhance Treg 
numbers and function, whereas Class I HDAC inhibitors show more complex 
effects on Treg, including decreased numbers and function, that need to be 
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studied in more detail. In this respect, Class I HDAC or panHDAC inhibitors 
might be more suited to combine with immunotherapy than Class II HDAC 
inhibitors (Figure 1).
MDSC are immature myeloid cells that can actively suppress T cell re-
sponses and contribute to an immune suppressive TME106, 119. Murine bone 
marrow precursor cells cultured for 7 days in the presence of GM-CSF & 
TSA or GM-CSF alone, revealed striking differences in myeloid cell differen-
tiation. The presence of the panHDAC inhibitor TSA throughout this culture 
period resulted in the accumulation of a pool of undifferentiated myeloid 
cells. These cells were CD11b(+)Ly6C(+)F4/80(int)CD115(+) and showed 
immune suppressive properties in vitro, thus mimicking MDSC120. Treatment 
of naïve mice with GM-CSF and TSA resulted in a similar accumulation of 
CD11b(+)Gr1(+) cells in the spleens of these mice, showing immune sup-
pressive activity ex vivo. Youn et al. showed that the Class I HDAC inhibitor 
VPA could differentiate tumor induced MDSC into macrophages and DC fol-
lowing in vitro culture121. These MDSC were isolated from the BM of tumor 
bearing mice and cultured with GM-CSF and tumor conditioned medium in 
the presence or absence of VPA. Thus, panHDAC inhibition affects myeloid 
cell differentiation from precursors towards MDSC, whereas Class I inhibi-
tion directs MDSC to more differentiated macrophages and DC. In the latter 
study, the Rb1 gene was shown to regulate the differentiation from MDSC 
to macrophages and DC. Rb1 expression in turn was regulated by HDAC2, 
showing a role for HDAC2 in MDSC differentiation. The effects of Class II 
specific HDAC inhibitors on MDSC have not been reported.
TAM expressing low levels of MHCII also accumulate in tumors and are 
associated with tumor progression122. Similarly to MDSCs, TAM have been 
reported to be sensitive to the Class I HDAC inhibitor VPA and the panHDAC 
inhibitor TSA, resulting in restoration of MHC class II expression, reversal of 
immune suppression and delayed tumor growth123, 124. The effects of Class II 
specific HDAC inhibitors on TAM have not been reported.
Overall, the available data suggest that the effect of HDAC inhibitors on 
regulatory immune cells differ between the immune cell type studied, the 
differentiation status and the HDAC inhibitor used. The precise effects of 
HDAC inhibitors on myeloid cells in cancer, like MDSC and TAM, deserve 
further exploration.
hDac inhibitors in immunocombination therapy in vivo
HDAC inhibitors can impact the immune cascade by influencing different 
cell types in various life-cycle stages including activation, differentiation, 
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and proliferation. The complex interactions of immune cells in this cascade 
makes the infl uence of HDAC inhibitors on the overall outcome of an im-
mune response diffi cult to predict. In the tumor setting, the growing tumor 
infl uences the various immune cells locally and systemically, which further 
increases the complexity. Thus, the effect of HDAC inhibitor treatment com-
bined with immunotherapy should be investigated by the use of autologous 
and immunocompetent preclinical models.
As can be concluded from previous sections, HDAC inhibitors can have 
immune suppressive as well as immune stimulating effects in vitro. There 
are not many studies reporting on detrimental effects of HDAC inhibitors in 
combination with cancer immunotherapy in vivo. HDAC inhibitors, however, 
have been used to limit cytokine production and immune damage in autoim-
mune diseases, for example in rheumatoid arthritis78, 125. The few studies 
that have reported synergistic effects of treatments combining HDAC inhibi-
tors and immunotherapy in the treatment of cancer, will be discussed here.
The panHDAC inhibitors Vorinostat or Panobinostat showed a synergistic 
effect in combination with the immune cell stimulating antibodies anti-CD40 
and anti-CD137 in immunocompetent models of mammary, renal and colon 
carcinoma60. This synergistic inhibition of tumor growth was highly depen-
dent on CD8 T cells. Vo et al. demonstrated that the panHDAC inhibitor 
LAQ824 potentiated both adoptive transfers of tumor specifi c T cells as 
well as a prime/boost vaccination scheme in mice bearing B16 melanoma 
tumors126. The authors showed that the adoptively transferred T cells were 
more abundant in the tumor when LAQ824 was co-administered. Similar 
to what has been reported in vitro99, naïve T cells were more sensitive to 
LAQ824 mediated cell death in vivo, suggesting a survival advantage of the 
transferred CD8 T cells. In addition, upon LAQ824 treatment, the tumor cells 
expressed higher levels of the tumor antigen gp100 and MHCI presenting 
molecules, implying enhanced recognition by the tumor specifi c T cells. The 
adoptively transferred T cells in LAQ824 treated mice produced higher levels 
of IFN-γ upon re-stimulation ex vivo, indicating also direct enhancement 
of CD8 T cell function by this HDAC inhibitor. In addition to the panHDAC 
inhibitor LAQ824, also the Class I inhibitor Entinostat showed synergistic 
anti-tumor effects when combined with IL-2 in mice bearing established 
RENCA tumors127. This synergistic effect was also dependent on the pres-
ence of CD8 T cells. More recently, Bridle et al showed that administration 
of Entinostat enhanced tumor specifi c T cell function only when Entinostat 
was given at the time of the booster vaccination, but not at the prime vac-
cination39. Surprisingly, the tumor specifi c CD8 T cell expansion was not 
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enhanced directly by Entinostat in this study. Instead, Entinostat enhanced 
functionality of the tumor specific CD8 T cells by creating a prolonged state 
of lymphopenia following vaccination. The selective elimination of unwanted 
precursor lymphocytes from the BM resulted in tumor specific CD8 cytotoxic 
lymphocytes exhibiting enhanced functionality. This study elegantly shows 
that the timing of HDAC inhibitor treatment is essential for the combination 
with immunotherapy in order to boost anti-tumor immune responses. Taken 
together, these studies indicate that carefully designed regimens of HDAC 
inhibitor treatment and immunotherapy have the potential to be synergistic 
in the treatment of cancer. The underlying mechanisms of these successful 
immunocombination therapies are, however, complex and diverse and may 
include direct tumor cell killing, reprogramming of the tumor microenviron-
ment as well as different effects on innate and adaptive immune cells like 
depletion of bystander lymphocytes and activation of effector lymphocytes.
conclusions anD future Directions
Although HDAC inhibitors have negative/detrimental effects on immune cell 
viability and function, increasing evidence also supports a rationale to com-
bine HDAC inhibitors with immunotherapy to obtain synergistic anti-tumor 
effects. HDAC inhibitors induce tumor cell specific apoptosis already result-
ing in tumor debulking. Selective elimination of tumor cells also reduces the 
tumor induced immune suppression and makes the tumor more accessible 
for immune cells. In addition, HDAC inhibitors can increase tumor cell rec-
ognition by NK and T cells. More recently, it was shown that HDAC inhibitors 
can have both stimulatory as well as detrimental effects on immune cell 
viability and function, depending on cell type and activation status. Timing 
is therefore emerging as a crucial factor in obtaining synergistic effects with 
immunotherapy (Figure 1). For example, based on present data, the admin-
istration of HDAC inhibitors should take place following immune activation/
CD8 T cell priming, as activated lymphocytes seem less affected and CD8 T 
cells become more activated by HDAC inhibitors. Besides timing, the Class of 
the HDAC inhibitor is very important. Inhibition or downregulation of Class 
II HDACs enhanced Treg numbers and function, whereas the Class I HDAC 
inhibitor Entinostat enhanced NK cell and CD8 T cell functions. Finally, due 
to the vast complexity of molecular and cellular events, rational combination 
therapies of immunotherapy with HDAC inhibitors should be designed and 
tested using autologous and immunocompetent preclinical models, to eluci-
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date the complex underlying mechanisms. Understanding the mechanisms 
of such synergistic combinations will be instrumental to effi ciently translate 
these fi ndings into effective immunocombination therapies for cancer pa-
tients.
Michel Kroesen - Binnenwerk V7.indd   67 05-08-15   10:36
chapter 3 | HDAC inhibitors and immunotherapy
68
references
 1. You JS and Jones PA. Cancer genetics and epigenetics: two sides of the same 
coin? Cancer Cell. 2012; 22(1):9-20.
 2. Iglesias-Bartolome R, Callejas-Valera JL and Gutkind JS. Control of the epithelial 
stem cell epigenome: the shaping of epithelial stem cell identity. Curr Opin Cell 
Biol. 2013; 25(2):162-169.
 3. Xu Z, Bolick SC, DeRoo LA, Weinberg CR, Sandler DP and Taylor JA. Epigenome-
wide association study of breast cancer using prospectively collected sister 
study samples. J Natl Cancer Inst. 2013; 105(10):694-700.
 4. Cicek MS, Koestler DC, Fridley BL, Kalli KR, Armasu SM, Larson MC, Wang C, 
Winham SJ, Vierkant RA, Rider DN, Block MS, Klotzle B, Konecny G, Winterhoff 
BJ, Hamidi H, Shridhar V, et al. Epigenome-wide ovarian cancer analysis iden-
tifies a methylation profile differentiating clear-cell histology with epigenetic 
silencing of the HERG K+ channel. Hum Mol Genet. 2013; 22(15):3038-3047.
 5. Akhtar-Zaidi B, Cowper-Sal-lari R, Corradin O, Saiakhova A, Bartels CF, Bala-
subramanian D, Myeroff L, Lutterbaugh J, Jarrar A, Kalady MF, Willis J, Moore 
JH, Tesar PJ, Laframboise T, Markowitz S, Lupien M, et al. Epigenomic enhancer 
profiling defines a signature of colon cancer. Science. 2012; 336(6082):736-
739.
 6. Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, Garraway 
LA, Beltran H, Rubin MA and Elemento O. Epigenomic alterations in localized and 
advanced prostate cancer. Neoplasia. 2013; 15(4):373-383.
 7. Baylin SB and Jones PA. A decade of exploring the cancer epigenome - biological 
and translational implications. Nat Rev Cancer. 2011; 11(10):726-734.
 8. Campbell MJ and Turner BM. Altered histone modifications in cancer. Adv Exp 
Med Biol. 2013; 754:81-107.
 9. Witt O, Deubzer HE, Milde T and Oehme I. HDAC family: What are the cancer 
relevant targets? Cancer Lett. 2009; 277(1):8-21.
 10. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bon-
aldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez 
JA, Cano A, Calasanz MJ, et al. Loss of acetylation at Lys16 and trimethylation at 
Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005; 
37(4):391-400.
 11. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, 
Klasen IS, Hilbrands LB, Figdor CG, de Vries IJ and Adema GJ. Dendritic cell 
vaccination in combination with anti-CD25 monoclonal antibody treatment: 
a phase I/II study in metastatic melanoma patients. Clin Cancer Res. 2010; 
16(20):5067-5078.
 12. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith 
M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger 
R, Reynolds CP, Buxton A, Reisfeld RA, et al. Anti-GD2 antibody with GM-
CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010; 
363(14):1324-1334.
 13. de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen 
MJ, Ruiter DJ, Figdor CG, Punt CJ and Adema GJ. Immunomonitoring tumor-
Michel Kroesen - Binnenwerk V7.indd   68 05-08-15   10:36
69
HDAC inhibitors and immunotherapy | chapter 3
3
specifi c T cells in delayed-type hypersensitivity skin biopsies after dendritic cell 
vaccination correlates with clinical outcome. J Clin Oncol. 2005; 23(24):5779-
5787.
 14. Aarntzen EH, Bol K, Schreibelt G, Jacobs JF, Lesterhuis WJ, Van Rossum MM, 
Adema GJ, Figdor CG, Punt CJ and De Vries IJ. Skin-test infi ltrating lymphocytes 
early predict clinical outcome of dendritic cell-based vaccination in metastatic 
melanoma. Cancer Res. 2012; 72(23):6102-6110.
 15. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 
2011; 144(5):646-674.
 16. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan 
G, Vyas P, Cavenagh J, Stankovic T, Moss P and Craddock C. Induction of a CD8+ 
T-cell response to the MAGE cancer testis antigen by combined treatment with 
azacitidine and sodium valproate in patients with acute myeloid leukemia and 
myelodysplasia. Blood. 2010; 116(11):1908-1918.
 17. Ramachandran IR, Martner A, Pisklakova A, Condamine T, Chase T, Vogl T, Roth 
J, Gabrilovich D and Nefedova Y. Myeloid-derived suppressor cells regulate 
growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol. 
2013; 190(7):3815-3823.
 18. Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG, Hebeda K, 
Falkenburg JH, Schaap N, de Witte TM, van der Voort R and Dolstra H. PD-1/
PD-L1 interactions contribute to functional T-cell impairment in patients who 
relapse with cancer after allogeneic stem cell transplantation. Cancer Res. 2011; 
71(15):5111-5122.
 19. Kroesen M, Lindau D, Hoogerbrugge P and Adema GJ. Immunocombination 
therapy for high-risk neuroblastoma. Immunotherapy. 2012; 4(2):163-174.
 20. Lawlor ER and Thiele CJ. Epigenetic changes in pediatric solid tumors: promising 
new targets. Clin Cancer Res. 2012; 18(10):2768-2779.
 21. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R 
and Pavletich NP. Structures of a histone deacetylase homologue bound to the 
TSA and SAHA inhibitors. Nature. 1999; 401(6749):188-193.
 22. Khan O and La Thangue NB. HDAC inhibitors in cancer biology: emerging 
mechanisms and clinical applications. Immunol Cell Biol. 2012; 90(1):85-94.
 23. Hahn CK, Ross KN, Warrington IM, Mazitschek R, Kanegai CM, Wright RD, 
Kung AL, Golub TR and Stegmaier K. Expression-based screening identifi es the 
combination of histone deacetylase inhibitors and retinoids for neuroblastoma 
differentiation. Proc Natl Acad Sci U S A. 2008; 105(28):9751-9756.
 24. Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth 
GK and Johnstone RW. HDAC inhibitors induce tumor-cell-selective pro-apoptotic 
transcriptional responses. Cell Death Dis. 2013; 4:e519.
 25. Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez 
Saiz F, Gronda M, Eberhard Y, MacLean N, Ketela T, Reed JC, Moffat J, Minden 
MD, Batey RA, et al. Selective inhibition of histone deacetylases sensitizes ma-
lignant cells to death receptor ligands. Mol Cancer Ther. 2010; 9(1):246-256.
 26. Condorelli F, Gnemmi I, Vallario A, Genazzani AA and Canonico PL. Inhibitors of 
histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br 
J Pharmacol. 2008; 153(4):657-668.
Michel Kroesen - Binnenwerk V7.indd   69 05-08-15   10:36
chapter 3 | HDAC inhibitors and immunotherapy
70
 27. Terui T, Murakami K, Takimoto R, Takahashi M, Takada K, Murakami T, Minami 
S, Matsunaga T, Takayama T, Kato J and Niitsu Y. Induction of PIG3 and NOXA 
through acetylation of p53 at 320 and 373 lysine residues as a mechanism 
for apoptotic cell death by histone deacetylase inhibitors. Cancer Res. 2003; 
63(24):8948-8954.
 28. Lee JH, Choy ML, Ngo L, Foster SS and Marks PA. Histone deacetylase inhibitor 
induces DNA damage, which normal but not transformed cells can repair. Proc 
Natl Acad Sci U S A. 2010; 107(33):14639-14644.
 29. Nalabothula N and Carrier F. Cancer cells’ epigenetic composition and pre-
disposition to histone deacetylase inhibitor sensitization. Epigenomics. 2011; 
3(2):145-155.
 30. Krennhrubec K, Marshall BL, Hedglin M, Verdin E and Ulrich SM. Design and 
evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors. Bioorg 
Med Chem Lett. 2007; 17(10):2874-2878.
 31. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider 
A, Westermann F, Ulrich SM, von Deimling A, Fischer M and Witt O. Histone 
deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009; 15(1):91-
99.
 32. Lauffer BE, Mintzer R, Fong R, Mukund S, Tam C, Zilberleyb I, Flicke B, Ritscher 
A, Fedorowicz G, Vallero R, Ortwine DF, Gunzner J, Modrusan Z, Neumann L, 
Koth CM, Lupardus PJ, et al. Histone deacetylase (HDAC) inhibitor kinetic rate 
constants correlate with cellular histone acetylation but not transcription and 
cell viability. J Biol Chem. 2013; 288(37):26926-26943.
 33. Chang J, Varghese DS, Gillam MC, Peyton M, Modi B, Schiltz RL, Girard L and 
Martinez ED. Differential response of cancer cells to HDAC inhibitors trichostatin 
A and depsipeptide. Br J Cancer. 2012; 106(1):116-125.
 34. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, 
Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, 
Reznikov LL, et al. The antitumor histone deacetylase inhibitor suberoylanilide 
hydroxamic acid exhibits antiinflammatory properties via suppression of cyto-
kines. Proc Natl Acad Sci U S A. 2002; 99(5):2995-3000.
 35. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, 
Pozzi P, Reznikov LL, Siegmund B, Fantuzzi G, Dinarello CA and Mascagni P. The 
histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory 
cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005; 11(1-
12):1-15.
 36. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright 
KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E and Sotomayor EM. The histone 
deacetylase HDAC11 regulates the expression of interleukin 10 and immune 
tolerance. Nat Immunol. 2009; 10(1):92-100.
 37. Bravo-San Pedro JM and Senovilla L. Immunostimulatory activity of lifespan-
extending agents. Aging (Albany NY). 2013; 5(11):793-801.
 38. Blagosklonny MV. Immunosuppressants in cancer prevention and therapy. On-
coimmunology. 2013; 2(12):e26961.
 39. Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, 
Bramson JL, Bell JC, Lichty BD and Wan Y. HDAC inhibition suppresses primary 
Michel Kroesen - Binnenwerk V7.indd   70 05-08-15   10:36
71
HDAC inhibitors and immunotherapy | chapter 3
3
immune responses, enhances secondary immune responses, and abrogates 
autoimmunity during tumor immunotherapy. Mol Ther. 2013; 21(4):887-894.
 40. Dickinson M, Johnstone RW and Prince HM. Histone deacetylase inhibitors: po-
tential targets responsible for their anti-cancer effect. Invest New Drugs. 2010; 
28 Suppl 1:S3-20.
 41. Murakami T, Sato A, Chun NA, Hara M, Naito Y, Kobayashi Y, Kano Y, Ohtsuki 
M, Furukawa Y and Kobayashi E. Transcriptional modulation using HDACi dep-
sipeptide promotes immune cell-mediated tumor destruction of murine B16 
melanoma. J Invest Dermatol. 2008; 128(6):1506-1516.
 42. Roulois D, Blanquart C, Panterne C, Gueugnon F, Gregoire M and Fonteneau JF. 
Downregulation of MUC1 expression and its recognition by CD8(+) T cells on 
the surface of malignant pleural mesothelioma cells treated with HDACi. Eur J 
Immunol. 2012; 42(3):783-789.
 43. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser 
N, Santaniello F and Tomasi TB. Activation of MHC class I, II, and CD40 gene 
expression by histone deacetylase inhibitors. J Immunol. 2000; 165(12):7017-
7024.
 44. Khan AN, Gregorie CJ and Tomasi TB. Histone deacetylase inhibitors induce TAP, 
LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. 
Cancer Immunol Immunother. 2008; 57(5):647-654.
 45. Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, Simova 
J, Jandlova T, Bubenik J and Reinis M. Induction of MHC class I molecule cell 
surface expression and epigenetic activation of antigen-processing machinery 
components in a murine model for human papilloma virus 16-associated tu-
mours. Immunology. 2008; 123(2):218-227.
 46. Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, Choi KB and 
Jefferies WA. Epigenetic enhancement of antigen processing and presentation 
promotes immune recognition of tumors. Cancer Res. 2008; 68(23):9601-9607.
 47. Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja 
P, Seto E, Weber J, Sotomayor EM and Villagra A. The antimelanoma activity of 
the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct 
tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013.
 48. Chou SD, Khan AN, Magner WJ and Tomasi TB. Histone acetylation regulates 
the cell type specifi c CIITA promoters, MHC class II expression and antigen 
presentation in tumor cells. Int Immunol. 2005; 17(11):1483-1494.
 49. Tarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, 
Modak S, Heller G, Dupont B, Cheung NK and Hsu KC. Unlicensed NK cells tar-
get neuroblastoma following anti-GD2 antibody treatment. J Clin Invest. 2012; 
122(9):3260-3270.
 50. Vivier E, Tomasello E, Baratin M, Walzer T and Ugolini S. Functions of natural 
killer cells. Nat Immunol. 2008; 9(5):503-510.
 51. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst 
J, Smirnow I, Wagner A, Steinle A and Salih HR. Natural killer cell-mediated 
lysis of hepatoma cells via specifi c induction of NKG2D ligands by the histone 
deacetylase inhibitor sodium valproate. Cancer Res. 2005; 65(14):6321-6329.
Michel Kroesen - Binnenwerk V7.indd   71 05-08-15   10:36
chapter 3 | HDAC inhibitors and immunotherapy
72
 52. Lopez-Soto A, Folgueras AR, Seto E and Gonzalez S. HDAC3 represses the ex-
pression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications 
for the immunosurveillance of cancer. Oncogene. 2009; 28(25):2370-2382.
 53. Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, 
Yamada N, Hata M, Nishioka T, Fukunaga S, Futani H, Okamura H and Terada 
N. Sodium valproate, a histone deacetylase inhibitor, augments the expression 
of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms 
to enhance susceptibility of human osteosarcoma cells to NK cell-mediated 
cytotoxicity. Oncol Rep. 2010; 24(6):1621-1627.
 54. Kato N, Tanaka J, Sugita J, Toubai T, Miura Y, Ibata M, Syono Y, Ota S, Kondo T, 
Asaka M and Imamura M. Regulation of the expression of MHC class I-related 
chain A, B (MICA, MICB) via chromatin remodeling and its impact on the suscep-
tibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia. 
2007; 21(10):2103-2108.
 55. Berghuis D, Schilham MW, Vos HI, Santos SJ, Kloess S, Buddingh EP, Egeler 
RM, Hogendoorn PC and Lankester AC. Histone deacetylase inhibitors enhance 
expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer 
cell-mediated cytolysis. Clin Sarcoma Res. 2012; 2(1):8.
 56. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M and Zocchi MR. Effective in vivo 
induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic 
acid or sodium valproate. Leukemia. 2009; 23(4):641-648.
 57. Fiegler N, Textor S, Arnold A, Rolle A, Oehme I, Breuhahn K, Moldenhauer G, 
Witzens-Harig M and Cerwenka A. Downregulation of the activating NKp30 
ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. 
Blood. 2013.
 58. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn 
RD, Song W, Li D, Sharp LL, Torigian DA, O’Dwyer PJ and Vonderheide RH. CD40 
agonists alter tumor stroma and show efficacy against pancreatic carcinoma in 
mice and humans. Science. 2011; 331(6024):1612-1616.
 59. Kroemer G, Galluzzi L, Kepp O and Zitvogel L. Immunogenic cell death in cancer 
therapy. Annu Rev Immunol. 2013; 31:51-72.
 60. Christiansen AJ, West A, Banks KM, Haynes NM, Teng MW, Smyth MJ and 
Johnstone RW. Eradication of solid tumors using histone deacetylase inhibitors 
combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A. 2011; 
108(10):4141-4146.
 61. West AC, Mattarollo SR, Shortt J, Cluse LA, Christiansen AJ, Smyth MJ and 
Johnstone RW. An intact immune system is required for the anti-cancer activi-
ties of histone deacetylase inhibitors. Cancer Res. 2013.
 62. Sonnemann J, Gressmann S, Becker S, Wittig S, Schmudde M and Beck JF. 
The histone deacetylase inhibitor vorinostat induces calreticulin exposure in 
childhood brain tumour cells in vitro. Cancer Chemother Pharmacol. 2010; 
66(3):611-616.
 63. Guillot F, Boutin B, Blanquart C, Fonteneau JF, Robard M, Gregoire M and 
Pouliquen D. Vaccination with epigenetically treated mesothelioma cells induces 
immunisation and blocks tumour growth. Vaccine. 2011; 29(33):5534-5543.
Michel Kroesen - Binnenwerk V7.indd   72 05-08-15   10:36
73
HDAC inhibitors and immunotherapy | chapter 3
3
 64. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt 
E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Metivier D, Pichard E, Au-
couturier P, Pierron G, Garrido C, et al. Caspase-dependent immunogenicity of 
doxorubicin-induced tumor cell death. J Exp Med. 2005; 202(12):1691-1701.
 65. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 
1994; 12:991-1045.
 66. Banchereau J and Steinman RM. Dendritic cells and the control of immunity. 
Nature. 1998; 392(6673):245-252.
 67. Medzhitov R and Janeway CA, Jr. Innate immune recognition and control of 
adaptive immune responses. Semin Immunol. 1998; 10(5):351-353.
 68. Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ and Dalpke AH. 
Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of 
proinfl ammatory gene expression by impairing transcription factor recruitment. 
Immunology. 2007; 122(4):596-606.
 69. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, Ding XC, Chanson 
AL, Reymond MK, Miconnet I, Schrenzel J, Francois P and Calandra T. Histone 
deacetylase inhibitors impair innate immune responses to Toll-like receptor 
agonists and to infection. Blood. 2011; 117(4):1205-1217.
 70. Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez 
I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A and Sotomayor EM. 
Histone deacetylase inhibitor LAQ824 augments infl ammatory responses in 
macrophages through transcriptional regulation of IL-10. J Immunol. 2011; 
186(7):3986-3996.
 71. Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, Lovelace E, Reid 
RC, Le GT, Hume DA, Irvine KM, Matthias P, Fairlie DP and Sweet MJ. Differential 
effects of selective HDAC inhibitors on macrophage infl ammatory responses to 
the Toll-like receptor 4 agonist LPS. J Leukoc Biol. 2010; 87(6):1103-1114.
 72. Cheng F, Lienlaf M, Perez-Villarroel P, Wang HW, Lee C, Woan K, Woods D, Knox 
T, Bergman J, Pinilla-Ibarz J, Kozikowski A, Seto E, Sotomayor EM and Villagra 
A. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 
(HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. 
Mol Immunol. 2014; 60(1):44-53.
 73. Chen X, Barozzi I, Termanini A, Prosperini E, Recchiuti A, Dalli J, Mietton F, Mat-
teoli G, Hiebert S and Natoli G. Requirement for the histone deacetylase Hdac3 
for the infl ammatory gene expression program in macrophages. Proc Natl Acad 
Sci U S A. 2012; 109(42):E2865-2874.
 74. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA and Ferrara JL. 
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute 
graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl 
Acad Sci U S A. 2004; 101(11):3921-3926.
 75. Leng C, Gries M, Ziegler J, Lokshin A, Mascagni P, Lentzsch S and Mapara MY. Re-
duction of graft-versus-host disease by histone deacetylase inhibitor suberonyl-
anilide hydroxamic acid is associated with modulation of infl ammatory cytokine 
milieu and involves inhibition of STAT1. Exp Hematol. 2006; 34(6):776-787.
 76. Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E, Maeda 
Y, Tawara I, Krijanovski O, Gatza E, Liu C, Malter C, Mascagni P, Dinarello CA 
Michel Kroesen - Binnenwerk V7.indd   73 05-08-15   10:36
chapter 3 | HDAC inhibitors and immunotherapy
74
and Ferrara JL. Histone deacetylase inhibition modulates indoleamine 2,3-diox-
ygenase-dependent DC functions and regulates experimental graft-versus-host 
disease in mice. J Clin Invest. 2008; 118(7):2562-2573.
 77. Glauben R, Batra A, Stroh T, Erben U, Fedke I, Lehr HA, Leoni F, Mascagni P, 
Dinarello CA, Zeitz M and Siegmund B. Histone deacetylases: novel targets for 
prevention of colitis-associated cancer in mice. Gut. 2008; 57(5):613-622.
 78. Grabiec AM, Krausz S, de Jager W, Burakowski T, Groot D, Sanders ME, Prakken 
BJ, Maslinski W, Eldering E, Tak PP and Reedquist KA. Histone deacetylase inhibi-
tors suppress inflammatory activation of rheumatoid arthritis patient synovial 
macrophages and tissue. J Immunol. 2010; 184(5):2718-2728.
 79. Bosisio D, Vulcano M, Del Prete A, Sironi M, Salvi V, Salogni L, Riboldi E, Leoni 
F, Dinarello CA, Girolomoni G and Sozzani S. Blocking TH17-polarizing cyto-
kines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol. 2008; 
84(6):1540-1548.
 80. Salvi V, Bosisio D, Mitola S, Andreoli L, Tincani A and Sozzani S. Trichostatin A 
blocks type I interferon production by activated plasmacytoid dendritic cells. 
Immunobiology. 2010; 215(9-10):756-761.
 81. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D and Huang Q. Histone 
deacetylase activities are required for innate immune cell control of Th1 but not 
Th2 effector cell function. Blood. 2007; 109(3):1123-1130.
 82. Nencioni A, Beck J, Werth D, Grunebach F, Patrone F, Ballestrero A and Brossart 
P. Histone deacetylase inhibitors affect dendritic cell differentiation and immu-
nogenicity. Clin Cancer Res. 2007; 13(13):3933-3941.
 83. Song W, Tai YT, Tian Z, Hideshima T, Chauhan D, Nanjappa P, Exley MA, Ander-
son KC and Munshi NC. HDAC inhibition by LBH589 affects the phenotype and 
function of human myeloid dendritic cells. Leukemia. 2011; 25(1):161-168.
 84. Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, Mascagni P and 
Dinarello CA. Pharmacokinetics, safety and inducible cytokine responses during 
a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol 
Med. 2011; 17(5-6):353-362.
 85. Kim ES and Lee JK. Histone deacetylase inhibitors decrease the antigen present-
ing activity of murine bone marrow derived dendritic cells. Cell Immunol. 2010; 
262(1):52-57.
 86. Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar 
VC and Liby KT. The combination of the histone deacetylase inhibitor vorinostat 
and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. 
Carcinogenesis. 2013; 34(1):199-210.
 87. Lugrin J, Ding XC, Le Roy D, Chanson AL, Sweep FC, Calandra T and Roger T. 
Histone deacetylase inhibitors repress macrophage migration inhibitory factor 
(MIF) expression by targeting MIF gene transcription through a local chromatin 
deacetylation. Biochim Biophys Acta. 2009; 1793(11):1749-1758.
 88. Steinman RM. Dendritic cells: understanding immunogenicity. Eur J Immunol. 
2007; 37 Suppl 1:S53-60.
 89. Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Sch-
reibelt G, Mus R, De Wilt JH, Haanen JB, Schadendorf D, Croockewit A, Blokx 
WA, Van Rossum MM, Kwok WW, Adema GJ, et al. Targeting CD4(+) T-helper 
Michel Kroesen - Binnenwerk V7.indd   74 05-08-15   10:36
75
HDAC inhibitors and immunotherapy | chapter 3
3
cells improves the induction of antitumor responses in dendritic cell-based vac-
cination. Cancer Res. 2013; 73(1):19-29.
 90. Church SE, Jensen SM, Antony PA, Restifo NP and Fox BA. Tumor-specifi c CD4 T 
cells maintain effector and memory tumor-specifi c CD8 T cells. Eur J Immunol. 
2013.
 91. Moreira JM, Scheipers P and Sorensen P. The histone deacetylase inhibitor 
Trichostatin A modulates CD4+ T cell responses. BMC Cancer. 2003; 3:30.
 92. Edens RE, Dagtas S and Gilbert KM. Histone deacetylase inhibitors induce 
antigen specifi c anergy in lymphocytes: a comparative study. Int Immunophar-
macol. 2006; 6(11):1673-1681.
 93. Dagtas AS, Edens RE and Gilbert KM. Histone deacetylase inhibitor uses 
p21(Cip1) to maintain anergy in CD4+ T cells. Int Immunopharmacol. 2009; 
9(11):1289-1297.
 94. Beliakova-Bethell N, Zhang JX, Singhania A, Lee V, Terry VH, Richman DD, Spina 
CA and Woelk CH. Suberoylanilide hydroxamic acid induces limited changes in 
the transcriptome of primary CD4(+) T cells. AIDS. 2013; 27(1):29-37.
 95. Moradei O, Maroun CR, Paquin I and Vaisburg A. Histone deacetylase inhibitors: 
latest developments, trends and prospects. Curr Med Chem Anticancer Agents. 
2005; 5(5):529-560.
 96. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T and 
Mazitschek R. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 
2010; 6(3):238-243.
 97. Moradei O, Vaisburg A and Martell RE. Histone deacetylase inhibitors in cancer 
therapy: new compounds and clinical update of benzamide-type agents. Curr 
Top Med Chem. 2008; 8(10):841-858.
 98. Kelly-Sell MJ, Kim YH, Straus S, Benoit B, Harrison C, Sutherland K, Armstrong 
R, Weng WK, Showe LC, Wysocka M and Rook AH. The histone deacetylase 
inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell 
lymphoma patients. Am J Hematol. 2012; 87(4):354-360.
 99. Schmudde M, Friebe E, Sonnemann J, Beck JF and Broker BM. Histone deacety-
lase inhibitors prevent activation of tumour-reactive NK cells and T cells but 
do not interfere with their cytolytic effector functions. Cancer Lett. 2010; 
295(2):173-181.
 100. Wang D, Iclozan C, Liu C, Xia C, Anasetti C and Yu XZ. LBH589 enhances T cell 
activation in vivo and accelerates graft-versus-host disease in mice. Biol Blood 
Marrow Transplant. 2012; 18(8):1182-1190 e1181.
 101. Agarwal P, Raghavan A, Nandiwada SL, Curtsinger JM, Bohjanen PR, Mueller DL 
and Mescher MF. Gene regulation and chromatin remodeling by IL-12 and type 
I IFN in programming for CD8 T cell effector function and memory. J Immunol. 
2009; 183(3):1695-1704.
 102. Northrop JK, Thomas RM, Wells AD and Shen H. Epigenetic remodeling of the 
IL-2 and IFN-gamma loci in memory CD8 T cells is infl uenced by CD4 T cells. J 
Immunol. 2006; 177(2):1062-1069.
 103. Zhang F, Zhou X, DiSpirito JR, Wang C, Wang Y and Shen H. Epigenetic Manipu-
lation Restores Functions of Defective CD8 T Cells from Chronic Viral Infection. 
Mol Ther. 2014.
Michel Kroesen - Binnenwerk V7.indd   75 05-08-15   10:36
chapter 3 | HDAC inhibitors and immunotherapy
76
 104. Ogbomo H, Michaelis M, Kreuter J, Doerr HW and Cinatl J, Jr. Histone deacety-
lase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett. 2007; 
581(7):1317-1322.
 105. Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, 
Kleinerman ES and Lee DA. The Narrow-Spectrum HDAC Inhibitor Entinostat 
Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced 
Recognition of Cancer Cells. Pharm Res. 2013.
 106. Lindau D, Gielen P, Kroesen M, Wesseling P and Adema GJ. The immunosuppres-
sive tumour network: myeloid-derived suppressor cells, regulatory T cells and 
natural killer T cells. Immunology. 2013; 138(2):105-115.
 107. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, Li B, Turka 
LA, Olson EN, Greene MI, Wells AD and Hancock WW. Deacetylase inhibition 
promotes the generation and function of regulatory T cells. Nat Med. 2007; 
13(11):1299-1307.
 108. Donas C, Fritz M, Manriquez V, Tejon G, Bono MR, Loyola A and Rosemblatt M. 
Trichostatin A promotes the generation and suppressive functions of regulatory 
T cells. Clin Dev Immunol. 2013; 2013:679804.
 109. Johnson J, Pahuja A, Graham M, Hering B, Hancock WW and Bansal-Pakala P. 
Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory 
T cells in rhesus macaques. Transplant Proc. 2008; 40(2):459-461.
 110. Akimova T, Ge G, Golovina T, Mikheeva T, Wang L, Riley JL and Hancock WW. 
Histone/protein deacetylase inhibitors increase suppressive functions of human 
FOXP3+ Tregs. Clin Immunol. 2010; 136(3):348-363.
 111. Saouaf SJ, Li B, Zhang G, Shen Y, Furuuchi N, Hancock WW and Greene MI. 
Deacetylase inhibition increases regulatory T cell function and decreases 
incidence and severity of collagen-induced arthritis. Exp Mol Pathol. 2009; 
87(2):99-104.
 112. de Zoeten EF, Wang L, Sai H, Dillmann WH and Hancock WW. Inhibition of 
HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastro-
enterology. 2010; 138(2):583-594.
 113. de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H, Bradner JE, Ma-
zitschek R, Kozikowski AP, Matthias P and Hancock WW. Histone deacetylase 6 
and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. 
Mol Cell Biol. 2011; 31(10):2066-2078.
 114. Kalin JH, Butler KV, Akimova T, Hancock WW and Kozikowski AP. Second-gener-
ation histone deacetylase 6 inhibitors enhance the immunosuppressive effects 
of Foxp3+ T-regulatory cells. J Med Chem. 2012; 55(2):639-651.
 115. Beier UH, Wang L, Han R, Akimova T, Liu Y and Hancock WW. Histone deacety-
lases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through 
shared and isoform-specific mechanisms. Sci Signal. 2012; 5(229):ra45.
 116. Lucas JL, Mirshahpanah P, Haas-Stapleton E, Asadullah K, Zollner TM and 
Numerof RP. Induction of Foxp3+ regulatory T cells with histone deacetylase 
inhibitors. Cell Immunol. 2009; 257(1-2):97-104.
 117. Zhang ZY and Schluesener HJ. HDAC inhibitor MS-275 attenuates the inflam-
matory reaction in rat experimental autoimmune prostatitis. Prostate. 2012; 
72(1):90-99.
Michel Kroesen - Binnenwerk V7.indd   76 05-08-15   10:36
77
HDAC inhibitors and immunotherapy | chapter 3
3
 118. Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, 
Fenstermaker R and Pili R. Class I histone deacetylase inhibitor entinostat sup-
presses regulatory T cells and enhances immunotherapies in renal and prostate 
cancer models. PLoS One. 2012; 7(1):e30815.
 119. Nagaraj S, Schrum AG, Cho HI, Celis E and Gabrilovich DI. Mechanism of T 
cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010; 
184(6):3106-3116.
 120. Rosborough BR, Castellaneta A, Natarajan S, Thomson AW and Turnquist 
HR. Histone deacetylase inhibition facilitates GM-CSF-mediated expansion 
of myeloid-derived suppressor cells in vitro and in vivo. J Leukoc Biol. 2012; 
91(5):701-709.
 121. Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, 
Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E and 
Gabrilovich DI. Epigenetic silencing of retinoblastoma gene regulates pathologic 
differentiation of myeloid cells in cancer. Nat Immunol. 2013; 14(3):211-220.
 122. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon 
S and Balkwill FR. Ovarian cancer cells polarize macrophages toward a tumor-
associated phenotype. J Immunol. 2006; 176(8):5023-5032.
 123. Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC and Hsieh SL. Epi-
genetic control of MHC class II expression in tumor-associated macrophages by 
decoy receptor 3. Blood. 2008; 111(10):5054-5063.
 124. Tai SK, Chang HC, Lan KL, Lee CT, Yang CY, Chen NJ, Chou TY, Tarng DC and 
Hsieh SL. Decoy receptor 3 enhances tumor progression via induction of tumor-
associated macrophages. J Immunol. 2012; 188(5):2464-2471.
 125. Grabiec AM, Korchynskyi O, Tak PP and Reedquist KA. Histone deacetylase 
inhibitors suppress rheumatoid arthritis fi broblast-like synoviocyte and mac-
rophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis. 2012; 
71(3):424-431.
 126. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, de la Rocha P, 
Yang MY, Mok S, Garban HJ, Craft N, Economou JS, Marincola FM, Wang E and 
Ribas A. Enhanced antitumor activity induced by adoptive T-cell transfer and 
adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009; 
69(22):8693-8699.
 127. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, 
Van Erp K, Schulick R and Pili R. Synergistic in vivo antitumor effect of the his-
tone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine 
model of renal cell carcinoma. Clin Cancer Res. 2007; 13(15 Pt 1):4538-4546.
Michel Kroesen - Binnenwerk V7.indd   77 05-08-15   10:36
Michel Kroesen - Binnenwerk V7.indd   78 05-08-15   10:36
chapter 4
A transplantable TH-MYCN transgenic 
tumor model in C57Bl/6 mice for 
preclinical immunological studies in 
neuroblastoma.
Michiel Kroesen
Stefan Nierkens
Marleen Ansems
Melissa Wassink
Rimas Orentas
Louis Boon
Martijn den Brok
Peter M. Hoogerbrugge
Gosse J. Adema
Int J Cancer (2014) 134(6):1335-45.
Michel Kroesen - Binnenwerk V7.indd   79 05-08-15   10:36
chapter 4 | Immunological tumor model for Neuroblastoma
80
abstract
Current multimodal treatments for patients with neuroblastoma (NBL), 
including anti-disialoganglioside (GD2) monoclonal antibody (mAb) based 
immunotherapy, result in a favorable outcome in around only half of the 
patients with advanced disease. To improve this, novel immuno-combina-
tional strategies need to be developed and tested in autologous preclini-
cal neuroblastoma models. A genetically well-explored autologous mouse 
model for NBL is the TH-MYCN model. However, the immunobiology of the 
TH-MYCN model remains largely unexplored. We developed a mouse model 
using a transplantable TH-MYCN cell line in syngeneic C57Bl/6 mice and 
characterized the immunobiology of this model. In this report we show the 
relevance and opportunities of this model to study immunotherapy for hu-
man NBL. Similar to human NBL cells, syngeneic TH-MYCN derived 9464D 
cells endogenously express the tumor antigen GD2 and low levels of MHC 
class I. The presence of the adaptive immune system had little or no influ-
ence on tumor growth, showing the low immunogenicity of the NBL cells. In 
contrast, depletion of NK1.1+ cells resulted in enhanced tumor outgrowth 
in both wild-type and Rag1-/- mice, showing an important role for natural 
killer (NK) cells in the natural anti-NBL immune response. Analysis of the 
tumor infiltrating leukocytes ex vivo revealed the presence of both tumor 
associated myeloid cells and T regulatory cells, thus mimicking human NBL 
tumors. Finally, anti-GD2 mAb mediated NBL therapy resulted in ADCC in 
vitro and delayed tumor outgrowth in vivo. We conclude that the transplant-
able TH-MYCN model represents a relevant model for the development of 
novel immuno-combinatorial approaches for NBL patients.
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introDuction
Neuroblastoma (NBL) is an extracranial solid tumor of childhood that ac-
counts for 12% of all deaths associated with cancer in children under 15 years 
of age1. Genomic amplifi cation of the proto-oncogene MYCN is consistently 
associated with poor prognosis and occurs in around 20% of primary NBL 
tumors2. MYCN amplifi ed and other high-risk patients have a poor long-term 
survival despite intensive multimodal treatments3. Immunotherapy emerges 
as a clinical therapy for high-risk disease in the minimal residual disease 
setting following autologous stem cell transplantation4.
Several reports have provided evidence that natural killer (NK) cells play 
an important role in the anti-NBL immune response in patients. Killer-cell 
immunoglobulin-like receptor (KIR) - human leukocyte antigen (HLA) mis-
match genotype was associated with favourable disease outcome, suggesting 
that NK cells can exert anti-NBL effects5. Similarly, KIR-HLA mismatch was 
associated with clinical outcome in a phase II trial using the tumor specifi c 
anti-GD2 mAb ch14.18 fused to IL-2 (hu14.18-IL2)6. In another cohort, 
benefi t was demonstrated for KIR-HLA mismatch in patients receiving the 
anti-GD2 mAb 3F87. These data suggest that NK cells play an important role 
in the natural anti-tumor immune response towards NBL cells.
The role of adaptive immune effector cells in the anti-NBL immune response 
remains to be elucidated. Human NBL cells have been reported to express 
low levels of MHC class I and co-stimulatory molecules8, 9. Therefore NBL 
cells may be poorly recognized by tumor specifi c T cells. NBL cells, however, 
were also shown to upregulate MHC class I molecules upon infl ammation, 
especially following exposure to interferon–γ (IFN-γ)10. Detailed insight in 
the exact role of the adaptive immune response in anti-NBL immunity is 
however currently lacking11-13.
Immunotherapy in the minimal residual disease setting was shown suc-
cessful in a COG phase III trial4. In this study, addition of the anti-GD2 
mAb ch14.18 in combination with systemic administration of the cytokines 
IL-2 and GM-CSF proved superior to standard treatment4. Recent data from 
Tarek et al. supported the role of NK cells in anti-GD2 mAb therapy7. Despite 
these major improvements coming from immunotherapy, around half of 
the patients still relapse or show progressive disease. Therefore, a better 
understanding and improvement of immunotherapy for NBL patients is of 
utmost importance.
One drawback in the development of novel immunotherapies for NBL is 
the lack of suitable autologous mouse models. Most immunotherapeutic 
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studies have been performed using C1300 derived cell lines in A/J mice for 
which only limited immunological tools are available due to the A/J genetic 
background14-17. Additionally, C1300 derived cell lines, like Neuro-2a, do not 
express the tumor antigen GD2. TH-MYCN transgenic mice generated by 
Weiss et al. spontaneously develop NBL18,19. These NBL tumors have strong 
histological and genetic similarities with human NBL20-22. However, the immu-
nobiology of the TH-MYCN model remains largely unexplored. Understanding 
the immunobiology of an autologous NBL model is crucial in order to develop 
and study novel immunotherapeutic strategies for NBL.
In this study we developed and characterized a transplantable syngeneic 
tumor model based on TH-MYCN transgenic tumor cells in C57BL/6 mice. 
We show that TH-MYCN transgenic 9464D cells have low expression levels 
of MHC class I and are targeted by NK cells both in vitro and in vivo. 9464D 
cells express the tumor antigen GD2 endogenously and anti-GD2 mAb result 
in immune mediated killing of these cells in vitro and reduced tumor growth 
in vivo. Analysis of the tumor infiltrating leucocytes revealed potential im-
mune evasion strategies. These data suggest that this syngeneic NBL tumor 
model in C57BL/6 mice provides a relevant model to study and develop novel 
immunotherapeutic approaches for NBL.
materials anD methoDs
animals and cell lines
6-8 weeks old female C57Bl/6 WT and Rag1-/- (C57Bl/6 background) mice 
were purchased from Charles River. Animals were held under specified 
pathogen-free conditions in the Central Animal Laboratory (Nijmegen, The 
Netherlands). All experiments were performed according to the guidelines 
for animal care of the Nijmegen Animal Experiments Committee. Neuro-
2a and B16F10 cell lines were purchased from the American Type Culture 
Collection (Manassas,VA). The transgenic cell lines 9464D and 975A2 were 
derived from spontaneous tumors from TH-MYCN transgenic mice on C57Bl/6 
background and were a kind gift from Dr. Orentas (NIH, Bethesda). The 
hybridoma 14.g2a producing a mouse IgG2a monoclonal antibody specific 
for GD2 was a kind gift from Dr. Reisfeld (Scripps, La Jolla). B16F10 cells 
were cultured in Minimal Essential Medium (MEM) containing 5% fetal bovine 
serum (FCS, Greiner Bio-one, Alphen a/d Rijn, the Netherlands), 1% non –
essential amino acids (Invitrogen), 0.5% antibiotic-antimycotic (AA) (Gibco), 
1% pyruvate (Gibco), 2% NaH2CO3 (Gibco), 1.5% MEM Vitamins (Gibco) 
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and 0.05% β-mercaptoethanol. Neuro-2a, 9464D and 975A2 cell lines were 
cultured in Dulbecco’s modifi ed Eagle (DMEM) medium containing 10% FCS, 
1% non–essential amino acids, 0.5% AA and and 0.05% β-mercaptoethanol 
(complete medium).
facsort 9464D cells
Cells were sorted for GD2 expression. The 14.g2a mAb was directly coupled 
to Cy5 in our lab. 9464D cells were stained with the anti-GD2-Cy5 mAb or 
isotype control mIgG2a-Cy5 (HOPC-1) from Southern Biotech. Cells were 
sorted using a Coulter Elite FACSort into a GD2 negative and GD2 positive 
fraction. GD2 expression was determined after each passage of the sorted 
cells by staining with the anti-GD2-Cy5 mAb or isotype control mIgG2a-Cy5 
(Southern Biotech).
tumor induction and follow-up
For induction of subcutaneous tumors 1*106 9464D cells were injected s.c. 
in a volume of 50 μl PBS on the right fl ank of the mice. Viability of tumor 
cells before injection was determined by Tryptan Blue staining and always 
exceeded 95%. Subcutaneous tumor growth was measured every 3-4 days 
using standard calipers. Tumor volume was calculated with the following for-
mula: (A x B2) x 0.4 in which A is the largest and B is the shortest dimension.
isolation of tumors and generation of single-cell suspensions
Tumors with a size between 300 and 600 mm3 were excised and mechanical 
dissociated using large needles followed by enzymatic digestion with 1 mg/ml 
Collagenase Type III (Worthington) and 30 μg/ml DNAse Type I (Roche) for 1 
hour at 37 degrees. After 1 hour EDTA was added (12.5 mM fi nal concentra-
tion) and single cell suspensions were made by passing the tumor fragments 
over a 100 μm cell strainer. A Ficoll centrifugation step was performed to 
remove debris and dead cells from the suspension. The viable fraction was 
aspirated and washed 1x in complete medium and resuspended in PBA for 
the staining procedure. For staining of GD2, tumor cell suspensions were 
extensively washed with PBS to decrease background staining.
Antibodies and fl owcytometry
Anti NK1.1 (PK136) and anti-GD2 (14.g2a) monoclonal antibodies were 
obtained from hybridoma supernatants, purifi ed and fi lter sterilized in PBS. 
Total mouse IgG control Ab was obtained from Jackson Immunoresearch. Di-
rectly labeled mAbs for staining were MHC I-PE (H-2Kb/H-2Db) (28-8-2006), 
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CD8-PerCP (53-6.7), CD11c-APC (N418), CD11b-PerCP (M1/70), Ly-6G-FITC 
(1A8) from Biolegend, MHC I-PE (H-2Kk)(36-7-5), CD40-PE (3/23), CD45.2-
FITC (104), NK1.1-PE (PK136), CD4-APC-Cy7 (L3T4), Ly-6C-APC-Cy7 (AL-
21) and CD3-APC (145-2C11) from BD, CD49b-PECy7 (VLA-2), MHC II-PE 
(M5/114.15.2), PD-L1-PE (MIH5), PD-L2-PE (TY25), NKp46-FITC (29A1.4), 
CD25-APC (PC61.5), FoxP3-PE-Cy7 (FJK-16s) and Mult1-PE (5D10) from 
eBioscience, Rae1-APC (186107) from R&D Systems and anti-GD2-Cy5 (14.
g2a) generated in our lab. Cells for staining were resuspended in ice cold PBA 
and transferred to a V-bottom 96-wells plate. After incubation for 30 minutes 
with PBA containing anti-CD16/CD32 Fc-block (BD), cells were stained us-
ing specific monoclonal antibodies or the appropriate isotype controls for a 
period of 30 minutes. Cells were washed in PBA and measured on a Cyan 
apparatus (BD) and analyzed using Summit software.
Quantitative pcr
1.5 * 106 9464D, 975A2, Neuro-2a or B16F10 cells were lysed and RNA was 
isolated using RNeasy (Qiagen) kit following the manufacturer´s protocol. 
The amount and quality of mRNA were determined by spectrophotometry. 
Two μg of total RNA was pretreated with DNase I (Invitrogen). cDNA was 
synthesized using random primers and Moloney murine leukemia virus 
Superscript Reverse Transcriptase (II-MMLV) (Invitrogen). Relative mRNA 
levels were determined with a Biorad CFX96 cycler using the Fast Start SYBR 
Green Kit (Invitrogen). The following primers were used:
Porphobilinogen deaminase (PBGD) forward (5’-CCTACCATACTACCTCCTG-
GCTTTAC -3’); reverse (5’-TTTGGGTGAAAGACAACAGCAT-3’)
hMYCN forward (5´- CGACCACAAGGCCCTCAGTA-3´); hMYCN reverse (5´- 
CAGCCTTGGTGTTGGAGGAG-3´)
GD2-synthase forward (5´- CCAAGGAGCCGAGTACAACAT-3´); GD2-
synthase reverse (5´-GTAGGGTAAAAGCGTCGGATG-3´)
Survivin forward (5´- CTGCTTTAAGGAATTGGAAGGCT-3´); Survivin reverse 
(5´- CTGACGGGTAGTCTTTGCAGT-3´)
S100A6 forward (5´- TGGCTCCAAGCTGCAGG-3´); S100A6 reverse (5´- 
CCCAGGAAGGCGACATACTC-3´)
ODC forward (5´- GCACATCCAAAGGCAAAGTTG-3´); ODC reverse (5´- 
CAAACTTAACACTGAGGCGACAGA-3´)
MRP1 forward (5´- CCCCAGTGTTACTGGTCAG-3´); MRP1 reverse (5´- 
TTCCCGAGGATTGGACTCCC-3´)
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Primers were obtained from Sigma-Aldrich. Data were analyzed with Bio-rad 
CFX manager version 1.6 (Bio-rad) and checked for correct amplifi cation and 
dissociation of the PCR-products. PBGD served as a reference gene. mRNA 
expression was determined relative to PBGD expression using the formula: 2 
(CT index – CT PBGD). Mean relative expression levels were determined by triplicate 
measurements.
generation of nK/laK effector cells
NK/LAK cells were generated from splenocytes of naïve WT mice. A 10-mL 
syringe was fi lled with 1.2 gram of Nylon Wool (Polysciences) and sterilized. 5 
spleens were collected from 6-8 weeks old naïve C57Bl/6 mice and single cell 
suspensions were made by passage over a 100 μm cell strainer. Ery-lysis was 
performed using ACK-buffer and stopped with complete medium. The nylon 
wool ‘column’ was calibrated using Iscove’s modifi ed Dulbecco’s Modifi cation 
of Eagle’s Medium, containing 5% FCS, 1% AA, 2mM Glutamine and 0.05% 
β-mercaptoethanol (medium) for 1 hour at RT. Splenocytes were loaded on 
the nylon wool and incubated at 37 degrees for 1 hour. The column was 
then washed with 40 ml of medium and cells were plated at a density of 2.5 
*106 cells/mL in medium containing 1000 IU of human rIL-2. On day 3 and 
6 non-adherent cells were washed away by extensive washing with medium 
and fresh medium containing IL-2 was added. On day 7 adherent cells were 
harvested using 1,5 mM EDTA. The harvested adherent cells were >90% 
NK1.1+NKp46+ cells as determined by fl ow cytometry.
facs-based killing assay
9464D cells were harvested and washed once in PBS. Cells were labeled with 
1 μM CFSE (Invitrogen) according to the manufacturer’s protocol. Labeled 
target cells were washed twice using medium and plated at 20.000 cells 
per well in a fl at bottom 96-well plate. Target cells were pre-incubated with 
medium, 10 μg/mL anti-GD2 mAb or isotype control for 2 hours at 4 degrees. 
Effector NK/LAK cells were added at 2:1, 4:1 and 6:1 effector:target cell ra-
tios. After 12 hours of co-incubation all cells were harvested and resuspended 
in 100 μl PBA. Cells were stained with 7-AAD (BD) and Annexin-V-Cy5 (BD) 
according to the manufacturer’s protocol. Triplicate samples were acquired 
using a Cyan fl ow cytometer and numbers of dead CFSE+7AAD+ (necrotic), 
CFSE+Annexin-V+ (apoptotic) and CFSE+7AAD+Annexin-V+(late apoptotic) 
versus life CFSE+7AAD-Annexin-V- target cells were determined. Percentage 
specifi c killing was calculated using the formula: (percentage of total dead 
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target cellstarget – percentage of total dead target cellscontrol) / (100 - percent-
age of total dead target cellscontrol) x 100.
Depletion of nK1.1+ cells and anti-gD2 treatment in vivo
Depletion of NK1.1+ cells was achieved by injecting 100 μg of anti-NK1.1 
mAb i.p. (PK136, mouse IgG2a isotype) on day -8 before tumor inoculation 
and thereafter every 4 days until day 24 post-inoculation. Efficacy of NK 
cell depletion was determined in peripheral blood on days 1 and 29. Blood 
was drawn from the tail veins of isotype and anti-NK1.1 injected mice. Ery-
lysis was performed using ACK-buffer and stopped with complete medium. 
Cells were resuspended in PBA and stained for CD3, NKp46 and CD49b as 
described earlier. For anti-GD2 treatment mice were inoculated with 1*106 
9464D cells s.c. on the right flank. Anti-GD2 treatment was started on day 
7 after tumor inoculation by i.p. injections of 200 μg anti-GD2 mAb in 200 
ul PBS. Injections of anti-GD2 or isotype control Ab were repeated 4 times 
every 3 days until day 19 post-inoculation.
Immunohistofluorescence
9464D and Neuro-2a tumors with a size between 300 and 600 mm3 were 
excised and snap frozen. Cryosections were made and directly fixated in 
-20 degrees acetone. Sections were stained with anti-GD2-Cy5 mAb or iso-
type control mIgG2a-Cy5 (HOPC-1) for 1 h. at room temperature. Nuclear 
staining was performed using DAPI. Sections were imaged using a Leica DM 
fluorescence microscope and analyzed using ImageJ software.
statistics
Data were analyzed using Graphpad 5.0 software. Unpaired T-test was used 
to determine significant differences between two groups. ANOVA test was 
used to determine significant differences between three or more groups, 
including Bonferroni post test to compare all pairs of columns.
results
characterization of th-mycn derived nbl cell lines.
The 9464D and 975A2 cell lines were both derived from spontaneous NBL 
tumors arising in C57Bl/6 TH-MYCN mice. They contain the human MYCN 
transgene and express the corresponding human MYCN transcript23. As ex-
pected, no expression of the MYCN transgene was detected in the C1300 NBL 
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figure 1: Characterization of TH-MYCN derived cell lines. (A) Expression of neuroblas-
toma-associated genes in MYCN transgenic cell lines 9464D and 975A2 compared to 
Neuro-2a (C1300 derived NBL cell line) and B16F10 (mouse melanoma) cell lines. Total 
RNA was isolated and reverse transcribed to cDNA. Quantitative expression was deter-
mined for hMYCN (the human MYCN cDNA transgene used in the TH-MYCN transgenic 
mouse), GD2 synthase, Survivin, S100A6, MRP1 and ODC and related to the expres-
sion of the household gene PBGD. Data are representative of 2 independent experi-
ments. (B) GD2 is dynamically and stably expressed by 9464D cells. 9464D cells were 
stained for GD2 and sorted for low/negative GD2 expression. Sorted cells were taken 
into culture and after each passage GD2 expression was determined. Grey shadings = 
isotype control, black lines = specifi c staining. Representative data from 2 experiments 
with similar results. (C) Surface expression of MHC class I, PD-L1, and Rae1 by 9464D, 
975A2 and Neuro-2a cells. Cells were either cultured with medium alone or in the pres-
ence of TNF-α (25 ng/mL) and IFN-γ (20 ng/mL) for 48 hours and then analyzed. Cells 
were analyzed for the expression of MHC class I, PD-L1 and Rae1 by fl owcytometry 
using specifi c antibodies or the appropriate isotype controls. Grey shadings = isotype 
control, black lines = specifi c staining.
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derived cell line Neuro-2a or the mouse melanoma cell line B16F10 (Fig. 1A). 
To further establish the NBL phenotype of the TH-MYCN transgenic cell lines 
the expression of several other NBL associated genes was determined by 
quantitative RT-PCR. Survivin, an anti-apoptotic gene highly expressed in 
neuroblastoma, was readily detected in all tumor cell lines, but was more 
abundantly present in 9464D cells. S100A6 or Calcyclin, which is expressed 
by more differentiated human NBL cells, could be detected in the three 
murine NBL lines, but not in the melanoma cell line B16F1024. Multidrug re-
sistance protein 1 (MRP1) and ornithine decarboxylase (ODC) are correlated 
with MYCN expression in tumors from TH-MYCN mice and is expressed by the 
TH-MYCN derived cell lines (Fig. 1A)25.
GD2 synthase, one of the key enzymes in the production of the disialo-
ganglioside GD2, was expressed at significant levels by 9464D cells, but at 
very low levels in 975A2 and Neuro-2a cells (Fig. 1A). The tumor antigen 
GD2 is expressed on the surface of virtually all human NBL cells and has 
been shown to be an effective target for immunotherapy4, 26. The absence of 
murine NBL cell lines expressing significant amounts of GD2 has hampered 
the development of autologous murine NBL tumor models. Strikingly, 9464D 
cells, but not 975A2 or Neuro-2a cells, expressed low but significant amounts 
of GD2 on their cell surface (Fig. 1B). GD2 immunostaining of cytospins 
from 9464D and Neuro-2a cells confirmed GD2 expression by 9464D cells 
(Supplementary Fig. 1A). To further determine the significance and stability 
of GD2 expression on 9464D cells, low/negative GD2 cells were sorted and 
taken into culture to monitor GD2 expression after each passage. The GD2 
low/negative cells regained GD2 expression already after a single passage 
in culture. Moreover, GD2 expression on the sorted cells was identical to the 
parental pre-sorted cell line and remained stable in time (Fig. 1B). Similarly, 
upon sorting of GD2 high expressing cells, a decrease in GD2 expression to 
baseline levels was observed over time (Supplementary Fig. 1B). Based on 
these findings, we conclude that GD2 is dynamically expressed on the cell 
surface of all 9464D cells.
Next we screened the NBL cells for surface molecules related to the rec-
ognition of the tumor cells by immune effector cells. MHC class I expres-
sion was found to be expressed by all tested murine NBL cells at low levels 
(Fig. 1C). Expression of MHC class II could not be detected (data not shown). 
Exposure of the NBL cells to the pro-inflammatory cytokines IFN-γ and TNF-α 
strongly upregulated MHC class I molecules while MHC class II expression 
remained negative (Fig. 1C and Supplementary Fig. 2). Next, we stained for 
ligands for the programmed death receptors 1 (PD-L1) and -2 (PD-L2) that 
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figure 2: Role of lymphocyte subsets in 9464D tumor outgrowth. (A) Experimental 
setup is depicted schematically. WT mice and Rag1-/- mice were injected i.p. with iso-
type control or anti-NK1.1 mAb every 4 days. During the depletion, mice were inocu-
lated subcutaneously with 1*106 9464D cells. Nine depleting injections or control were 
given in total until day 23 post-inoculation. (B) Isotype control WT and Rag1-/- mice 
(9 mice / group) were inoculated s.c. with 1 * 106 9464D cells on the right fl ank. Tu-
mor growth was measured every 3-4 days using calipers. (C) Depletion of NK cells in 
peripheral blood was confi rmed on day 1 and 29 post tumor inoculation. Percentages 
of CD49b+NKp46+ NK cells were determined in WT mice and Rag1 -/- mice receiving 
anti-NK1.1 or control Ab. (D) Depletion of NK cells results in enhanced 9464D tumor 
outgrowth speed. WT and Rag1-/- mice (9 mice / group) depleted or not for NK1.1+ 
cells were inoculated with 1 * 106 9464D cells s.c. on the right fl ank. Tumor growth was 
measured every 3-4 days using calipers and mean tumor volume was calculated. Mean 
tumor volumes of WT control and NK1.1 depleted (left) and Rag 1-/- control and NK1.1 
depleted (right) are shown. Differences in mean tumor volume were calculated per time 
point (** p < 0,01 ; *** p <0,001). (E) NK cells infi ltrate 9464D tumors. CD45.2+ 
leukocytes in spleen and tumor were analyzed for the presence of CD3+CD4+ and 
CD3+CD8+ T cells and NK1.1+CD49b+ NK cells. 
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have been implicated in tumor immune evasion through negative regulation 
of immune effector cells27. PD-L1 was only expressed at low levels by 9464D 
cells, while PD-L2 could not be detected on any of the cell lines (Fig. 1C and 
supplementary Fig. 2). Stimulation with IFN-γ and TNF-α strongly upregu-
lated PD-L1 on all NBL cell lines (Fig. 1C), suggesting a possible immune 
escape mechanism. We then investigated the expression of the ligands for 
the activating NKG2D receptor, which is present on NK cells and activated 
CTLs. We found expression of the NKG2D receptor ligand Rae1, but not H60 
and Mult1, on 9464D cells. 975A2 and Neuro-2a cells did not express any of 
the NKG2D ligands tested (Fig. 1C). The expression of CD40, B7H2, B7H3 
and B7H4 was absent and not induced upon IFN-γ and TNF-α exposure on all 
NBL cell lines tested. Based on these data we decided to focus on 9464D cells 
for further studies as they not only endogenously express the tumor antigen 
GD2 but also express other immunological relevant molecules like MHC class 
I, Rae1, and PD-L1.
nK cells are involved in the natural immune response against 
9464D cells
In an initial set of experiments we determined the growth characteristics of 
9464D cells in vivo in autologous C57Bl/6 mice and found solid tumor take 
following subcutaneous (s.c.) injection of 1 * 106 cells (data not shown). We 
tested whether the presence of T and B-cells affects tumor outgrowth. For 
this, 9464D cells were injected s.c. on the flank of WT and Rag1-/- C57Bl/6 
mice (Fig. 2A). We observed that the outgrowth of tumors and survival of 
the mice was not different between isotype treated WT and Rag1-/- mice, 
suggesting low immunogenicity of the 9464D cells in vivo (Fig. 2B). Of note, 
injection of isotype control Ab did not influence tumor growth compared to 
non-injected mice (Supplementary Fig. 3). As the 9464D NBL cells express 
low levels of MHC class I and Rae1, an activating ligand for NK cells, we 
tested the hypothesis that NK cells have an anti-tumor effect during the 
outgrowth of 9464D tumors. Depletion of NK cells was achieved by admin-
istration of a depleting mAb specific for NK1.1 in a 4-day interval regimen 
(Fig. 2A). NK1.1 is a receptor expressed on both NK and NKT cells in the 
mouse system. Complete depletion of NKp46+CD49b+ NK cells in peripheral 
blood was apparent on day 1 and maintained for at least 29 days after tumor 
cell inoculation in both WT and Rag1-/- mice (Fig. 2C). Isotype control Ab 
treated WT and Rag1-/- mice had normal levels of NK cells. Upon depletion 
of NK1.1+ cells in WT mice, we observed enhanced tumor outgrowth speed 
and reduced survival compared to isotype control injected WT mice (Fig. 2D, 
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left). Rag1-/- mice lack functional T cells and NKT cells but do contain normal 
numbers of NK cells. Therefore, NK cells are the only NK1.1 expressing cells 
in Rag1-/- mice. Upon depletion of NK1.1+ cells in Rag1-/- mice we again 
observed a similar increase in tumor outgrowth and a reduced survival of the 
mice compared to control treated Rag1-/- mice (Fig. 2D, right). Upon analy-
sis of tumors from control treated WT mice, we found that NK cells highly 
infi ltrated 9464D tumors, in contrast to CD4+ and CD8+ T cells, compared 
to spleen as a reference organ (Fig. 2E). Collectively, these results suggest 
that NK cells are important anti-tumor effector cells in the natural anti-tumor 
immune response towards 9464D cells in vivo. In contrast the adaptive im-
mune system seems to have no apparent effect on the tumor outgrowth in 
this non-treatment setting. This suggests low immunogenicity of NBL tumors 
for the adaptive immune system and/or a functionally impaired adaptive 
immune system induced by 9464D NBL tumors.
analysis of the tumor microenvironment reveals potential 
immune evasion strategies
To study the tumor microenvironment and potential immune evasion strate-
gies of NBL tumors, we analyzed 9464D NBL tumors for tumor cell-surface 
markers and infi ltrating immune cell subsets. The CD45.2 negative tumor 
cells expressed low levels of MHC class I and PD-L1 and high levels of Rae1 
ex vivo, mimicking the expression in vitro (Fig. 3A). The expression of GD2 
in vivo was determined by immunofl uorescence microscopy. GD2 was readily 
detected in 9464D tumors, but was absent in Neuro-2a tumors (Fig. 3B, left 
and data not shown). The expression of GD2 in 9464D tumors showed a 
‘patchy’ pattern, suggesting the expression of GD2 is also variable in vivo. 
FACS analysis of the tumor cells also revealed expression of GD2 by the 
tumor cells ex vivo (Fig. 3B, right).
Analysis of tumor infi ltrating T cells revealed that 9464D tumors contained 
CD4+ and CD8+ T cells (Fig. 2E). Within the CD4+ T cells, the T regula-
tory (Treg) population was highly present in the tumor (Fig. 3C). The same 
leukocyte populations in spleen are shown as internal controls. Further 
analysis showed that approximately 75% of all tumor infi ltrating leucocytes 
expressed the myeloid cell marker CD11b (Fig. 3D). Upon phenotypic char-
acterization of the tumor infi ltrating CD11b+ myeloid cells, we observed 
more than 30% CD11cintLy6-GnegLy-6CnegMHCIIint cells corresponding to the 
phenotype of macrophages and around 10% CD11chighLy6-GnegLy-6CnegMH-
CIIhigh cells, most likely dendritic cells (Fig. 3D). Using a separate panel of 
markers we confi rmed that the CD11cintLy6-GnegLy-6CnegMHCIIint cells indeed 
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figure 3: Analysis of the TME of 9464D NBL tumors. (A) Tumor cell surface expres-
sion of 9464D cells ex vivo. 9464D tumors having a size between 300-600 mm3 were 
excised, digested and made into single cell suspensions. CD45.2 negative tumor cells 
were gated and stained with antibodies specifi c for MHC class I, Rae1 and PD-L1 or the 
appropriate isotype control mAb (left panels). Isotype corrected MFI for 5 tumors are 
depicted for MHCI, Rae1 and PD-L1 (right graph). Representative data are shown of 2 
independent experiments. (B) GD2 is expressed in 9464D tumors in vivo. 9464D tumors 
having a size between 300-600 mm3 were excised and snap frozen or digested and 
made into single cell suspensions. Cryosections were stained for GD2 (green) or isotype 
control and DAPI (blue) (left panel). CD45.2 negative tumor cells were stained for GD2 
(black line) or isotype (grey shading) and isotype corrected mean MFI was calculated for 
5 mice (right panel) (C) Analysis of tumor infi ltrating leucocytes for the presence of Treg 
cells. CD45.2+ tumor infi ltrating leucocytes were gated and analyzed for the presence 
of Treg. Percentages CD25+FoxP3+ cells of CD45.2+CD4+ cells in spleen and tumor 
are depicted (4 mice). Representative data are shown for 3 independent experiments. 
(D) Myeloid cells highly infi ltrate 9464D NBL tumors. Left: Analysis of CD11b express-
ing cells of all CD45.2+ tumor infi ltrating leucocytes. Middle: CD45.2+CD11b+ myeloid 
cells were gated on Ly-6G negative cells and analyzed for the expression of CD11c 
and Ly-6C. Percentages of CD11bposLy-6GnegCD11cintLy-6Cneg macrophages, CD11bposLy-
6GnegCD11chighLy-6Cneg dendritic cells and CD11bposLy-6GnegCD11clowLy-6Cpos M-MDSC are 
shown for spleen and tumor. Representative data are shown for 2 independent experi-
ments showing similar results.
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expressed the macrophage marker F4/80, further defi ning these cells as 
macrophages. The phenotype of myeloid derived suppressor cells (MDSC) 
can be either CD11bposLy-6CintLy-6Ghigh for granulocytic MDSC (G-MDSC) or 
CD11bposLy6GnegCD11clowLy6Chigh for monocytic MDSC (M-MDSC)28. Myeloid 
cells corresponding to the phenotype of M-MDSC were found at relevant 
levels in 9464D tumors (Fig. 3D). We conclude that 9464D tumors are highly 
infi ltrated by tumor associated macrophages, dendritic cells, and MDSC. 
Besides for the observed presence of Tregs, these data hint towards a role 
for myeloid cells in creating an immune suppressive environment in 9464D 
NBL tumors.
anti-gD2 mab mediate aDcc and delayed tumor outgrowth
As the tumor antigen GD2 was found to be expressed by 9464D cells in 
vitro and ex vivo, we tested the effect of anti-GD2 mAb immunotherapy in 
vitro and in a fully autologous tumor model in vivo. 9464D cells were ef-
fi ciently lysed by spleen derived NK/LAK cells. The presence of anti-GD2 mAb 
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figure 4: Targeting of GD2 using mAb induces ADCC and reduces tumor growth. (A) 
Immune mediated killing is enhanced by anti-GD2 mAb. NK/LAK cells were co-cultured 
with 9464D, 975A2 and B16F10 cells at different effector : target cell ratio’s for 12 hours 
in the presence of anti-GD2 mAb or isotype control Ab. Specifi c killing was calculated 
following FACS analysis of CFSE labeled target cells (***p <0,001). Representative 
data from 3 independent experiments with similar results. (B) Anti-GD2 mAb therapy 
reduces tumor growth in vivo. Mice were inoculated s.c. with 1 * 106 9464D cells on the 
right fl ank. On day 7 post-inoculation therapy was initiated. Mice were injected intraper-
itoneally with anti-GD2 mAb (200 ug) or isotype control Ab every 3 days. Tumor growth 
was monitored by caliper measurements. Mean tumor volume is shown for 9 mice per 
group (**p<0,01; ***p<0,001). Representative data from 2 independent experiments 
with similar results.
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resulted in enhanced killing of the GD2+ 9464D, but not the GD2- 975A2 or 
B16F10 cells (Fig. 4A), indicative for anti-GD2 mAb mediated ADCC. Of note, 
incubation of 9464D cells with up to 40 ug/mL anti-GD2 mAb in vitro had no 
direct effect on tumor cell viability as determined by a standard MTT assay 
(Supplementary Fig. 4). Next, we tested whether anti-GD2 mAb could have 
an effect on tumor outgrowth of 9464D cells in a therapeutic setting in vivo. 
Mice were inoculated s.c. on the flank with 1*106 9464D cells. Treatment was 
started on day 7 following tumor challenge by intraperitoneal injection of 
anti-GD2 mAb or isotype control Ab. Tumor growth in mice treated with anti-
GD2 therapy was significantly reduced compared to isotype control treated 
mice but could not cure mice as a standalone treatment (Fig. 4B). These 
results indicate that anti-GD2 mAb can mediate ADCC in vitro and result in 
reduced tumor outgrowth in vivo.
Discussion
In this study we report on the relevance of a novel transplantable NBL tumor 
model in mice for preclinical immunological studies in NBL. This novel model 
is based on the use of the transplantable MYCN transgenic cell line 9464D 
in C57Bl/6 mice. The genetical and histological relevance of the transgenic 
TH-MYCN model for NBL has been shown extensively in previous studies20-22. 
The TH-MYCN mouse model closely recapitulates the human disease and 
resembles mostly high risk MYCN amplified NBL tumors29. Interestingly, the 
overexpression of MYCN in this model was recently shown to enhance the 
tumorigenic potential of the ALKF1174L mutation, which is present in around 
8% of NBL patients30. Cell lines derived from spontaneous tumors retain 
many molecular and biological characteristics of NBL31. Moreover, newly 
formed tumors from transplantable cell lines show close correspondence with 
spontaneous NBL tumors in many ways32. For these reasons, the TH-MYCN 
model has been used to study the pathophysiology of NBL and to test novel 
targeted therapeutics19, 33-35. We now extend the use of the TH-MYCN model 
to immunotherapeutic studies, by showing the striking similarities with the 
reported immunobiology of human NBL.
In general, NBL is a low immunogenic tumor that is not targeted by the 
CD8+ T cell compartment because of the low expression of HLA molecules 
on human NBL cells10, 36, 37. 9464D NBL cells express low levels of MHC class 
I and lack expression of co-stimulatory molecules. Like human NBL cells, the 
murine 9464D cells upregulate MHC class I molecules upon IFN-γ exposure38, 
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suggesting that NBL recognition by T cells can be enhanced under infl amma-
tory conditions in the tumor. In steady state conditions however, we observed 
that tumor growth of 9464D cells in Rag1-/- mice, lacking functional T- and 
B-cells, was similar to to tumor growth in WT mice. These data confi rm the 
low immunogenicity of the TH-MYCN cells for the adaptive immune system. 
Sensitivity to NK cell mediated killing has been reported for human NBL 
cells and is currently being exploited in anti-GD2 mAb therapies39. We found 
that NK cells have an important function in the natural anti-tumor immune 
response in the 9464D NBL model system. The action of NK cells provides a 
platform to develop novel immunotherapy for NBL. Because of the similarity 
with the human disease, it will be interesting to be able to generate and 
detect effective T cell responses against the tumor in this model. Especially 
since activated NK cells can boost adaptive immune responses via NK-DC 
cross-talk, and subsequent induction of anti-tumor T cell responses40.
The 9464D tumor cells express low levels of MHC class I and express the 
NKG2D activating ligand Rae1 in vivo. Transcripts of NKG2D ligands were 
reported earlier in human primary tumors, but protein products were not de-
tected. This could be due to shedding of these molecules leading to receptor 
downregulation on effector cells as an evasion strategy41. Whether shedding 
of Rae1 is an immune evasive mechanism in the TH-MYCN model as well re-
mains to be shown. Although we found upregulation of MHCI and PD-L1 upon 
IFN-γ and TNF-α stimulation in vitro, both were not highly expressed on the 
tumor cells ex vivo, suggesting the absence of these infl ammatory cytokines 
in the tumor microenvironment. Upon analyzing the tumor infi ltrating leuko-
cytes we observed high levels of tumor infi ltrating Treg among the infi ltrating 
CD4 T cells. The major tumor infi ltrating immune cells were, however, my-
eloid cells. Cells having the phenotype corresponding to macrophages were 
the largest subset within these tumor infi ltrating myeloid cells. The exact role 
of myeloid cells in the tumorigenesis and/or immune suppression of 9464D 
NBL tumors needs to be determined. Strikingly, Asgharzadeh et al. recently 
showed an association between the presence of a M2 macrophage gene 
signature in NBL tumors and adverse disease outcome in NBL patients42. 
The authors suggested a direct role of tumor associated macrophages in 
stimulating NBL growth via cytokine secretion. M2 macrophages have also 
been suggested to suppress anti-tumor immune responses43. In this respect, 
the novel 9464D tumor model thus seems to refl ect human NBL pathology. 
Moreover, a population of 9464D tumor infi ltrating myeloid cells had the 
phenotype consistent with MDSC, which have been reported to suppress T 
cell responses44. It will be interesting to further dissect the role and function 
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of the myeloid cells in 9464D tumors and correlate these findings for their 
relevance for human NBL.
Recently, progress in NBL therapy has been made using mAb, which are 
specific for the tumor antigen GD24. GD2 emerges therefore as one of the 
most prominent TAA of NBL, since it is stably expressed by virtually all NBL 
cells and has limited expression in normal tissues45. Many preclinical studies 
using anti-GD2 mAb have been performed in xenograft models using human 
NBL cell lines in immunodeficient mice46. However, the adaptive immune 
system is absent in these mice and interactions between the present innate 
murine immune cells and the human tumor cells may not be translatable. To 
study immunotherapy in the autologous setting, a hybrid cell line between 
Neuro-2a on A/J background and GD2+ dorsal root ganglion cells on C57Bl/6 
background, called NXS2, was generated47. Because of the different genetic 
backgrounds of the original cells, NXS2 cells are not fully autologous on 
A/J nor on C57Bl/6 background and therefore not suitable to study T cell 
responses. We have developed a fully autologous NBL model endogenously 
expressing GD2. We show that GD2 is dynamically expressed by 9464D cells 
in vitro and 9464D derived tumors in vivo. Although the expression levels of 
GD2 by the murine NBL cells appear lower than their human counterparts, 
we have shown that anti-GD2 mAb can induce relevant levels of ADCC in 
vitro and also mediate a significant reduction in tumor growth in a therapeu-
tic setting in vivo. We observed diminished GD2 expression on tumor cells 
ex vivo following anti-GD2 therapy. This could be explained by GD2 specific 
immune mediated elimination of tumor cells expressing significantly high 
amounts of GD2. As an alternative explanation GD2 antigen loss variants 
may grow out. This latter explanation seems less likely, however, as we have 
shown that the GD2 negative cells readily start to re-express GD2 in vitro. 
These data imply that the 9464D NBL model is a stringent model for im-
munotherapy further showing its relevance for human NBL. It also opens up 
opportunities to further explore novel anti-GD2 mAb therapy with additional 
immune activation strategies or targeted therapies.
The transplantable autologous model using 9464D cells in C57Bl/6 mice 
presents a novel tool to develop novel immunotherapeutic approaches 
including improved anti-GD2 directed therapies. The combination of both 
genetic and immunological NBL properties in this model allows for the rapid 
discovery of relevant novel combination therapies for NBL. The mechanisms 
of novel effective therapies found in this model can be rapidly dissected 
because of the availability of multiple gene–deficient mice on the C57Bl/6 
background. Knowing the mechanism of an effective therapy may result in 
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faster translation of novel therapies to the clinic, since the same mechanisms 
can be pursued in patients. In conclusion, our investigations provide the 
basis for testing novel immunotherapeutic or immuno-combinational strate-
gies in a novel immunologic relevant model.
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supplementary figure 1: (A) GD2 is expressed by 9464D cells. Cytospins were per-
formed using 9464D and Neuro-2a cells and stained by immunofl uorescence using anti-
GD2-Cy5 (green) or isotype control mAb. (B) GD2 is dynamically expressed by 9464D 
cells. 9464D cells were sorted for high GD2 expression. Sorted cells were taken into cul-
ture and after each passage GD2 expression was determined. Grey shadings = isotype 
control, black lines = specifi c staining.
PD-L2MHCII
9464D
supplementary figure 2: Surface expression of MHC class II and PD-L2 by 9464D 
cells. Cells were either cultured with medium alone or in the presence of TNF-α (25 ng/
mL) and IFN-γ (20 ng/mL) for 48 hours and then analyzed. Cells were analyzed by fl ow-
cytometry using specifi c antibodies or the appropriate isotype controls. Grey shadings = 
isotype control, black lines = specifi c stainings.
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supplementary figure 3: Injection of isotype control Ab does not infl uence tumor 
growth. WT non-injected mice, isotype control injected mice or mice depleted for NK1.1+ 
cells were inoculated with 1 * 106 9464D cells s.c. on the right fl ank. Tumor growth was 
measured every 3-4 days using calipers and mean tumor volume was calculated. Tumor 
growth curves for WT non-injected and isotype injected mice largely overlap.
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supplementary figure 4: Anti-GD2 mAb have no direct effect on tumor cell viability. 
9464D cells were cultured in the presence of increasing concentrations of anti-GD2 
mAb. After 36 hours of culture a standard MTT viability assay was performed. Viability 
was determined as percentage of metabolic activity to control 9464D cells.
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abstract
In around half of the patients with neuroblastoma (NBL) the primary tumor is 
located in one of the adrenal glands. We have previously reported on a trans-
plantable TH-MYCN model of subcutaneous (SC) growing NBL in C57Bl/6 mice 
for immunological studies. In this report, we describe an orthotopic TH-MYCN 
transplantable model where the tumor cells were injected intra-adrenal (IA) 
by microsurgery. Strikingly, 9464D cells grew out much faster in IA tumors 
compared to the subcutis. Tumors were infiltrated by equal numbers of 
lymphocytes and myeloid cells. Within the myeloid cell population, however, 
tumor infiltrating macrophages were more abundant in IA tumors compared 
to SC tumors and expressed lower levels of MHC class II, indicative of a more 
immune suppressive phenotype. Using 9464D cells stably expressing firefly 
luciferase, enhanced IA tumor growth could be confirmed using biolumines-
cence. Collectively, these data show that the orthotopic IA localization of 
TH-MYCN cells impacts the NBL tumor microenvironment, resulting in a more 
stringent NBL model to study novel immunotherapeutic approaches for NBL.
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introDuction
Neuroblastoma (NBL) is an aggressive malignancy of childhood with a dismal 
prognosis in high-risk patients. NBL arises from any of the parasympathetic 
nervous tissues in the body. In around half of patients the primary tumor 
is located in one of the adrenal glands1. In a recent phase III trial, im-
munotherapy was added to the current standard therapy regimen, which 
consists of chemotherapy, surgery, radiation therapy and autologous stem 
cell transplantation followed by retinoic acid treatment2. The addition of this 
immunotherapy regimen to the standard treatment resulted in an improved 
survival of these high risk NBL patients. However, since around half of these 
patients eventually did show progressive disease, a clear need remains to 
improve (immuno)therapy regimens for the treatment of NBL.
Most tumors are highly infi ltrated by cells of the immune system exert-
ing either pro- or anti-tumor effects, depending on cell type and activation 
status3. In established tumors, however, there is a state of chronic infl amma-
tion, paradoxically resulting in local immune suppression4, 5. Regulatory im-
mune cell subsets are actively attracted to the tumor that interact with each 
other and create an immune suppressive microenvironment6. For example, 
M2 macrophages infi ltrating tumors can actively suppress anti-tumor im-
mune responses via the production of anti-infl ammatory cytokines7, 8. In NBL 
tumors, the presence of tumor associated macrophages was shown to be an 
independent prognostic factor associated with an adverse prognosis8. The im-
mune suppressive environment also contributes to progressive or recurrent 
disease during or after immunotherapy. Counteracting the tumor-induced 
immune suppression therefore is an important step in improving cancer im-
munotherapy9. To achieve this, there is a need for a more comprehensive 
understanding of the mechanisms involved in the process of tumor induced 
immune suppression. To get a better understanding of the immune suppres-
sive environment of NBL tumors and to fi nd novel ways to counteract the 
local immune suppression, relevant preclinical tumor models are needed10.
Genomic amplifi cation of the proto-oncogene MYCN is consistently as-
sociated with a poor prognosis and occurs in around 20% of primary NBL 
tumors11. The TH-MYCN transgenic mouse model of NBL is driven by the over 
expression of MYCN in the developing sympathetic nervous system, eventu-
ally resulting in paraspinous NBL12. In our transplantable model we inject 
the tumor cells into the adrenal gland, which is a different location than the 
tumors arising in the TH-MYCN transgenic, but more like in human adrenal 
NBL13. The spontaneous arising NBL tumors in the TH-MYCN model are very 
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similar to high risk human NBL with respect to tumor histology and genet-
ics14, 15. Cell lines were derived from NBL tumors that arose in transgenic 
TH-MYCN mice. Transplantation of these cell lines in syngeneic mice also re-
sulted in NBL tumors with similar histology and genetics compared to human 
NBL16, 17. We recently set up and described such a transplantable TH-MYCN 
model by transplanting the TH-MYCN derived NBL cell line 9464D in C57Bl/6 
mice18. In these studies, we found that the immunological properties of the 
transplantable TH-MYCN model were similar to those of high-risk human 
NBL, rendering this model a powerful tool in the pre-clinical development of 
novel immunotherapies for NBL19.
In our previous studies, the TH-MYCN 9464D NBL cells were injected sub-
cutaneous (SC), allowing for external measurement of tumor growth18. In 
this study, we established an orthotopic transplantable TH-MYCN model us-
ing 9464D NBL cells and a luciferase expressing 9464D variant. Interestingly, 
the orthotopic intra-adrenal (IA) NBL tumors grew out much faster compared 
to SC NBL tumors and were more heavily infiltrated by macrophages exhibit-
ing an immunosuppressive M2 phenotype. We conclude that this orthotopic 
transplantable TH-MYCN model represents a highly relevant model to develop 
and understand the mechanisms of novel immunotherapies for NBL.
materials anD methoDs
animals and cell lines
6-8 weeks old female C57Bl/6J wild-type (WT) mice were purchased from 
Charles River. Animals were held under specified pathogen-free conditions 
in the Central Animal Laboratory (Nijmegen, The Netherlands). All experi-
ments were performed according to the guidelines for animal care of the 
Nijmegen Animal Experiments Committee. The transgenic cell line 9464D 
was derived from spontaneous tumors from TH-MYCN transgenic mice on 
C57Bl/6 background and was a kind gift from Dr. Orentas (NIH, Bethesda). 
9464D, cells were cultured in Dulbecco’s modified Eagle medium (DMEM) 
containing 10% fetal calf serum (FCS), 1% non–essential amino acids, 1.0% 
amino acids (AA) and and 0.05% β-mercaptoethanol (medium). 9464D-luc 
cells were generated as described below and cultured in medium containing 
G418 (200 ng/mL).
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generation of 9464D-luciferase (9464D-luc) clone
9464D cells were transfected with a construct containing a Green Fluorescent 
Protein (GFP)-Ires-Luciferase sequence under the control of a cytomega-
lovirus (CMV) promoter. Stably transfected 9464D cells were selected by 
adding increasing amounts of G418 to the medium to a fi nal concentration 
of 200 ng/mL. GFP-positive cells were FACsorted and plated as single cells 
in 96-well plates. GFP-positive clones were expanded and selected for stable 
transfection by monitoring GFP-positivity by FACS. Luciferase expression was 
determined using a luciferase reporter assay; 1 * 105 cells were lysed in 100 
μl Passive Lysis Buffer (Promega) and the lysates were analyzed for lumines-
cence with the use of the Dual-luciferase Reporter Assay System (Promega, 
Leiden, the Netherlands) according to manufacturer’s protocol and a Victor 
3 luminometer (PerkinElmer, Groningen, the Netherlands). Several stably 
transfected clones were expanded, tested for cell surface marker expression 
and frozen for later use.
subcutaneous and intra-adrenal injection of 9464D and 
9464D-luc cells
To compare subcutaneous and intra-adrenal tumor growth, 1 * 106 9464D 
or 9464D-luc cells from the same batch were injected either subcutaneous 
or intra-adrenal. Viability of tumor cells before injection was determined by 
Tryptan Blue staining and always exceeded 95%. For intra-adrenal injec-
tions, microsurgery was performed by a skilled biotechnician. Institutional 
protocols and guidelines were adhered to for the delivery of anesthesia and 
analgesia. Briefl y, a dorsal incision was made right lateral to the spinal cord 
and the retroperitoneum was accessed. The kidney and adrenal gland were 
located and using a 0,3 mL Becton Dickinson (BD) Micro-FineTM needle, 1 * 
106 9464D or 9464D-luc cells were injected in a volume of 30 μl into the ad-
renal gland. Using sutures the retroperitoneum and skin were closed. Within 
7 days sutures could be removed and wounds were fully healed without any 
signs of infl ammation.
monitoring tumor growth by bioluminescence
Tumor growth of 9464D-luc tumors at subcutaneous and adrenal sites was 
monitored in time. To prevent blockage of light by the black fur, the mice were 
shaved before each measurement. Mice were injected intraperitoneal with 
150 μg D-Luciferin (PerkinElmer, Massachusetts, USA) in 200 μl phophate 
buffered saline (PBS) and anaesthetized using isofl urane. 10 minutes after 
injection of D-Luciferin, mice were imaged using an in vivo imaging system 
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(IVIS) Lumina (Xenogen, Almeda, CA, USA) camera by taking consecutive 10 
sec to 2 min imaging frames.
generation of single-cell suspensions of tumors
Tumors were excised on indicated time points and mechanically dissociated 
using large needles followed by enzymatic digestion with 1 mg/ml collage-
nase Type III (Worthington) and 30 μg/ml DNAse type I (Roche) for 1 hour 
at 37°C. After 1 hour ethylenediaminetetraacetic acid (EDTA) was added (1,5 
mM final concentration) and single cell suspensions were made by passing 
the tumor fragments over 100 μm cell strainers.
Antibodies and flow cytometry
For flow cytometric analysis, the directly labeled mAbs used were CD11b-
PerCP (M1/70), CD4-APC-Cy7 (L3T4), Ly-6G-PE-Cy7 (1A8), from Biolegend, 
CD45.2-FITC (104), CD11c-APC (HL3), NK1.1-PE (PK136), Ly-6C-APC-Cy7 
(AL-21) and CD3-PE (145-2C11) from BD, MHC II-PE (M5/114.15.2) from 
eBioscience, Cells for staining were washed in PBS and incubated with Fix-
able Viability Dye eFluor 780 (eBioscience). Cells were resuspended in ice 
cold PBA and transferred to a V-bottom 96-wells plate. After incubation for 
30 minutes with PBA containing anti-CD16/CD32 Fc-block (BD), cells were 
stained using specific monoclonal antibodies or the appropriate isotype con-
trols for a period of 30 minutes. Cells were washed in PBA and measured on 
a Cyan apparatus (BD) and analyzed using Summit software.
statistics
Data were analyzed using Graphpad 5.0 software. Data are presented as 
means +- standard error of the mean (SEM). An unpaired T-test (confidence 
intervals 95%) was used to determine significant differences between two 
groups. Correlation between tumor weight and bioluminescent signal was 
determined using a Pearson correlation test (confidence intervals 95%).
results
9464D tumors grow out faster in the adrenal gland compared 
to the subcutis
We determined tumor growth of 9464D NBL cells at SC and IA sites. A sig-
nificant difference in tumor weight between SC and IA tumors was readily 
observed at day 20 post-inoculation (Fig. 1A). Isolation of tumors at day 
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35 revealed that IA tumors were again signifi cantly larger compared to SC 
tumors (Fig. 1A). IA tumors grew out aggressively, thereby completely de-
structing the adrenal gland, as was evident at necropsy (Fig. 1B). Similar to 
human NBL and to previous reports of TH-MYCN transgenic tumor models17, 
20, 21, the 9464D tumors were hyper vascular already on macroscopic exami-
nation (Fig 1B). These data show that 9464D tumors grow out faster in the 
adrenal gland compared to the subcutis.
Adrenal tumors are inﬁ ltrated by myeloid cells having a more 
immune suppressive phenotype
Next, we compared immune infi ltration of IA tumors harvested on day 20 
with SC tumors harvested on day 35. Tumors harvested at these time points 
showed comparable tumor weight averages of 624,8 (+/- 357,8 SEM) and 
557,0 (+/- 143,8 SEM) mg (p= 0,86), respectively. Tumors growing at 
both anatomical sites were equally infi ltrated by CD45.2+ tumor infi ltrating 
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figure 1: 9464D NBL tumors grow faster in the adrenal gland compared to the sub-
cutis. (A) Tumor weights of SC and IA 9464D tumors harvested on day 20 and day 35 
were compared (*p< 0,05; **p< 0,01). (B) Tumors grow out and destruct the adrenal 
gland as shown by necropsy.
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leukocytes (TIL); the percentage of CD45.2+ TIL of the total tumor cell 
suspension was around 20% for both anatomical locations (Fig. 2A). The 
amounts of CD11b+ myeloid cells, CD3+CD4+ and CD3+CD8+ T cells as 
well as CD3-NK1.1+ natural killer (NK) cells within the CD45.2+ TIL were 
also similar for SC and IA tumors (Fig 2B). Similar to our previous observa-
tions18, the largest population of tumor infi ltrating leukocytes at both tumor 
locations were CD11b+ myeloid cells, making up around 80% of all CD45.2+ 
TIL (Fig. 2B). Using mAb directed towards the cell surface markers CD11c, 
Ly-6C, Ly-6G and MHC class II (MHCII), we were able to identify some of 
the major myeloid cell subsets (Fig. 2C). We observed several alterations in 
the distribution of these myeloid cell populations (Fig. 2D). In IA tumors, 
CD11cintLy-6C-Ly-6G-MHCIIint cells having a phenotype consistent with mac-
rophages were signifi cantly increased compared to SC tumors (Fig. 2D). 
The percentages of CD11chighLy-6C-Ly-6G-MHCIIhigh dendritic cells (DC) were 
decreased in IA tumors compared to SC tumors. Also, CD11c-Ly-6ChighLy-
6G-MHCIIlow cells having a phenotype consistent with monocytic myeloid 
derived suppressor cells (M-MDSC) were decreased in IA tumors compared 
to SC tumors. In contrast, the CD11c-Ly-6CdimLy-6GhighMHCIIlow cells having 
a phenotype consistent with granulocytic myeloid derived suppressor cells 
(G-MDSC) were increased in IA tumors compared to SC tumors (Fig. 2D). 
To further determine the phenotype of these tumor infi ltrating macrophages 
in SC and IA tumors the surface expression of MHCII on these cells was 
determined (Fig. 2D). The expression levels of MHCII on DC, M-MDSC and 
G-MDSC in IA and SC tumors, however, were not altered. In contrast, tumor 
infi ltrating macrophages in IA tumors expressed signifi cantly lower levels of 
figure 2: Intra-adrenal NBL tumors are higher infi ltrated by macrophages expressing 
lower levels of MHCII. (A) Leukocyte infi ltrating is similar for SC and IA tumors. Percent-
ages of CD45.2+ TIL of life gated total tumor cells are depicted for SC and IA tumors. 
(B) The distribution of immune cell types within the TIL was similar for SC and IA tu-
mors. CD45.2+ TIL were gated and analyzed for the expression of CD11b, CD3, CD4, 
CD8 and NK1.1. Percentages of CD11b+ myeloid cells, CD3+CD4+ & CD3+CD8+ T cells 
and CD3-NK1.1+ NK cells are depicted for SC and IA tumors. (C, D) The distribution 
of myeloid cell subsets within total CD11b+ myeloid cells is altered between SC and IA 
tumors. CD45.2+CD11b+ tumor infi ltrating myeloid cells were gated and analyzed for 
the expression of CD11c, Ly-6C, Ly-6G and MHCII. Percentages of CD11cintLy-6C-Ly-6G- 
macrophages, CD11chighLy-6C-Ly-6G- dendritic cells, CD11c-Ly-6ChighLy-6G- M-MDSC and 
CD11c-Ly-6CdimLy-6Ghigh G-MDSC are depicted for SC and IA tumors. (*p< 0,05; ***p< 
0,001) (E) Macrophages express lower levels of MHCII in IA tumors compared to SC 
tumors. MFI’s of MHCII on previously gated myeloid cell subsets are depicted for SC and 
IA tumors (**p< 0,01).
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MHCII compared to macrophages infiltrating SC tumors, suggesting a more 
M2 phenotype (Fig. 2E).
Upon analysis of IA NBL tumors harvested at day 35, these ‘late-stage’ 
IA tumors were equally infiltrated by CD45.2+ TIL, compared to the ‘early-
stage’ day 20 IA tumors (Fig. 3A). Within the CD45.2+ TIL, infiltration of 
CD11b+ myeloid cells, CD3+CD4+ & CD3+CD8+ T cells and CD3-NK1.1+ 
NK cells was also similar between ‘late-stage’ and ‘early-stage’ IA tumors 
(Fig. 3B). Upon analysis of the CD45.2+CD11b+ myeloid cells, however, the 
presence of macrophages was reduced, while cells having a phenotype of 
M-MDSC were significantly increased in late-stage compared to early-stage 
IA tumors (Fig. 3C). Interestingly, while the tumor infiltrating macrophages 
expressed similar low levels of MHCII, the more abundant M-MDSC now also 
showed a significant reduction in the expression of MHCII (Fig. 3D).
orthotopic 9464D tumors can be monitored semi-
quantitatively using bioluminescence
9464D-luc cells were generated, which were stably bioluminescent in lu-
ciferase assays and expressed equal levels of immune related cell surface 
molecules MHC class I, retinoic acid early transcript 1 (Rae1), programmed 
death ligand 1 (PD-L1) and the tumor antigen GD2 in vitro compared to 
the parental 9464D cell line (Suppl. Fig. 1)18. Following an initial plateau 
phase, an exponential increase of bioluminescent signal was observed for 
both SC and IA 9464D-luc tumors in time (Fig. 4 A&B). Similar to the pa-
rental 9464D tumors, we observed a significant growth difference between 
SC and IA 9464D-luc tumors (Fig. 4C). There was a significant correlation 
between tumor size and the corresponding bioluminescent signal, showing 
semi-quantitative measurement of tumor size was feasible for both SC and 
IA tumors (Fig. 4D). The correlation between NBL tumor weight and the bio-
luminescent signal for IA growing tumors was confirmed in an independent 
experiment (Fig 4E). We observed around 15% CD45.2+ TIL in IA 9464D-
luc tumors, similar to parental 9464D tumors (Suppl. Fig. 2A and Fig. 2A). 
IA 9464D-luc tumors were also highly infiltrated by CD11b+ myeloid cells 
(Suppl. Fig. 2B). Within the tumor infiltrating CD45.2+CD11b+ myeloid frac-
tion, similar myeloid cell subset presence and distribution compared to the 
IA growing parental 9464D tumors was observed (Suppl. Fig. 2C).
In conclusion, IA 9464D NBL tumors have a distinct, more immune suppres-
sive tumor microenvironment and can be monitored using bioluminescence.
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figure 3: Late-stage adrenal tumors are higher infi ltrated by M-MDSC expressing lower 
levels of MHCII. (A) Percentage of tumor infi ltrating leukocytes (TIL) is similar for day 
20 (d20) and day 35 (d35) intra-adrenal (IA) tumors. Percentages of CD45.2+ TIL of 
life gated cells are depicted for d20 and d35 IA tumors. (B) The distribution of immune 
cell types within the TIL was similar for d20 and d35 IA adrenal tumors. Percentages of 
CD11b+ myeloid cells, CD3+CD4+ & CD3+CD8+ T cells and CD3-NK1.1+ NK cells are 
depicted for d20 and d35 IA tumors. (C) The distribution of myeloid cell subset within 
total CD11b+ myeloid cells is altered between d20 and d35 IA tumors. CD45.2+CD11b+ 
tumor infi ltrating myeloid cells were gated and analyzed for the expression of CD11c, 
Ly-6C, Ly-6G and MHCII. Percentages of CD11cintLy-6C-Ly-6G- macrophages, CD11chigh-
Ly-6C-Ly-6G- dendritic cells, CD11c-Ly-6ChighLy-6G- M-MDSC and CD11c-Ly-6CdimLy-
6Ghigh G-MDSC are depicted for d20 and d35 IA tumors (***p< 0,001). (D) M-MDSC in 
late-stage adrenal tumors express lower levels of MHCII. CD45.2+CD11b+ myeloid cells 
subsets were analyzed for the expression of MHCII. MFI’s of MHCII on these cell types 
is depicted for d20 and d35 IA tumors (*p< 0,05).
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Discussion
In this report we describe an orthotopic model of NBL using TH-MYCN trans-
genic NBL cells. We observed that IA 9464D NBL tumors grew faster compared 
to SC tumors. IA NBL tumors were more heavily infi ltrated by macrophages 
expressing low levels of MHC class II, suggesting a more immune suppres-
sive microenvironment. Using luciferase transfected NBL cells, it was feasible 
to monitor tumor growth in the adrenal gland in a semi-quantitative manner 
by measuring the bioluminescence.
In previous studies, orthotopic tumors were shown to resemble the tumor 
biology of human tumors more closely than ectopic tumors22, 23. The local tu-
mor microenvironment can infl uence both tumor cell biology as well as tumor 
cell invasion or metastasis and even therapy responses23-29. For example, 
injection of syngeneic pancreatic adenocarcinoma cells in the pancreas 
resulted in enhanced tumor growth compared to subcutaneous sites and 
differential expression of the tumor antigen Muc130. Our data also show that 
orthotopic NBL tumors growing in the adrenal gland have a different growth 
pattern and immune infi ltration compared to ectopic growing NBL tumors. 
A plausible explanation for the faster 9464D NBL growth at orthotopic sites 
is the induction of a more immune suppressive environment. We observed 
marked alterations in myeloid cell subsets and phenotype between SC and 
IA tumors of similar size. The most striking fi nding was that IA tumors were 
more densely infi ltrated with macrophages expressing low levels of MHC 
Class II, suggesting a more M2-like macrophage phenotype. Asgharzadeh 
et al. showed that the infi ltration of M2 like macrophages in disseminated 
NBL tumors was associated with an adverse prognosis8. Therefore our data 
suggest that the local environment in IA NBL tumors is more immune sup-
pressive, resulting in more aggressive tumor growth.
These data are in agreement with data from Carlson et al, showing that 
tumor infi ltrating macrophages acquire a more M2 phenotype in sponta-
figure 4: Orthotopic 9464D-luc tumors show similar enhanced tumor growth and can 
be monitored semi-quantitatively using bioluminesence. (A,B) SC and IA 9464D-luc tu-
mors were monitored in time using bioluminescence (6 mice / group, two mice in the SC 
group were excluded from the analysis due to skin ulcerations). (C) On day 32 post-in-
oculation tumor weights of SC and IA 9464D-luc were compared. (*p< 0,05) (D) Tumor 
weight ex-vivo signifi cantly correlates with the bioluminescent signal in vivo (Pearson 
r = 0,90; p = 0,049 for SC tumors, Pearson r = 0,97; p = 0,0034 for IA tumors). (E) 
Adrenal tumor weight ex vivo signifi cantly correlates with the bioluminescent signal in 
vivo in a separate experiment (11 mice) (Pearson r= 0,88; p= 0,003).
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neous TH-MYCN transgenic tumors31. Thus, the immune infiltration in our 
orthotopic transplantable TH-MYCN model shows high similarity with the im-
mune infiltration observed in NBL tumors in the original TH-MYCN transgenic 
mouse. NBL tumors in these TH-MYCN transgenic mice, however, arise in a 
stochastic fashion after a latent period. Tumor growth can be controlled more 
easily using the transplantable TH-MYCN model presented here. This model 
therefore allows for faster screening of novel therapies for NBL.
In most orthotopic tumor models, as in our orthotopic TH-MYCN model, 
it was not feasible to monitor tumor growth via external measurements. 
For this purpose, we generated a stably transfected clone of 9464D cells 
expressing firefly luciferase. Using this 9464D-luc cell line, we were able to 
monitor growth of SC and IA tumors. Tumor size and bioluminescent signals 
significantly correlated, suggesting semi-quantitative monitoring of tumor 
growth was feasible. The observed correlation between tumor size and biolu-
minescent signal also suggests that the NBL tumors are not highly necrotic, 
as extensive tumor necrosis was shown to result in a loss of correlation 
between tumor size and bioluminescent signal32. The black fur of C57Bl/6 
mice can significantly block the light coming from the tumor. Shaving of the 
skin at the imaged areas was therefore performed to prevent loss of signal. 
In SC tumors the bioluminescent signal was higher compared to IA tumors, 
most likely as a result of the more superficial location of the subcutaneous 
tumors. One drawback of using bioluminescence in an immunological model 
is the introduction of potential novel tumor antigens. The 9464D-luc cells 
not only expressed firefly luciferase, but also GFP as a reporter protein. Both 
luciferase and GFP are foreign proteins in the mouse and can be recognized 
by the host immune system. This potentially increases the immunogenicity 
of the tumor cells resulting in a more immunogenic tumor model. Therefore, 
effective novel immune therapeutics in the 9646-luc model are preferentially 
also tested in the parental 9464D model and/or the spontaneous TH-MYCN 
transgenic mouse model.
In summary, IA 9464D NBL tumors grow faster and are infiltrated by 
myeloid cells having a more immune suppressive phenotype compared to 
SC NBL tumors. The feasibility of using bioluminescence allows for careful 
monitoring of the effect of novel therapies on tumor growth. We conclude 
that this orthotopic transplantable TH-MYCN model is a relevant model to 
study multiple aspects of the immunobiology of NBL and to develop novel 
(immuno)therapeutics for NBL.
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supplementary figure 1: 9464D-luc cells express relevant immune related surface 
molecules. 9464D-luc cells express low levels of MHCI and PD-L1 and highly express 
Rae1 and GD2 as determined by fl ow cytometry. Grey shading= isotype control, Black 
line= specifi c staining
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supplementary figure 2: Immune infi ltration of 9464D-luc tumors. (A) Percentages 
of tumor infi ltrating leukocytes (TIL) in intra-adrenal (IA) 9464D-luc tumors. Total tu-
mor cells in suspension were analyzed for the presence of CD45.2+ TIL. Percentages 
of CD45.2+ TIL of life gated cells are depicted. (B) Distribution of immune cell types 
within IA 9464D-luc tumors. CD45.2+ TIL were gated and analyzed for the expression 
of CD11b, CD3, CD4, CD8 and NK1.1. Percentages of CD11b+ myeloid cells, CD3+CD4+ 
& CD3+CD8+ T cells and CD3-NK1.1+ NK cells are depicted. (C) The distribution of 
myeloid cell subsets within total CD45.2+CD11b+ myeloid cells in IA 9464D-luc tumors. 
CD45.2+CD11b+ tumor infi ltrating myeloid cells were gated and analyzed for the ex-
pression of CD11c, Ly-6C, Ly-6G and MHCII. Percentages of CD11cintLy-6C-Ly-6G- mac-
rophages, CD11chighLy-6C-Ly-6G- dendritic cells, CD11c-Ly-6ChighLy-6G- M-MDSC and 
CD11c-Ly- 6CdimLy-6Ghigh G-MDSC are depicted.
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abstract
purpose: Neuroblastoma (NBL) is a childhood malignancy of the sympa-
thetic nervous system. For high-risk NBL patients the mortality rate is still 
over 50 percent, despite intensive multimodal treatment. Anti-GD2 monoclo-
nal antibody (mAb) in combination with systemic cytokine immunotherapy 
has shown clinical efficacy in these patients. Targeted therapy using histone 
deacetylase inhibitors (HDACi) is currently explored in cancer treatment, 
already showing promising results.
experimental design: Viability and surface expression of Mycn-transgenic 
NBL cells was determined upon exposure to HDACi. Combinatorial treatment 
using anti-GD2 mAb and the HDACi Vorinostat was tested in a novel trans-
plantable model of NBL. Following Vorinostat treatment, tumor infiltrating 
immune cells were analyzed by FACS, immunohistochemistry and RT-qPCR.
results: The HDACi Vorinostat synergized with anti-GD2 mAb therapy in 
reducing NBL tumor growth. Multiple mechanisms for this synergy were 
uncovered, including Vorinostat-induced specific NBL cell death and upregu-
lation of the tumor antigen GD2 on NBL cells in vivo. Furthermore, Vorinostat 
created a permissive tumor microenvironment by increasing macrophage 
effector cells expressing high levels of activating Fc-receptors. Moreover, 
the number of myeloid-derived suppressor cells is strongly decreased in 
Vorinostat treated tumors as well as the expression of immunosuppressive 
genes, like Arginase.
conclusions: We concluded that anti-GD2 mAb plus Vorinostat combina-
tion therapy mediates synergistic anti-NBL effects through novel effects of 
Vorinostat on tumor and immune cells in vivo. Collectively, these data imply 
further testing of epigenetic modulators with immunotherapy and provide a 
rationale for clinical testing of anti-GD2 plus Vorinostat combination therapy 
in NBL patients.
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introDuction
Neuroblastoma (NBL) is a childhood malignancy of the sympathetic nervous 
system accounting for 12% of cancer-associated deaths in children under 15 
years of age1. Patients with high risk NBL, including MYCN-amplifi ed NBL, 
have a poor long term survival despite intensive multimodal treatment2. 
In a recent phase III clinical trial, immunotherapy improved the event-free 
survival of high risk NBL patients by around 20%3. The immunotherapy in 
this trial consisted of a tumor specifi c monoclonal antibody (mAb) directed 
towards the tumor antigen GD2 in combination with administration of im-
mune stimulating cytokines IL-2 and GM-CSF. Fc-receptor (FcR) expressing 
immune cells, including natural killer (NK) cells, granulocytes and recently 
also other myeloid cells, have been implicated as the effector cells in the 
clinical response following anti-GD2 mAb4,5. However, despite the observed 
clinical benefi t using immunotherapy, still about half of the patients show 
progressive disease. Therefore, further improvement of NBL treatment is 
needed to increase the survival of these pediatric patients.
One approach to improve NBL treatment effi cacy is to combine anti-GD2 
mAb immunotherapy with tumor-targeted therapy. The ultimate goal of 
such an immunocombination therapy is to induce and boost potent anti-
tumor immunity and to counteract tumor induced immune suppression, as 
reviewed in6. An emerging tumor-targeting therapy involves the use of 
histone deacetylase inhibitors (HDACi) as epigenetic modulators to eliminate 
and modulate tumor cells7. HDAC inhibition results in increased acetylation 
of histone proteins leading to changes in gene expression8. HDACi target 
multiple cellular processes simultaneously and also impact normal cells, al-
though tumor cells appear much more sensitive9. Specifi cally in cancer cells, 
the altered gene expression leads to activation of and sensitization to intrin-
sic and extrinsic apoptosis pathways10. Besides targeting histone proteins, 
HDACi also induce hyperacetylation of pro-apoptotic cytosolic proteins like 
p53, thereby also inducing tumor cell death11. The classical HDACi block the 
function of one or more of the 11 classical zinc-containing HDAC enzymes. 
Among the zinc-containing HDACs are the Class-I HDAC (HDAC 1,2,3, and 
8) and Class-II HDAC (HDAC 4,5,6,7,9,10) enzymes12. Class specifi c HDACi 
inhibit HDAC from either Class, while panHDACi inhibit HDACs from both 
Class I and II. Various panHDACi are currently in phase I-III trials for the 
treatment of cancer13,14.
To design novel strategies that combine immunotherapy with tumor 
targeted therapies, we generated a transplantable autologous NBL model 
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derived from the TH-MYCN transgenic mouse. The MYCN proto-oncogene is 
frequently amplified on the genomic level in NBL, a phenomenon associated 
with an adverse prognosis15,16. The TH-MYCN transgenic mouse model is 
driven by over expression of N-Myc in developing sympathetic nervous cells 
and closely resembles high risk human NBL17,18. Using our transplantable 
TH-MYCN model in C57Bl/6 mice, we found that the immunobiology of this 
model was highly similar to human NBL, including endogenous expression 
of the tumor surface antigen GD219. Moreover, similar to NBL in patients, 
the NBL tumors arising in the TH-MYCN NBL model were highly infiltrated 
by myeloid cells, including macrophages and myeloid-derived suppressor 
cells (MDSC)19-21, suggestive for an important role in NBL pathogenesis. 
Macrophages in tumors are generally classified as either anti-tumor M1 
or pro-tumor M2 macrophages22,23. MDSC are immature myeloid cells that 
accumulate in tumors and can mediate potent local and systemic immune 
suppression24.
In the current study, we report that anti-GD2 mAb therapy combined with 
the HDACi Vorinostat results in synergistic anti-tumor effects in this novel 
NBL mouse model. As part of the explanation of this synergy, we uncovered 
that TH-MYCN NBL cells were highly sensitive to HDACi mediated cell death, 
while surviving NBL cells upregulated the tumor antigen GD2. Furthermore, 
Vorinostat treatment altered the composition and function of myeloid cells in 
NBL tumors, resulting in myeloid cells expressing less immune suppressive 
genes and more activating FcR. Our study provides a rationale for clinical 
testing of GD2 mAb plus Vorinostat combination therapy in NBL patients.
materials anD methoDs
animals and cell lines
6-8 weeks old female C57Bl/6 wild-type (WT) mice held under specified 
pathogen-free conditions in the Central Animal Laboratory (Nijmegen, The 
Netherlands) were purchased from Charles River (Sulzfeld, Germany). All 
experiments were performed according to the guidelines for animal care of 
the Nijmegen Animal Experiments Committee. GL261 cells were provided 
by U. Herrlinger (Bonn, Germany) in 2006 and were not re-authenticated 
by the author. IMR-32, Neuro-2a, 3T3 and B16F10 cell lines were obtained 
from and authenticated by ATCC (CCL-127, CCL-131, CRL-1658, CRL-6475, 
respectively) (Manassas, VA). 9464D and 975A2 cells were derived from 
spontaneous tumors from TH-MYCN transgenic mice on C57Bl/6 background 
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and were a kind gift from Dr. Orentas in 2010 (NIH, Bethesda) and were 
authenticated by the author last in 2013 by qPCR using primers against 
NBL specifi c genes, including Mycn and GD2 synthase. All cell lines were 
initially grown and multiple aliquots were cryopreserved and used within 6 
months after resuscitation and tested for mycoplasma using a mycoplasma 
detection kit (Lonza, Basel, Switzerland). The hybridoma 14.g2a producing a 
mouse IgG2a mAb specifi c for GD2 was a kind gift from Dr. Reisfeld (Scripps, 
La Jolla). B16F10 cells were cultured in Minimal Essential Medium (MEM) 
containing 5% fetal bovine serum (FBS, Greiner Bio-one, Alphen a/d Rijn, 
the Netherlands), 1% non-essential amino acids (NEAA) (Invitrogen), 0.5% 
antibiotic-antimycotic (AA) (Gibco), 1% pyruvate (Gibco), 2% NaH2CO3 
(Gibco), 1.5% MEM Vitamins (Gibco) and 0.05% β-mercaptoethanol. GL261 
cells were cultured in Iscove’s Modifi ed Dulbecco’s Medium (IMDM) (Gibco) 
containing 10% FCS, 1% NEAA, 0.5% AA and 0.05% β-mercaptoethanol. 
Neuro-2a, IMR-32, 9464D, 975A2 and 3T3 cell lines were cultured in Dul-
becco’s modifi ed Eagle (DMEM) medium containing 10% FCS, 1% NEAA, 
0.5% AA and and 0.05% β-mercaptoethanol.
hDac inhibitors
HDACi were purchased from SelleckChem, Houston, USA. An HDAC1,2 spe-
cifi c HDACi was synthesized similar to compound 5a in25. The HDAC6 specifi c 
HDACi was synthesized similar to compound 7 in26. All HDACi were dissolved 
in DMSO to a fi nal concentration of 5 mM. For in vivo studies Vorinostat was 
dissolved in DMSO/PBS 50 mg/mL.
tumor induction
For induction of tumors, 1*106 9464D cells were injected s.c. in 50 μl PBS 
on the right fl ank of mice. Tumor cell viability before injection was >95%. As 
determined by Trypan Blue staining. Tumor growth was measured every 3-4 
days using calipers. Tumor volume was calculated with the formula: (A x B2) 
x 0.4 in which A is the largest and B is the shortest dimension.
anti-gD2 mab and vorinostat treatment in vivo
Anti-GD2/control treatment started on day 8 following tumor inoculation by 
i.p. injection of 200 μg mAb and was repeated twice weekly until day 43. 
Vorinostat treatment started on day 14 following tumor inoculation by inject-
ing 150 mg/kg Vorinostat or DMSO/PBS control i.p. for 3 consecutive days 
and was repeated every week until day 45.
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vorinostat treatment and single-cell suspensions
Mice bearing 9464D tumors of 300 - 600 mm3 were injected i.p. with 150 
mg/kg Vorinostat or DMSO/PBS for 3 consecutive days. Tumors excised one 
day following the last injection, were mechanically dissociated, and enzy-
matically digested with 1 mg/ml collagenase Type III (Worthington) and 30 
μg/ml DNAse type I (Roche) for 1 hour at 37°C. EDTA was added to 12.5 mM 
and fragments were passaged over 100 μm cell strainers. For GD2 staining 
ex vivo, cell suspensions were washed with PBS to decrease background 
staining.
Antibodies and flow cytometry
Anti-GD2 (clone 14.g2a) mAb was purified and filter sterilized in PBS. Total 
mouse IgG control Ab was obtained from Jackson Immunoresearch. Directly 
labeled mAbs used for staining were CD11b-A700 (M1/70), H-2Kb/H-2Db-
PE (28-8-2006), F4/80-PE-Cy7 (BM8), CD11c-PerCP (N418), CD4-PerCP 
(L3T4), Ly-6G-PE-Cy7 (1A8), CD64-PE (X54-5/7.1), CD16/CD32-A647 
(2.4G2), CD206-APC (MR5D3) from Biolegend, CD45.2-FITC (104), CD11c-
APC (HL3), NK1.1-PE (PK136), Ly-6C-PE (AL-21) and CD3-APC (145-2C11) 
from BD, MHC II-PE (M5/114.15.2) and FoxP3-PE-Cy7 (FJK-16s) from eBio-
science, CD8-A700 (53-6.7) from Exbio. Cells for staining were washed in 
PBS, incubated with Viability Dye eFluor 780 (eBioscience), resuspended in 
PBA, transferred to a V-bottom 96-wells plate and stained using specific mAb 
or the appropriate isotypes. Cells analyzed on a Cyan apparatus (Beckman 
Coulter) using Summit software.
cD45.2+ macs and facsort
Mice (18 mice/group) bearing 9464D tumors were treated i.p. with 150 
mg/kg Vorinostat or DMSO/PBS for 3 consecutive days. Tumors excised 
one day following the last injection and pooled single cell suspensions were 
resuspended in MACS buffer (1,5 mM EDTA, 1% FBS). Cells were passaged 
over a washed MACS Column (Miltenyi) to remove aggregates, followed by 
a CD45.2 MACS according to the manufacturer’s protocol. Purified cells were 
stained with anti-CD11b-A700 (M1/70) and CD45.2+CD11b+ cells were 
subsequently FACsorted to homogeneity on a FACS Aria (BD) with a typical 
purity of >98 percent.
Quantitative pcr
CD45.2+CD11b+ FACS-sorted cells were lysed and RNA was isolated and 
quantified by spectrophotometry. cDNA was synthesized using random prim-
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ers and Moloney murine leukemia virus Superscript Reverse Transcriptase 
(II-MMLV) (Invitrogen). Relative mRNA levels were determined with a Bio-
rad CFX96 cycler using the Fast Start SYBR Green Kit (Invitrogen). Intron 
spanning primers (Sigma-Aldrich) were designed and tested in our lab and 
are provided upon request Data were analyzed with Bio-rad CFX manager 
version 1.6 (Bio-rad) and checked for correct amplifi cation and dissociation 
of the PCR-products. PBGD and GUSB served as reference genes. mRNA 
expression was determined relative to PBGD expression using the formula: 
2 (CT index – CT PBGD).
mtt assay
Cells were seeded in fl at-bottom 96-well plates (Costar) at 5*103 cells/well 
and cultured overnight to adhere. HDACi were added to fi nal concentra-
tions of 32, 256, 2048, and 16348 nM. After 36h incubation, medium was 
refreshed and 10 µl MTT reagent (4mg/ml) (Sigma) was added in PBS. Plates 
were incubated for 2-4 h at 37°C after which supernatant was removed and 
100 µl lysis buffer (0.5% SDS, 4% HCl, and 3.5% Milli-Q in isopropanol) 
added. After 30 min. of incubation, absorbance was measured using an 
ELISA reader (Bio-Rad) at 595 nm. Metabolic activity versus control was 
calculated as (treatment – blank) / (control – blank) * 100%. Triplicate wells 
for each concentration were performed.
generation of nK/laK effector cells
NK/LAK cells were generated from splenocytes of naïve mice. A 10-mL syringe 
was fi lled with 1.2 gram of Nylon Wool (Polysciences) and sterilized. 5 spleens 
were collected from 6-8 weeks old naïve female C57Bl/6 WT mice and single 
cell suspensions were made by passage over a 100 μm cell strainer. Ery-lysis 
was performed using ACK-buffer and stopped with complete medium. The 
nylon wool ‘column’ was prepared using IMDM, containing 5% FCS, 1% AA, 
2 mM Glutamine and 0.05% β-mercaptoethanol (medium) for 1 hour at RT. 
Splenocytes were passaged over a nylon wool column and were plated at 
a density of 2.5 *106 cells/mL in medium containing 1000 IU/mL of human 
rIL-2. On day 3 and 6, non-adherent cells were washed away by extensive 
medium washings. On day 7 adherent cells were harvested using 1.5 mM 
EDTA. The harvested adherent cells were >90% NK1.1+NKp46+ cells, as 
determined by fl ow cytometry.
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generation of bone marrow Derived macrophages (bmDm)
Bone marrow cells were isolated from the femurs of 6-8 weeks old female 
C57Bl/6 WT mice. 4 * 106 bone marrow cells were cultured in a 10 cm2 pe-
tridish (Gibco) in medium supplemented with 20 ng/mL M-CSF (Peprotech). 
On day 3 and day 6, fresh M-CSF was added to the culture. When indicated, 
20 ng/mL IL-4 (Peprotech) was added on day 6 to the BMDM culture to obtain 
M2 BMDM. On day 7 the non-adherent cells were discarded and washed away 
and adherent cells were harvested using cold 1,5 mM EDTA for experimental 
use.
facs-based killing assay
9464D cells were incubated for 24 hours in the presence of 256 nM Vorino-
stat or control. 9464D (target) cells were harvested and labeled with 1 μM 
CFSE (Invitrogen) according to the manufacturer’s protocol. Labeled target 
cells were plated at 20.000 cells/well in a flat bottom 96-well plate. Target 
cells were pre-incubated with medium containing 10 μg/mL anti-GD2 mAb 
or isotype control for 1 hour at 4°C. Effector cells NK/LAK, BMDM or BMDM 
treated with IL-4 for 24 hours, were added in effector: target cell ratios of 
2:1, 4:1 and 6:1 for NK/LAK and 0,75:1, 1,5:1 and 3:1 for BMDM. After 
8 hours of co-culture, cells were harvested and stained with 7-AAD (BD) 
and Annexin-V-Cy5 (BD) according to the manufacturer’s protocol. Triplicate 
samples were analysed using a Cyan flow cytometer and the percentages of 
7-AAD+, Annexin-V+ and 7-AAD+Annexin-V+ of CFSE+ target cells were 
determined. Percentage specific killing was calculated using the formula: 
(percentage of total dead target cellstarget – percentage of total dead target 
cellscontrol) / (100- percentage of total dead target cellscontrol) x 100.
Immunohistofluorescence
Mice bearing established 9464D tumors were treated Vorinostat or DMSO/
PBS control after which tumors were excised and snap frozen. Cryo-sections 
were made and directly fixated in -20°C acetone. Sections were stained with 
anti-GD2-Cy5 mAb or isotype control mIgG2a-Cy5 (HOPC-1) for 1 hour at 
RT. Nuclear staining was performed using DAPI (Sigma) Sections were im-
aged using a Leica DM fluorescence microscope and analyzed using ImageJ 
software.
Western blot analysis
9464D cells were incubated for 24 hours with 0-2048nM Vorinostat and 
lysed in lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM TRIS pH 7.5 and 
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1% Triton X-100, 1x protease inhibitor cocktail). For western blot analysis, 
samples were separated on 8% SDS-PAGE resolving gels and transferred 
to PVDF membranes. Membranes were incubated overnight at 4 °C with 
primary anti-GD2-Synthase (Novus Biologicals, Littleton, CO) or anti-actin 
(Sigma-Aldrich, St. Louis, MO) antibodies in blocking buffer (1x PBS, 0.25% 
bovine serum albumin, 0.5% nonfat dry milk). After washing with PBS-T (1x 
PBS, 0.1% Tween-20), they were incubated with secondary IRDye 680LT-
conjugated polyclonal goat anti-rabbit IgG (H&L) antibody (LI-COR, Lincoln, 
NE) in blocking buffer 1 hour at RT. Membranes were washed thoroughly with 
PBS-T, scanned with an Odyssey infrared imaging system (LI-COR, Lincoln, 
NE) and band intensities were quantifi ed using ImageJ (NIH, Bethesda, MD).
statistics
Data were analyzed using Graphpad 5.0 software. An unpaired T-test was 
used to determine signifi cant differences between two groups. ANOVA test 
with a Bonferroni post test was used to determine signifi cant differences 
between three or more groups. IC50s were calculated by fi tting log (inhibi-
tor) – normalized response curves.
results
th-mycn nbl cells are highly sensitive to hDaci mediated 
cell death
To determine whether the murine TH-MYCN cell lines 9464D and 975A2 were 
sensitive to HDACi-mediated cell death, these cells were exposed to increas-
ing concentrations of various HDACi, after which viability was determined via 
standard MTT metabolic activity assays. For comparison, the MYCN-negative 
NBL Neuro-2a, the glioblastoma GL261 and the fi brosarcoma 3T3 cell lines 
were used. TH-MYCN Mycn-transgenic 9464D and 975A2 NBL cells, incubated 
with the panHDACi Vorinostat, Givinostat, Belinostat and PCI-24781, showed 
a signifi cantly stronger reduction in metabolic activity and hence in viability 
compared to the non-MYCN NBL cell line Neuro-2a and the other non-NBL 
cell lines GL261 and 3T3 (Fig. 1). Subsequent analysis revealed that the 
9464D and 975A2 NBL cells were also more sensitive for the Class-I specifi c 
HDACi Entinostat and a HDAC1,2 specifi c HDACi compared to the control cell 
lines (Fig. 1). In contrast, the Class-II HDACi Tubacin and a HDAC6 specifi c 
HDACi had little impact on either the TH-MYCN cells or the control tumor 
cell lines (Fig. 1). The half maximal inhibitory concentrations (IC50) for the 
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figure 1: Neuroblastoma cells are sensitive to HDACi-mediated cell death. (A) TH-
MYCN derived 9464D and 975A2 neuroblastoma cells, Neuro-2a neuroblastoma, GL261 
glioblastoma and 3T3 fi brosarcoma cells were incubated for 36 hours with 32, 256, 2048 
and 16384 nM of the indicated HDACi. Following a 36 hour incubation, standard MTT 
assays were performed, metabolic activity was compared to control treated cells and 
plotted in dose response curves (*p< 0,05 for 9464D or 975A2 vs. Neuro-2a or GL261 
or 3T3). Representative graphs of 3 independent experiments.
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different HDACi and cell lines tested are depicted in Suppl. Table 1. These 
IC50 values and 95% confi dence intervals demonstrated that the murine 
TH-MYCN NBL cells were highly sensitive to pan- and Class-I HDACi, relative 
to murine cancer cell lines from other origins and the non-MYCN NBL cell line 
Neuro-2a.
anti-gD2 mab plus vorinostat combination therapy is 
synergistic in reducing nbl growth
Next, we determined the effect of anti-GD2 mAb treatment alone or in com-
bination with HDACi treatment at stringent therapeutic conditions in vivo. 
We selected the panHDACi Vorinostat for these studies as it strongly reduced 
the viability of 9464D NBL cells and has entered phase I clinical trials in 
pediatric oncology patients, including NBL patients14 (www.clinicaltrials.gov). 
Mice bearing established 9464D NBL tumors were treated with anti-GD2 mAb 
or Vorinostat alone and with the combination of both. Anti-GD2 mAb mono-
therapy was initiated on day 8 following tumor inoculation and was repeated 
twice weekly until day 43. In this stringent therapeutic model, anti-GD2 
mAb treatment alone had no or very little impact on tumor growth relative 
to isotype control Ab (Fig. 2). Vorinostat treatment was initiated on day 14 
following tumor inoculation. I.p. injections of Vorinostat (150 mg/kg) were 
administered daily for 3 consecutive days and this treatment schedule was 
table 1: IC50’s (in nM) for the various HDACi and cell lines are depicted with correspond-
ing 95% confi dence intervals.
gl261 3t3 neuro-2a 9464D 975a2
vorinostat >16000 3535
(2175 – 5745)
1446
(882 – 2372)
608
(540 – 683)
657
(446 – 969)
givinostat >16000 5111
(3122 – 8368)
2426
(1603 – 3671)
1504
(1207 – 1874)
980
(753 – 1275)
belinostat >16000 627
(396 – 992)
579
(482 – 695)
84
(54 – 130)
58
(47 – 71)
pci-24781 >16000 363,7
(225 – 587)
406
(208 – 794)
138
(96 – 199)
89
(79 -102)
entinostat >16000 >16000 13453
(6941 – 26075)
2997
(2245 – 4000)
1001
(555 – 1804)
hDac1,2 >16000 587
(360 – 957)
408
(184 – 903)
468,5
(393 – 558)
194,8
(141 – 297)
tubacin 9362
(5416 – 16085)
7207
(4710 -11029)
4064
(6010 – 22358)
9710
(4222 – 22382)
2737
(2198 – 3408)
hDac6 >16000 9948
(4925 – 20093)
4807
(2182 – 10591)
10837
(3584 – 12652)
4099
(1830 – 6459)
Michel Kroesen - Binnenwerk V7.indd   135 05-08-15   10:36
chapter 6 | Anti-GD2 plus Vorinostat for Neuroblastoma
136
repeated weekly, until day 45. Vorinostat monotherapy caused a signifi cant 
reduction in tumor growth compared to PBS/DMSO control treatment (Fig. 2). 
Interestingly, the combination of Vorinostat plus anti-GD2 mAb therapy re-
sulted in a synergistic reduction of tumor growth in this therapeutic setting 
(Fig. 2). On day 45, the last day of the combination treatment, all (9/9) 
mice in the anti-GD2 plus Vorinostat combination group versus 4/9 mice in 
the Vorinostat monotherapy group were still alive. We concluded that the 
combination of anti-GD2 mAb based immunotherapy and targeted therapy 
using Vorinostat reduced NBL tumor growth in a synergistic manner.
0 5 10 15 20
0
500
1000
1500
2000
25 30 35 40 45 50
Isotype
Anti-GD2 mAb
Vorinostat
Anti-GD2 mAb + Vorinostat
Days post-inoculation
M
ea
n 
tu
m
or
 v
ol
um
e 
(m
m
3 )
*
#
* 9/9 alive
4/9 alive
figure 2: Anti-GD2 mAb and Vorinostat mediate synergistic anti-NBL effects in vivo. 
Mice were inoculated s.c. with 1*106 9464D cells on day 0. Anti-GD2 mAb therapy (200 
μg/mouse, i.p.) was initiated on day 8 and repeated twice weekly. Vorinostat treatment 
(150 mg/kg, i.p.) was initiated on day 14 and given for 3 consecutive days and this 
scheme was repeated weekly until day 45. Tumor growth was monitored and tumor 
volumes were calculated. Occasionally (< 5% of all mice), tumors caused skin ulceration 
which was randomly divided over the treatment groups; these mice were sacrifi ced and 
excluded from the analysis. Mean tumor volumes for each treatment group (9 mice/
group) are depicted (#p < 0,05 for isotype or anti-GD2 vs. Vorinostat or Vorinostat + 
anti-GD2) (*p < 0,05 for Vorinostat vs. Vorinostat + anti-GD2). On day 45, 9/9 mice of 
the anti-GD2 plus Vorinostat group, whereas 4/9 mice of the Vorinostat monotherapy 
group were still alive (defi ned by tumor volume< 1000 mm3). Representative experi-
ment of 2 independent experiments showing similar results.
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vorinostat increases gD2 expression on nbl cells and anti-
gD2 mab mediated killing
To uncover the mechanisms responsible for the observed synergy of anti-GD2 
mAb plus Vorinostat combination therapy in vivo, we fi rst investigated the 
effect of Vorinostat on the expression of immune relevant antigens on surface 
of the tumor cells in vitro. Hereto, tumor cells were exposed for 18 hours to 
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figure 3: HDACi increase GD2 expression by NBL cells resulting in increased anti-GD2 
mAb mediated killing. (A) Expression of MHCI and MHCII by 9464D and B16F10 cells 
following incubation with 256 nM Vorinostat or control for 18 hours. Grey shading= 
isotype control, Thin line= control treated, Thick line= Vorinostat treated. Represen-
tative data from 3 independent experiments. (B) Expression of GD2 by 9464D and 
IMR-32 cells after incubation with 2,5 μM and 256 nM Vorinostat, respectively, for 18 
hours. Grey shading= isotype control, Thick line= specifi c staining. Representative data 
from 3 independent experiments. (C) Expression of GD2 relative to control by 9464D 
and IMR-32 cells after incubation with the indicated HDACi for 18 hours. Representa-
tive data from 3 independent experiments. (D) 9464D cells were exposed to indicated 
concentrations of Vorinostat for 24 hours after which cells were lysed and analyzed by 
RT-qPCR (left) and Western Blot (right) for expression of GD2 Synthase (*=p < 0,05 
**=p < 0,01). Representative data from 2 independent experiments. (E) Day 6 BMDM 
were treated with 20 ng/mL IL-4 for 24 hours and analyzed for the expression of CD86, 
MHCII, CD206 and FcRγ2/3. Pooled data from 2 independent experiments. (F,G) Treat-
ment of 9464D cells with Vorinostat increases anti-GD2 mAb mediated killing. 9464D 
cells were incubated for 18 hours with 256nM Vorinostat or control and then co-cultured 
with indicated effector cells in the presence of isotype control Ab or anti-GD2 mAb (*=p 
< 0,05 **=p < 0,01 ***=p < 0,001). Representative data from 2-3 independent ex-
periments for each immune effector cell type.
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Vorinostat in concentrations which affected viability only mildly, maximally 
20 percent. The data revealed that Vorinostat treatment upregulated MHC 
class I (MHCI), but not MHC class II (MHCII) expression, on surviving 9464D 
NBL and B16F10 melanoma cells (Fig. 3A). The expression of other immune 
related molecules tested, including the NK cell activating ligands Rae1 and 
Mult-1 as well as the co-inhibitory molecule PD-L1, were not altered follow-
ing HDACi exposure (data not shown).
Next, we determined whether the expression of the GD2 antigen itself 
was affected by Vorinostat treatment. Strikingly, Vorinostat increased GD2 
expression in both murine 9464D and human IMR-32 NBL cells up to more 
than 150 percent of control treated cells (Fig. 3B). We also observed a dose 
dependent upregulation of GD2 by the panHDACi Givinostat, the Class-I in-
hibitor Entinostat and a HDAC1,2 specific inhibitor (Fig. 3C). In contrast, GD2 
levels were not increased by the Class-II HDACi Tubacin or a HDAC6 specific 
inhibitor (Fig. 3C). Next, the effect of increasing concentrations of Vorinostat 
on the transcription of GD2 Synthase27,28, an essential gene for GD2 expres-
sion, was assessed using qPCR. No significant changes were observed in 
GD2 Synthase mRNA levels in 9464D cells following Vorinostat treatment 
(Fig. 3D, left). Vorinostat exposure, however, did result in increased GD2 
Synthase protein levels in a dose dependent manner (Fig. 3D, right).
To determine the functional consequences of increased GD2 expression, 
9464D cells were treated with Vorinostat or control for 24 hours, washed 
and subsequently co-cultured with immune effector cells in the presence 
of anti-GD2 mAb or an isotype control Ab. As effector cells, BM derived 
macrophages (BMDM) treated with or without IL-4 and NK/LAK cells were 
used. Addition of IL-4 upregulated CD206 and FcRy1/3 expression in BMDM, 
suggestive of an M2-like phenotype with enhanced phagocytic capacity29,30 
(Fig. 3E). Vorinostat pre-treated tumor cells were not killed more efficiently 
by BMDM or NK cells relative to control treated tumor cells (Fig. 3F + 3G). 
Addition of anti-GD2 mAb, but not isotype control mAb, however, resulted in 
significantly enhanced killing of the Vorinostat pre-treated tumor cells rela-
tive to control cells irrespective of the type of immune effector cell (Fig. 3F 
+ 3G). Interestingly, IL-4 treated, M2-like BMDM mediated anti-GD2 mAb 
mediated killing of Vorinostat pre-treated tumor cells even at low effector : 
target ratio’s (Fig. 3F, right). Collectively, these data indicate that Vorinostat 
treatment of NBL cells enhanced GD2 expression on NBL cells, resulting in 
more efficient anti-GD2 mAb mediated tumor cell killing by NK cells, macro-
phages and especially M2-like macrophages.
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vorinostat increases gD2 expression and affects the 
composition of tumor myeloid cells
To determine whether Vorinostat could also increase GD2 expression in 
vivo, mice bearing NBL tumors were treated with Vorinostat or DMSO/PBS 
control. Similar to our in vitro observations, GD2 expression on tumors was 
signifi cantly increased following Vorinostat treatment as measured by FACS 
(Fig. 4A) and immunohistochemistry (Fig. 4B). Vorinostat treatment also 
seemed to upregulate the expression of MHCI on the tumor cells in vivo, but 
this did not reach statistical signifi cance (Fig. 4A).
Effects of Vorinostat on tumor cells have been extensively studied, but 
much less is known regarding its effect on immune cell infi ltration and func-
tion in tumors in vivo. Therefore, we determined the presence and pheno-
type of immune cells in the NBL tumor microenvironment (TME) following 
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figure 4: Vorinostat increases GD2 expression by NBL cells in vivo. (A) Mice bearing 
9464D tumors (6 mice/group) were treated with Vorinostat (150 mg/kg) for 3 consecu-
tive days. One day after the last injection tumors were excised and single cell suspen-
sions were made. Expression of MHCI and GD2 was determined on the CD45.2 negative 
tumor cells for Vorinostat and control tumors (* p < 0,05). Representative data from 3 
independent experiments. (B) Cryo-sections of 9464D tumors treated with Vorinostat 
or control were stained using isotype control Ab or anti-GD2-Cy5 mAb. Representative 
data from 2 independent experiments.
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Vorinostat treatment. Percentages of CD45.2+ tumor infiltrating leukocytes 
(TIL) within the total tumor cell suspension were unaltered in Vorinostat and 
control treated tumors (Fig. 5A). Within these CD45.2+ TIL, the percentages 
of CD3+CD4+ and CD3+CD8+ T cells, CD3-NK1.1+ NK cells and CD11b+ 
myeloid cells were all very similar in Vorinostat and control treated tumors 
(SFig. 1A and Fig. 5B). T cell subset analysis revealed that also the level of 
CD4+FoxP3+ Treg within the CD4+ T cell population was not affected by 
Vorinostat treatment (SFig. 1B).
Analysis of the tumor infiltrating CD45.2+CD11b+ myeloid cells showed 
a significant increase in the percentage of CD11cdimF4/80highMHCIIint macro-
phages upon Vorinostat treatment (Fig. 5C). In contrast, there was a strong 
decrease in the CD11clowF4/80lowMHCIIlow non-APC, while the percentage of 
CD11chighF4/80dimMHCIIhigh DC was not altered (Fig. 5C). These data indi-
cate the presence of more macrophages in NBL tumors following Vorinostat 
treatment. Strikingly, these macrophages expressed high levels of FcRy1 
and FcRy2/3 resulting in a significantly increased expression of these FcR 
in the total CD45+CD11b+ myeloid population (SFig. 2 + Fig 5D). The 
CD11cdimF4/80highMHCIIint macrophages after Vorinostat treatment showed 
increased surface expression of CD206 and CD80, while expression of MHCII 
was significantly decreased (SFig. 3). These data suggest a mixed M1/M2 
phenotype of these tumor macrophages following Vorinostat treatment.
We next analyzed the tumor infiltrating myeloid cells using mAbs directed 
towards the markers Ly-6C and Ly-6G to discriminate between polymorpho-
nuclear MDSC (PMN-MDSC) and monocytic MDSC (M-MDSC), respectively31. 
Strikingly, CD11cnegLy-6ChighLy-6GnegMHCIIlow cells with a phenotype corre-
sponding to M-MDSC were largely depleted from Vorinostat treated tumors 
(Fig. 5E).The percentage of CD11cint/highLy-6CnegLy-6GnegMHCIIint/high cells with 
a phenotype corresponding to APC was increased, while the percentage of 
CD11clow/intLy-6CdimLy-6GhighMHCIIlow cells corresponding to PMN-MDSC was 
unaltered (Fig. 5E). Thus, Vorinostat treatment significantly changes the 
composition of the tumor infiltrating myeloid cells in these NBL tumors, 
resulting in more macrophages showing a mixed M1/M2 phenotype and less 
M-MDSC.
vorinostat creates a more permissive tme for tumor directed 
mab therapy
To determine the functional consequences of Vorinostat treatment on the 
tumor infiltrating myeloid cells in NBL tumors, myeloid cells were isolated 
from tumors of mice treated with Vorinostat or control. First, CD45.2+ TIL 
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from pooled tumor cell suspensions of 18 mice per treatment arm were 
isolated using MACS. Next, the CD45.2+CD11b+ myeloid cells were puri-
fi ed to homogeneity by FACsort and directly lysed for RNA extraction. RT-
qPCR analysis of the house keeping genes Gusb and Pbgd relative to each 
other showed unaltered expression levels for control and Vorinostat treated 
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figure 5: Vorinostat treatment increases the presence of macrophages while reducing 
M-MDSC in the TME of NBL tumors. Mice bearing 9464D tumors (6 mice/group) were 
treated with Vorinostat (150 mg/kg) for 3 consecutive days after which tumors were 
excised and single cell suspensions were made. (A) Vorinostat does not alter total leu-
kocyte infi ltration of NBL tumors. The total tumor cell suspension was analyzed for the 
presence of CD45.2+ leukocytes. Representative data from 3 independent experiments. 
(B) Vorinostat does not alter myeloid cell presence in spleen and tumor. CD45.2+ leu-
kocytes were gated and analyzed for the expression of CD11b. Representative data 
from 3 independent experiments. (C) Vorinostat increases the presence of macrophages 
within the tumor infi ltrating myeloid cells. CD45.2+CD11b+ tumor infi ltrating myeloid 
cells were gated and analyzed for the expression of CD11c, F4/80 and MHCII. Per-
centages of CD11cdimF4/80highMHCIIint macrophages, CD11chighF4/80dimMHCIIhigh DC and 
CD11clowF4/80lowMHCIIlow non-APC are depicted (*=p < 0,05; ***=p < 0,001). Rep-
resentative data from 3 independent experiments. (D) Vorinostat upregulates the ex-
pression of FcRγ1 and FcRγ2/3 on the cell surface of tumor infi ltrating myeloid cells. 
CD45.2+CD11b+ myeloid cells were gated and analyzed for the expression of FcRγ1 
and FcRγ2/3 (*=p< 0,05 **=p< 0,01). Representative data from 3 independent ex-
periments. (E) Vorinostat reduces M-MDSC within the tumor infi ltrating myeloid cells. 
CD45.2+CD11b+ tumor myeloid cells were gated and analyzed for the expression of 
CD11c, Ly-6C, Ly-6G and MHCII. Percentages of and CD11cnegLy-6ChighLy-6GnegMHCIIlow 
M-MDSC, CD11clow/intLy-6CdimLy-6GhighMHCIIlow PMN-MDSC and CD11cint/highLy-6CnegLy-
6GnegMHCIIint/high APCs are depicted (*=p < 0,05; ***=p < 0,001). Representative data 
from 3 independent experiments.
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samples, indicating these housekeeping genes could be used for relative 
gene expression analysis following Vorinostat treatment (SFig. 4).
To better understand the nature of the Vorinostat-induced myeloid cells 
in NBL tumors, the expression of commonly used macrophage markers was 
determined. The transcript levels of the M2 macrophage markers Cd206, 
Cd163, Il4ra were all increased, whereas the levels of M2 markers Fizz1 
and Ym1, were decreased in the tumor infi ltrating myeloid cells following 
Vorinostat, suggesting a mixed M1/M2 macrophage phenotype (Fig. 6A).
These data are in line with the aforementioned FACS data comparing control 
versus Vorinostat-induced macrophages (SFig. 3).
Next, we determined the expression of genes related to myeloid cell func-
tion, like FcR essential for ADCC and immunosuppressive mediators. The 
FACS analysis already revealed a signifi cant increase in the levels of FcRy1 
and FcRy2/3 expressed on CD45.2+CD11b+ myeloid cells in the tumor 
(Fig. 5D). The latter mAb, however, recognizes both FcRy2b and FcRy3, and 
does not discriminate between inhibiting and activating FcR 32-34. Vorinostat 
treatment induced an increase in mRNA levels of the activating, low-affi nity 
Fcrg3, while expression of the inhibitory, low-affi nity Fcrg2b was not altered 
(Fig. 6B). Moreover, the high-affi nity, transcripts of the activating receptors 
Fcrg1 and Fcrg4 were both increased in the tumor infi ltrating myeloid cells 
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figure 6: Vorinostat treatment results in a TME containing myeloid cells expressing 
more activating FcR and less immune suppressive genes. (A-C) Mice (18 mice / group) 
bearing 9464D tumors were treated with Vorinostat (150 mg/kg) for 3 consecutive 
days. One day after the last injection tumors were excised and single cell suspen-
sions were made and pooled. CD45.2+ TIL were isolated from the pooled tumor cell 
suspensions by CD45.2+ MACS separation. CD45.2+CD11b+ cells were subsequently 
FACsorted and directly lysed for RNA isolation. Following cDNA synthesis, qPCR analysis 
was performed in triplicate and mRNA expression level relative to PBGD was determined 
for the indicated genes. Fold-change expression relative to control was compared to a 
hypothetical value of 1 (*=p < 0,05; **=p < 0,01; ***=p < 0,001).
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upon Vorinostat treatment (Fig. 6B). In addition, transcript levels of four 
genes directly involved in immune suppression31, Arginase, S100a8, S100a9 
and Pdl1, were all strongly decreased in the myeloid cells of Vorinostat 
treated tumors (Fig. 6C). In agreement with the reduced expression of these 
immunosuppressive genes, the markers Cd49d and Ly6c, expressed mainly 
by immunosuppressive M-MDSC35,36, were also expressed to a much lesser 
extent in the myeloid compartment of Vorinostat treated tumors (Fig. 6D). 
Collectively, these data indicate that Vorinostat treatment creates an im-
mune permissive TME for tumor directed mAb therapy in NBL tumors.
Discussion
Here we report that anti-GD2 mAb plus Vorinostat combination therapy medi-
ates synergistic anti-tumor effects in a novel autologous NBL mouse model. 
As an explanation for this synergy, we uncovered that TH-MYCN transgenic 
NBL cells were highly sensitive to HDACi mediated cell death. In addition, 
the HDACi Vorinostat upregulated the GD2 antigen on surviving NBL cells 
resulting in enhanced anti-GD2 mAb mediated killing. Finally, Vorinostat 
treatment completely altered the NBL TME, resulting in more macrophages 
expressing activating FcR and less M-MDSC expressing immune suppressive 
genes. These mechanistic insights into anti-GD2 plus Vorinostat combination 
therapy provide a rationale for clinical testing of this combination therapy in 
NBL patients.
Over the past decade, several tumor-targeted mAbs were shown to induce 
clinical responses6,37. Durable clinical responses following tumor specifi c mAb 
therapy, however, are observed in only 10-30% of cancer patients38. Previ-
ously, we observed an initial delay in the outgrowth of NBL tumor upon GD2 
mAb therapy in our transplantable model19, but in the current more stringent 
setting no signifi cant delay in overall survival was observed. Similar to these 
observations in mice, anti-GD2 mAb therapy alone did not have a major 
clinical effect in NBL patients when combined with Retinoic Acid therapy, 
a vitamin A metabolite inducing NBL differentiation39. Anti-GD2 mAb plus 
systemic cytokines IL-2 and GM-CSF and retinoic acid therapy, however, 
resulted in a 20% improved 5 year survival3. We now show that the effi cacy 
of anti-GD2 mAb therapy for NBL in mice is also enhanced by addition of the 
HDACi Vorinostat. Interestingly, the combination of the panHDACi Valproic 
acid and Retinoic Acid was previously shown to induce synergistic NBL dif-
ferentiation and apoptosis40. Therefore, it will be extremely interesting to 
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determine how addition of epigenetic modulators will affect the efficacy of 
anti-GD2 mAb therapy plus Retinoic Acid/IL-2/GM-CSF combination therapy. 
As Vorinostat exhibits less severe side effects compared to systemic IL-2 and 
GM-CSF, it may also be important to explore Vorinostat plus anti-GD2 mAb 
combination therapy in the absence of systemic cytokine administration3,14.
As an explanation for the synergy of Vorinostat plus anti-GD2 mAb combi-
nation therapy, we found novel effects of Vorinostat treatment on NBL cells 
and immune cells in vivo. MYCN transgenic NBL cells were highly sensitive for 
panHDACi and Class-I HDACi. One possible explanation for this high sensitiv-
ity are the reported interactions of N-MYC with several Class-I HDACs41,42. In 
addition to inducing efficient NBL cell death, Vorinostat treatment increased 
the expression of the tumor antigen GD2 on surviving NBL cells, resulting in 
enhanced anti-GD2 mAb mediated tumor cell killing in vitro. How Vorinostat 
treatment affects GD2 expression levels is not yet clear. The finding that 
Vorinostat did not induce significant changes in GD2 Synthase mRNA levels 
in 9464D cells, but did increase GD2 Synthase protein levels, implies that 
Vorinostat either acts via affecting the direct acetylation of GD2 Synthase 
or indirectly via (transcriptional) regulation of GD2 Synthase (de)stabilizing 
genes.
Immune suppressive Treg and MDSC can hamper the function of immune 
effector cells in tumors43. Several panHDACi were previously shown to 
increase the number and function of immune suppressive Treg44,45. Follow-
ing our Vorinostat treatment regimen, we did not observe increased Treg 
numbers. Vorinostat rather seemed to decrease FoxP3 expression levels in 
Treg, a phenomenon previously reported for the Class-I HDACi Entinostat46 
(SFig.1C). MDSC are immature myeloid cells that can actively inhibit anti-
tumor immune responses24,36,47 and accumulate in NBL tumors in TH-MYCN 
transgenic mice20,21. Our experiments now show that Vorinostat treatment 
essentially eliminates the presence of M-MDSC from these NBL tumors. 
Moreover, Vorinostat treatment reduced levels of Arginase and many 
other genes implicated in M-MDSC mediated immune suppression within the 
CD45+CD11b+ NBL tumor infiltrating myeloid cells. These data are therefore 
indicative for diminished tumor immune suppression as a consequence of 
Vorinostat treatment36,48.
FcR-expressing immune effector cells are highly important for the clinical 
response following tumor directed mAb therapy, including anti-GD2 mAb 
therapy4,5,49,50. We did not observe differences in the number of NK cells 
infiltrating NBL tumors after Vorinostat treatment (SFig. 1A). We, however, 
did observe increased numbers of macrophages in NBL tumors, expressing 
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high levels of the activating FcRy1 and FcRy2/3 on their cell surface following 
Vorinostat treatment. Expression of the activating receptors Fcrg1, Fcrg4 
and Fcrg3, but not the inhibitory receptor Fcrg2b, was also increased at the 
mRNA level.
Analysis of the macrophage type induced by Vorinostat treatment revealed 
a mixed M1/M2 macrophage gene signature. Although M2 type macrophages 
in NBL tumors were previously associated with an adverse disease out-
come51, tumor infi ltrating macrophages as a whole were repeatedly shown 
to be important immune effector cells, especially following tumor directed 
mAb therapy52-54. In addition, recent expression profi ling studies indicate 
that the M1 and M2 division for macrophages is a serious oversimplifi cation 
of the complexity of macrophage subtypes and functions in tumors22,23. Our 
data and other studies support that at least part of the M2 macrophage 
characteristics are not by default negative for cancer therapy, and may even 
be necessary for effective anti-tumor mAb therapy30.
Overall, our data imply that enhanced expression of GD2, lower numbers 
of immune suppressive M-MDSC and higher numbers of FcRhigh-expressing 
macrophages in the tumor all contribute to the effi cacy of the Vorinostat plus 
anti-GD2 mAb combination therapy.
The synergy of anti-GD2 mAb therapy with Vorinostat reported here, may 
have important implications for NBL patients. As both anti-GD2 mAb plus 
cytokine treatment and Vorinostat therapy are applied in pediatric oncology 
patients14, our study provides a rationale for immunocombination treatment 
with Vorinostat and anti-GD2 mAb therapy in the treatment of NBL patients.
A few studies have now reported on successful combinations of HDACi 
with immunotherapy46,55,56. One aspect that deserves further study is the 
optimal timing of HDACi treatment in immunocombination therapy, as this 
may critically determine the effi cacy in vivo46. In our experiments, anti-GD2 
mAb was administered prior to Vorinostat. Whether this order of administra-
tion is crucial for the observed synergy in anti-GD2 mAb plus Vorinostat 
combination therapy and whether the same order is required for T cell based 
immunotherapies remains to investigated.
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supplementary figure 1: (A+B) Vorinostat does not alter lymphocyte and Treg num-
bers in NBL tumors. (A) Mice (6 mice / group) bearing 9464D tumors were treated with 
Vorinostat (150 mg/kg) for 3 consecutive days. One day after the last injection, tumors 
were excised and single cell suspensions were made. CD45.2+ leukocytes were gated 
and analyzed for the expression of CD3, CD4, CD8 and NK1.1. Representative data from 
3 independent experiment. (B) CD3+CD4+ cells were gated and analyzed for the ex-
pression of intracellular FoxP3. Percentages of FoxP3+ cells of CD3+CD4+ are depicted 
for Vorinostat and control treated spleens and tumors (n.s.= not signifi cant). (C) Vori-
nostat decreases FoxP3 expression by Treg in spleen. CD3+CD4+ cells were gated and 
analyzed for MFI of intracellular FoxP3. Representative FACS plots for Vorinostat and 
control treated spleens are depicted.
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supplementary figure 2: CD45.2+CD11b+F4/80high macrophages express high levels 
of FcR in the tumor. Mice (6 mice / group) bearing 9464D tumors were treated with 
Vorinostat (150 mg/kg) for 3 consecutive days. One day after the last injection tumors 
were excised and single cell suspensions were made. CD45.2+CD11b+F4/80low and 
CD45.2+CD11b+F4/80high cells were gated and analyzed for the expression of FcRγ1 
and FcRγ2/3. Representative data from 3 independent experiments.
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supplementary figure 3: CD45.2+CD11b+F4/80+ macrophages in the tumor show 
a mixed M1/M2 phenotype following Vorinostat treatment. Mice (6 / group) bearing 
9464D tumors were treated with Vorinostat (150 mg/kg) for 3 consecutive days. One 
day after the last injection tumors were excised and single cell suspensions were made. 
CD45.2+CD11b+F4/80high cells were gated and analyzed for the expression of CD206, 
CD80 and MHCII (*=p < 0,05). Representative data from 3 independent experiments.
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supplementary figure 4: Vorinostat treatment does not alter the relative expression 
of PBGD and GUSB in the tumor infi ltrating myeloid cells. Mice (18 mice/group) bear-
ing 9464D tumors were treated with Vorinostat (150 mg/kg) for 3 consecutive days. 
One day after the last injection tumors were excised and single cell suspensions were 
made and pooled. CD45.2+ TIL were isolated from the pooled tumor cell suspensions by 
CD45.2+ MACS isolation. The CD45.2+CD11b+ cells were subsequently FACsorted and 
directly lysed for RNA isolation. Following cDNA synthesis, qPCR analysis was performed 
and the expression levels of PBDG and GUSB relative to each other were determined.
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derived suppressor cells, regulatory T cells and natural killer T cells.
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summary
Neuroblastoma is a childhood malignancy diagnosed at a median age of one 
year. Depending on age at diagnosis, histology, genetics and localization, 
neuroblastoma patients are categorized into several risk groups. Although 
low- and intermediate risk category patients generally have a more favor-
able prognosis, high-risk neuroblastoma patients have one of the poorest 
prognoses of all pediatric oncology patients. The long term survival of these 
patients is only 30-50%, a number which has remained virtually unchanged 
over the last decades. The treatment of high-risk neuroblastoma patients 
is one of the most intensive in pediatric oncology, involving chemotherapy, 
surgery, radiotherapy, autologous bone marrow transplantation and retinoic 
acid treatment. In the future, smart combinations of these and other thera-
pies are needed that mediate maximal synergistic anti-tumor effects with 
minimal toxicity. Immunotherapy aims to kill the tumor cells by making use 
of the patient’s own immune system. Antibody therapy directed towards the 
neuroblastoma specifi c antigen GD2 has recently show promising clinical ef-
fects. Despite these promising results, however, around half of the high-risk 
neuroblastoma patients still show progressive disease. Studies in patients 
and in mice have shown that effi cacy of immunotherapy can be hampered 
by immune suppression coming from the growing tumor. The primary aim 
of this study was to better understand the interactions of neuroblastoma 
with the immune system using a preclinical mouse model of neuroblastoma. 
This knowledge could lead to novel and/or improved immunotherapies for 
neuroblastoma patients in the future.
In chapter 1 we generally introduce neuroblastoma, the immune system 
and cancer immunotherapy as well as the aim and the scope of this thesis.
In chapter 2 we review the current literature on the immunobiology of neu-
roblastoma and the development of novel immunotherapy for neuroblastoma 
patients, with a special emphasis on preclinical mouse models for neuroblas-
toma. The emerging knowledge on the mechanisms by which neuroblastoma 
tumors evade and suppress the immune system are discussed. Furthermore, 
the term ‘immunocombination therapy’ is introduced and defi ned. In short, 
immunocombination therapy aims at maximal immune stimulation in com-
bination with removal or reversal of tumor induced immune suppression. 
Finally, an overview of the most commonly used autologous mouse models 
for neuroblastoma is provided and their advantages and/or disadvantages 
are discussed.
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In chapter 3 we review the current literature reporting on the effect of a 
group of tumor targeted drugs called the histone deacetylase (HDAC) inhibi-
tors. We discuss the effect of these tumor targeted drugs on tumor cells, but 
also on immune cells (white blood cells) and the role of these drugs in immu-
nocombination therapy. Several studies have shown synergistic anti-tumor 
effects using HDAC inhibitors in combination with immunotherapy in mice. 
We discuss these studies and the potential mechanisms involved in these 
observed synergistic interactions in vivo. We concluded from this literature 
study that the timing of administration and the type of HDAC inhibitor used 
are emerging factors determining the synergy of combination therapies us-
ing HDAC inhibitors with immunotherapy.
In chapter 4 we report on and describe the immunobiology of a novel 
transplantable mouse model for neuroblastoma, called the transplantable 
TH-MYCN model. The murine neuroblastoma cells used in this model are 
derived from a neuroblastoma tumor that arose in the so-called TH-MYCN 
transgenic mouse, which develops spontaneous neuroblastomas over time. 
These murine neuroblastoma cells were transplanted back into healthy 
C57Bl/6 mice, having the same genetic background as the TH-MYCN mouse 
in which these tumor cells arose. This genetic background is highly suitable 
for immunological models, as all of the immunological ‘tools’ are available on 
this background. The cell surface expression on the murine neuroblastoma 
cells showed high similarity to what was previously reported for human neu-
roblastoma, including expression of the neuroblastoma antigen GD2 on the 
cell surface. Anti-GD2 monoclonal antibodies mediated killing of the murine 
neuroblastoma cells by various types of immune cells. NK cells, but not T 
and B cells, reduced neuroblastoma tumor growth in vivo, similar as reported 
for human neuroblastoma. We found that the murine neuroblastoma tumors 
were highly infiltrated by immune cells of the myeloid lineage. Based on 
surface marker expression, these myeloid cells could be divided into differ-
ent myeloid cell subsets. Some of the identified myeloid cell subsets were 
previously reported to be highly immunosuppressive. We concluded from 
these studies that the novel transplantable TH-MYCN NBL model is a highly 
relevant neuroblastoma model to develop and understand novel immuno-
therapy for NBL.
In patients, the primary neuroblastoma tumor is mostly located in the ad-
renal gland. In chapter 5 we expanded this transplantable TH-MYCN mouse 
model to a so-called orthotopic model by injecting the murine neuroblastoma 
cells directly in the adrenal gland using microsurgery. We observed that 
neuroblastoma tumors grew out faster in the adrenal gland compared to the 
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subcutis. Upon analysis of the tumor infi ltrating leukocytes, we found that 
myeloid cells infi ltrating the adrenal neuroblastoma tumors expressed lower 
levels of MHCII, suggestive of a more immune suppressive environment 
in neuroblastoma tumors in the adrenal gland. Finally, using light emitting 
neuroblastoma cells expressing fi refl y luciferase, we were able to monitor 
tumor growth in a semi-quantitative manner by measuring the light emitted 
by the neuroblastoma tumors. We concluded that this orthotopic TH-MYCN 
neuroblastoma model also represented a highly relevant and even more ag-
gressive model to study immunotherapy for neuroblastoma.
In chapter 2 we hypothesized that specifi c combinations of tumor targeted 
therapy may act synergistic in combination with immunotherapy. In chapter 
6 we report on such a synergistic interaction in the transplantable TH-MYCN 
neuroblastoma model. We found an interaction between anti-GD2 monoclo-
nal antibody therapy and the HDAC inhibitor Vorinostat. The combination of 
these therapies resulted in synergistic inhibition of neuroblastoma growth. 
We uncovered multiple novel effects of the HDAC inhibitor Vorinostat on neu-
roblastoma cells and immune cells. First, Vorinostat highly induced cell death 
in the murine neuroblastoma cells, similar to what was previously reported 
for human neuroblastoma cells. Second, we found that both murine and hu-
man neuroblastoma cells that survived the HDAC inhibitor therapy expressed 
higher levels of the tumor antigen GD2 on the cell surface. This resulted 
in increased recognition and the killing of these surviving neuroblastoma 
cells by various immune cells in the presence of anti-GD2 antibodies. Third, 
Vorinostat treatment removed the group of previously identifi ed (chapter 
4) immune suppressive myeloid cells from neuroblastoma tumors. Finally, 
Vorinostat treatment increased the presence of macrophages in neuroblas-
toma tumors. These macrophages highly expressed activating Fc-receptors 
that are crucial for effective tumor directed antibody therapy. We concluded 
that the combination of anti-GD2 mAb and Vorinostat had synergistic anti-
neuroblastoma effects through newly discovered mechanisms of the HDAC 
inhibitor Vorinostat on neuroblastoma cells and immune cells in neuroblas-
toma tumors.
In chapter 7 we provide a general overview and discussion of the results 
with a special emphasis on the immune suppressive tumor microenvironment 
in neuroblastoma tumors. We provide directions for future research into the 
anti-GD2 therapy plus Vorinostat combination therapy. Finally, we discuss 
upcoming targeted therapies in neuroblastoma and provide directions for 
future research into combinations of these therapies with immunotherapy in 
neuroblastoma.
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Discussion
Around half of the newly diagnosed neuroblastoma (NBL) patients are classi-
fied as high risk patients1. NBL has a dismal prognosis in these patients; only 
around 30-50% of high-risk patients will survive the disease, despite the in-
tensive multimodal treatment2. In 2009, a phase III trial was conducted test-
ing anti-GD2 monoclonal antibody (mAb) plus cytokine therapy in high risk 
NBL patients. The addition of this immunotherapy to the standard treatment, 
showed a significant improvement in survival of 20%3. This trial represents 
a prime example of the therapeutic potential of immunotherapy even in a 
highly malignant disease such as high risk NBL. In this thesis, we suggest a 
new way to improve immunotherapy for NBL patients using a novel preclinical 
mouse model of NBL. In chapter 4 we describe this novel autologous mouse 
model for NBL, the so-called transplantable TH-MYCN model, which we set 
up to test and understand novel immuno(combination) therapies for NBL. In 
chapter 5 we expand this model to an orthotopic NBL model and describe 
some of its unique characteristics. In chapter 6, we report on a synergistic 
interaction between anti-GD2 mAb-based immunotherapy and the HDAC 
inhibitor Vorinostat in this model. We uncovered several novel effects of 
Vorinostat on tumor cells and immune cells, as part of the explanation for 
the synergistic anti-tumor effect induced by this novel immunocombination 
therapy. These studies may have significant implications for the future of 
immunotherapy in NBL patients, as it seems possible to create a synergistic 
interplay between tumor immunotherapy and tumor targeted therapy. In this 
chapter we will provide an overview and discuss the results of this thesis and 
give directions for future studies involving immunotherapy for NBL.
a transplantable th-mycn tumor model for nbl
To be able to study novel immunotherapy for NBL and unravel the underlying 
mechanisms, we first set up a preclinical mouse model of NBL. The choice 
for a specific mouse model depends largely on the scientific question to 
be answered. For our aim -which is to test and understand novel immuno-
therapy for NBL- we needed an immunocompetent mouse model of NBL. 
This ruled out the use of xenograft models, as these models are all more or 
less immunodeficient to prevent rejection of the transplanted human tumor 
cells. Within the immunocompetent mouse models for NBL there is a choice 
between either 1.) mouse models that are genetically engineered to (over)
express an oncogene in specific tissues, resulting in spontaneous tumor 
development in time or 2.) mouse models in which murine NBL cells are 
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transplanted in syngeneic wild-type mice, resulting in controlled tumor de-
velopment4. The TH-MYCN mouse model of NBL was genetically engineered 
by cloning the oncogene MYCN under the promoter of the gene Tyrosine 
Hydroxilase5. Tumor development in this transgenic model is driven by the 
over expression of MYCN specifi cally in developing neural crest cells, which 
later will form the sympathetic nervous system6. Both the spontaneous as 
well as the transplantable TH-MYCN models of NBL were shown to highly 
resemble MYCN amplifi ed human NBL, both histologically and genetically7, 8. 
The 9464D NBL cell line was derived from a NBL tumor that spontaneously 
arose in the TH-MYCN transgenic mouse. We set up and characterized an au-
tologous transplantable TH-MYCN model of NBL by transplanting this 9464D 
NBL cell line into syngeneic C57Bl/6 mice, a genetic background which is 
highly suitable for immunological studies (chapter 4). We will refer to this 
model from now on as the transplantable TH-MYCN model of NBL.
We observed that the 9464D NBL cells, used for this model, endogenously 
expressed the NBL associated surface antigen GD2 in vitro as well as in 
vivo (chapter 4). Therefore, to our knowledge, this transplantable TH-MYCN 
model is the fi rst syngeneic mouse model of NBL reported to express GD2. 
Although several immunotherapies, like cytokine therapy, whole tumor cell 
vaccination and DNA vaccination were effective in reducing NBL growth in 
other NBL mouse models9-11, some of the models used for these studies were 
not fully autologous9. The transplantable TH-MYCN model, however, is fully 
autologous and we have shown that the immunobiology of this model is 
highly similar to what was reported for human NBL (chapter 4). In chapter 2, 
in which we review the currently studied immunotherapies for NBL, we argue 
that the lack of relevant syngeneic NBL models may have contributed to the 
limited clinical translation of these preclinical studies in the past.
immune evasion and immune suppression by tumors
Preclinical as well as clinical studies have indicated that immunotherapy 
can mediate anti-tumor effects3, 12. Despite promising results using immu-
notherapy in the treatment of tumors, new cancers still arise in otherwise 
immune competent hosts in millions of people word wide every year (www.
who.org). To explain these apparent contradictory observations, the immune 
surveillance hypothesis has been postulated13. In short, the immune surveil-
lance theory states that cancers arise more often in a host than become 
manifest, because most early malignant lesions will be recognized and 
eliminated by the host’s immune system. Therefore, in order for cancers to 
become manifest, tumors should fi rst escape this early immune destruction 
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by avoiding or counteracting the immunity of the host. In line with the im-
mune surveillance hypothesis, it was shown that the carcinogen MCA induced 
far higher incidences of skin cancer in immunodeficient mice compared to WT 
mice14, 15. Counter intuitively, chronic inflammation is also observed in grow-
ing tumors16. Chronic inflammation, however, results in the recruitment of 
suppressive immune cells that produce growth factors and anti-inflammatory 
mediators17. These ‘inflammatory’ immune cells and their mediators thereby 
promote tumor growth and suppress anti-tumor immunity, respectively. This 
‘janus-face’ of the immune system in cancer was underscored by the recent 
addition of two apparently contradictory hallmarks of cancer -to the already 
established ones-, namely ‘avoiding immune destruction’ and ‘inflamma-
tion’18.
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figure 1: In the tumor network, different immune and non-immune cells respond to 
tumor stimuli and exhibit complex regulatory or immunosuppressive functions, either 
in a cell–cell contact-dependent manner or through the secretion of soluble mediators. 
ARG-1, arginase-1; Breg, regulatory B cell; DC, dendritic cell; G-MDSC and M-MDSC, 
granulocytic and myeloid-derived suppressor cells; IFN, interferon; IL, interleukin; NKT 
cells, natural killer T cells; NOS, nitric oxide species; ROS, reactive oxygen species; 
TAM, tumor-associated macrophage; TAN, tumor-associated neutrophils; TGF, trans-
forming growth factor; TNF, tumor necrosis factor; Treg, regulatory T cell; TSC, tumor 
stromal cell; VEGF, vascular endothelial growth factor.
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Tumors evolve to avoid and escape the immune system through several 
mechanisms. These mechanisms are diverse and some major mechanisms 
have been uncovered over the recent years19. For example, tumors can 
downregulate tumor antigens, antigen presentation machinery components 
or antigen presenting molecules like MHC class I (MHCI), thereby evading 
recognition by cytotoxic T cells20. Besides the down regulation of surface 
molecules involved in immune recognition, tumor cells also attract and 
condition immune cells to become immune suppressive within the TME21 
(Figure 1). Normal immune functions of effector immune cells in tumors can 
be counteracted by immunosuppressive lymphocytes like regulatory T cells 
(Treg)22, 23. Additionally, the tumor microenvironment (TME) conditions local 
myeloid cells to become immunosuppressive24, 25. In conclusion, it is evident 
that tumors can be recognized and eliminated by the immune system and 
have therefore evolved to evade and suppress anti-tumor immune responses.
immune evasion by nbl tumors; t cell evasion
In the transplantable TH-MYCN model of NBL, we were able to confi rm some 
of the known mechanisms as well as to uncover potential novel mechanisms 
of NBL immune evasion and immune suppression. We found that the murine 
9464D NBL cells expressed low levels of MHCI and lacked expression of 
a panel of co-stimulatory molecules (chapter 4). Upon transplantation of 
9464D NBL cells in Rag1-/- C57Bl/6 mice, lacking T- and B-cells, tumors grew 
out with similar growth speed compared to tumors growing in wild type mice, 
suggesting that T- and B-cells did not recognize and eliminate the 9464D 
NBL cells in vivo. Human NBL cells were previously shown to also express 
low levels of MHCI as well as to lack expression of co-stimulatory molecules, 
similarly suggesting that human NBL cells are not recognized and eliminated 
by CD8 T cells26-28. Although human NBL cells express low levels of MHCI 
in physiologic conditions, the expression of MHCI was shown to become up 
regulated upon exposure to the pro-infl ammatory cytokine IFN-γ29. Similarly, 
we observed up regulation of MHCI by the murine 9464D NBL cells upon 
exposure to infl ammatory cytokines IFN-γ and TNF-α (chapter 4). These 
data suggest that NBL cells can be recognized by T cells under infl ammatory 
conditions. Indeed, IFN-γ treatment induced T cell infi ltration in NBL tumors 
of mice and man, suggesting increased recognition of the tumor cells by CD8 
T cells30. NBLspecifi c T cells, however, were detected only in the blood of NBL 
patients, but were absent in NBL tumors, suggesting T cells do not infi ltrate 
NBL tumors to a high extend in non-infl ammatory conditions26. We found 
that T cells were also not highly present in non-stimulated murine 9464D 
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NBL tumors (chapter 4), also suggesting a minor role for T cell immunity in 
steady state NBL growth. The low T cell infiltration of 9464D NBL tumors was 
probably due to low expression levels of MHCI or, as an alternative explana-
tion, due to local immune suppression in the NBL tumors. In conclusion, 
by using the transplantable TH-MYCN model, we confirmed that NBL tumor 
cells express low levels of MHCI and are therefore likely to evade CD8 T cell 
mediated immune elimination.
immune evasion by nbl tumors; nK cell evasion
Because the 9464D NBL cells expressed low levels of MHCI, these NBL cells 
could potentially be recognized by natural killer (NK) cells. Therefore, be-
sides T and B cells, we also tested the role of NK cells in the transplantable 
TH-MYCN model. We found that NBL tumors grew out faster upon depletion 
of NK cells, indicating that NK cells indeed exerted anti-NBL effects in vivo 
(chapter 4). Similarly, human NBL cells were also shown to be recognized 
and eliminated by NK cells in vitro as well as in vivo31-33. Besides expressing 
low levels of MHCI, human NBL cells were shown to express so-called ‘stress-
induced’ ligands on the cell surface that are recognized by the activating re-
ceptor NKG2D, which is expressed on NK cells34. Similar to human NBL cells, 
murine 9464D NBL cells expressed the activating NKG2D ligand Rae1. We 
can conclude from these and our data that NBL tumors, while being poorly 
recognized by T cells, are recognized by NK cells in vivo. Nevertheless, as 
every NBL tumor in the transplantable TH-MYCN model eventually grew out, 
even in the presence of NK cells, apparently these NBL tumors eventually 
also evaded the NK cell mediated tumor destruction. In NBL patients, soluble 
forms of NKG2D ligands were detected in the serum of NBL patients, which 
bound to NKG2D receptors on circulating NK cells34. This resulted in a block 
of the activating NKG2D receptor, thereby leading to NK cell anergy. These 
data suggest that shedding of NKG2D ligands is an immune evasive mecha-
nism by which NBL tumors evade NK cell cytotoxicity. Whether the NKG2D 
ligand Rae1 is also shed from 9464D NBL tumors in vivo remains to be 
determined. Rae1 was still expressed in significant amounts on the surface 
of 9464D NBL cells ex vivo, suggesting at least not all Rae1 ligands are shed 
from the tumor cells in vivo (chapter 4). As another immune evasive mecha-
nism, expression of the co-inhibitory molecule Programmed Death receptor 
Ligand-1 (PD-L1) by tumor cells has been reported. PD-L1 signals a immune 
suppressive signal via the receptor PD1, which is expressed by NK cells and 
activated CD8 T cells35. PD-L1 expression was induced on the cell surface 
of 9464D NBL cells upon stimulation with the inflammatory cytokines INF-γ 
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and TNF-α (chapter 4). The expression of PD-L1 on human NBL cells has not 
been reported to date. Therefore, future research should investigate the role 
of PD-L1 in NBL immune evasion, especially since anti-PD1 and anti-PD-L1 
monoclonal antibodies have been reported in early phase clinical studies in-
cluding melanoma patients and lung carcinoma patients, showing promising 
results12, 36, 37. We concluded from these data that the immunobiology of the 
transplantable TH-MYCN model highly resembles the known immunobiology 
of human NBL, as the murine NBL cells are not eliminated by T cells, but are 
recognized and/or eliminated by NK cells in vivo.
role of treg in nbl tumors
We observed high percentages of FoxP3+ Treg within the CD4+ T cells, 
infi ltrating 9464D NBL tumors (chapter 4), suggesting Treg contribute to 
an immune suppressive TME in NBL tumors. Expression of the transcription 
factor FoxP3 in Treg is responsible for their immune suppressive capacity38. 
Treg use contact-dependent and contact-independent mechanisms to sup-
press the function of T cells. Other preclinical studies have suggested a role 
for Treg in the immune evasion of NBL tumors39, 40. The depletion of Treg 
enhanced an anti-NBL vaccination in an autologous murine NBL model39. In 
addition, depletion of Treg from bone marrow transplants after total body 
irradiation resulted in enhanced anti-tumor vaccination after transplantation 
in a NBL mouse model41. Recently, Tirak et al. showed that Treg numbers 
were elevated in the blood of NBL patients and that numbers of circulating 
Treg correlated with tumor load42. We found that 9464D NBL tumors were 
lowly infi ltrated by both CD4+ and CD8+ T cells, especially when compared 
to the far more abundant myeloid cells infi ltrating 9464D NBL tumors. There-
fore, the relative contribution of Treg to an immune suppressive TME in NBL 
tumors in the transplantable TH-MYCN NBL model should be determined and 
compared to immune suppression of the more abundant tumor infi ltrating 
myeloid population. This could be done by comparing tumor growth following 
selective depletion of Treg and/or specifi c myeloid cell subsets using deplet-
ing mAbs.
the role of myeloid cells in tumors
We comprehensively characterized the immune infi ltrates of NBL tumors in 
the transplantable TH-MYCN model using fl ow cytometry. We observed large 
numbers of myeloid cells infi ltrating 9464D NBL tumors; around 80 per-
cent of all tumor infi ltrating CD45.2+ leukocytes expressed the myeloid cell 
marker CD11b (chapters 4, 5, 6). The TME conditions the local myeloid cells 
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to become immunosuppressive, as evidenced by the identification of immune 
suppressive Tie2-expressing monocytes, tumor-associated macrophages 
(TAM) and tumor-associated neutrophils in other tumors43-46. More recently, 
another prominent effect of growing tumors on myeloid cells has been re-
ported: the aberrant activation of myelopoiesis resulting in the expansion 
and recruitment of immature myeloid cells called MDSC25, 47. During the early 
phase of infection, trauma or stress, these myeloid cells are believed to 
play an important role in replenishing dendritic cells (DCs), macrophages 
or neutrophils, while in the later phase they can prevent immune pathol-
ogy47. In tumor bearing patients this development process appears defective 
and results in the accumulation and retention of highly immunosuppressive 
MDSC25. Their proliferation, aberrant activation and persistence is induced 
by chronic inflammation in the TME48 and is characterized by the continu-
ous production of inflammatory mediators, including interleukin (IL)-1, IL-6, 
reactive oxygen species (ROS) and nitric oxide (NO)25, 47. It was previously 
proposed that MDSC entering the TME can differentiate into macrophages in 
mice25, 45, 46. Hypoxia and hypoxia-inducible factor (HIF)-1α within the TME 
seem to be responsible for the up-regulation of arginase (ARG)-1 and NOS 
in MDSC and their differentiation into macrophages49. The knowledge of the 
exact nature of the combination of tumor-derived factors that induce the 
mobilization, aberrant activation and expansion of tumor infiltrating myeloid 
cells, however, is still far from being complete.
role of macrophages in nbl tumors
Within the myeloid cells infiltrating 9464D NBL tumors, we identified func-
tionally determined subsets of myeloid cells, including macrophages, DCs 
and MDSC, based on the expression of cell surface markers (chapters 4, 
5, 6). These data were in agreement with data from Carlson et al., who 
also showed high presence of macrophages, DCs and MDSC in NBL tumors 
of the original TH-MYCN transgenic mouse model16. Macrophages were the 
largest functional myeloid cell subset within the tumor infiltrating myeloid 
cells infiltrating 9464D NBL tumors. In addition, we observed that orthotopic 
9464D NBL tumors -growing in the adrenal gland- were even more heavily 
infiltrated by macrophages (chapter 5). These macrophages also expressed 
lower levels of cell surface MHCII, indicative of a more immune suppressive 
macrophage phenotype50. In addition, the higher macrophage infiltration 
in adrenal NBL tumors was associated with faster tumor growth of these 
adrenal NBL tumors, compared to their subcutaneous equivalents (chapter 
5). Recently, Asgharzadeh et al. showed that the presence of these so-called 
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M2 macrophages in human NBL tumors was an independent prognostic 
factor indicating an adverse prognosis51. These data and our observations 
in orthotopic adrenal NBL tumors therefore suggest that tumor infi ltrating 
macrophages also contribute to an immune suppressive TME in NBL tumors, 
resulting in enhanced NBL tumor growth.
role of mDsc in nbl tumors
Another group of tumor infi ltrating myeloid cells in 9464D NBL tumors could 
becharacterized as MDSC, based on surface marker expression (chapter 
4, 5, 6). MDSC were also demonstrated to infi ltrate NBL tumors in several 
autologous mouse models of NBL, including the original TH-MYCN trans-
genic mouse model16, 52. Inactivation of MDSC by polyphenon E reduced 
spontaneous tumor onset in this model53. In tumor-bearing mice, two main 
MDSC subtypes have been reported, granulocytic (G-MDSCs) and monocytic 
MDSCs (M-MDSCs). G-MDSCs are defi ned by the combinatory expression 
of CD11b+Ly-6GhighLy-6Clow. M-MDSCs are characterized having the surface 
phenotype CD11b+Ly-6GlowLy-6Chigh 25. Around 20% and 15% of all tumor 
infi ltrating myeloid cells in 9464D NBL tumors consisted of G-MDSC and 
M-MDSC, respectively (chapter 4, 5, 6). The relative higher presence of the 
G-MDSCs does, however, not necessarily mean they are more important 
for immune suppression, as M-MDSCs have been proposed to be more im-
munosuppressive than G-MDSCs on a per cell basis54-56. To really show that 
the identifi ed MDSC in NBL tumors are really immune suppressive, these 
cells should be isolated from the NBL tumors and their immune suppres-
sive capacity should be tested in functional suppression assays ex vivo. We 
concluded that these cells having an MDSC phenotype are highly present 
in 9464D NBL tumors, at least suggesting an important role for MDSC in 
inducing immune suppression in NBL tumors.
In summary, our data suggests that NBL tumors can evade immune ef-
fector cells and attract and condition immune suppressive lymphocytes and 
myeloid cells, which leads to an immune suppressive TME in NBL tumors. 
This immune suppressive TME in NBL tumors implies that the TME should be 
an integrated target of future immunotherapy for NBL.
anti-gD2 mab therapy for nbl
Although NBL cells express tumor associated antigens (TAA) that can be rec-
ognized by tumor specifi c T cells26, 57, most clinical immunotherapy trials in 
NBL patients used mAb directed towards the NBL specifi c cell surface antigen 
GD23, 58, 59. Anti-GD2 mAb were developed and shown to induce complement 
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dependent cytotoxicity (CDC) and antibody dependent cellular cytotoxicity 
(ADCC) following specific binding to NBL cells, resulting in NBL cell death60, 61. 
The effect of anti-GD2 mAb therapy in the transplantable TH-MYCN model, 
however, ranged from only a small reduction of tumor growth to no signifi-
cant effect on tumor growth (chapter 4 & 6). Although we do not know the 
exact cause of these small variations in treatment response to anti-GD2 mAb 
in this model, we did observe variations in GD2 expression levels between 
cultures of 9464D cells, which might explain these observations. Neverthe-
less, if anything, anti-GD2 mAb monotherapy only induced a minor effect on 
NBL tumor growth (chapter 4). Similar to our observations in the transplant-
able TH-MYCN model, anti-GD2 mAb therapy alone also did not show high 
clinical efficacy in NBL patients either62. These similarities in the response to 
anti-GD2 mAb monotherapy, imply that the transplantable TH-MYCN model 
is a relevant model to test and improve anti-GD2 mAb based immunotherapy 
for NBL patients. In patients, however, the addition of immune activating 
cytokines IL-2 and GM-CSF to anti-GD2 mAb therapy, did show promising 
clinical efficacy3. Immune effector cells, like NK cells, granulocytes and re-
cently also myeloid cells, were shown to contribute to the observed clinical 
responses following anti-GD2 mAb therapy in NBL patients32, 33, 63, 64. The 
promising effect of targeting GD2 using mAb in NBL has boosted preclinical 
and clinical efforts to optimize or improve anti-GD2 mAb based therapy, for 
example by using anti-GD2 mAb to deliver immune stimuli or tumor targeted 
drugs to the NBL tumor65, 66. Also, T cells or NK cells were engineered to 
express chimeric anti-GD2 mAb on the cell surface and the adoptive transfer 
of these ‘GD2-targeted’ lymphocytes showed promising clinical responses in 
small cohorts of NBL patients58, 59, 67. In our studies, we hypothesized that 
specific combinations of tumor targeted therapy and anti-GD2 mAb therapy 
could enhance anti-GD2 mAb therapy (chapter 2, 3, 6).
tumor targeted therapy in cancer treatment
The genetic aberrations of NBL and other cancers and their functional conse-
quences are increasingly understood68, 69. This may help the rational design 
of small molecules that target the functional consequences of certain genetic 
aberrations in specific cancers70. In melanoma, for example, the BRAF inhibi-
tor Vemurafenib largely reduces tumor masses in patients in which the tumor 
cells carry the BRAF V600-mutation71. Although Vemurafenib monotherapy 
increased progression-free survival, tumors in most of the patients eventu-
ally progressed72. This observation suggests that tumor clones that do not 
carry the targeted mutation and are therefore resistant to the treatment, 
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will fi nally grow out to full tumors73. Because of their high specifi city for a 
single mutation, however, these targeted therapies generally have milder 
side effects, compared to classical chemotherapy. The same high specifi city, 
on the other hand, is the reason why these targeted therapies are likely not 
to be curative when administered as single therapy. Therefore, combinations 
of targeted therapy with other treatment modalities, for example immu-
notherapy, can potentially eliminate tumor clones that are resistant to the 
targeted therapy74.
tumor targeted therapy for nbl
Tumor targeted therapies using small molecules are also (being) tested 
in phase I/II studies in NBL patients or have been suggested as potential 
candidates in preclinical studies, as reviewed in75. Two examples of promis-
ing targets for NBL are the gene products of the genes Cyclin Dependent 
Kinase 2 (CDK2) and Anaplastic Lymphoma Kinase (ALK)70, 76. Molenaar et 
al. showed that MYCN amplifi ed NBL cells went into apoptosis upon RNAi 
mediated silencing of CDK270. The CDK2 inhibitor Roscovitine similarly re-
sulted in cell death of MYCN amplifi ed NBL cells, but not of MYCN single copy 
NBL cells. These data indicate that CDK2 is a promising target for MYCN 
amplifi ed NBL patients77, 78. ALK is an extracellular receptor that is frequently 
mutated or over-expressed in neuroblastoma, leading to more aggressive 
tumor growth79. Both ALK mutated and ALK over-expressing neuroblastoma 
cells were sensitive to ALK inhibitors in vitro80. The ALK inhibitor Crizotinib is 
currently in a phase I/II trial in NBL patients76.
Another group of promising tumor targeted drugs in NBL are the histone 
deacetylase (HDAC) inhibitors. HDAC inhibitors are epigenetic modifi ers that 
represent an emerging group of small molecules in the treatment of cancer 
as they were shown to induce tumor cell death specifi cally over normal cell 
death81, 82. We and others have observed that NBL cells are highly sensitive to 
HDAC inhibitor mediated cell death83-85 (chapter 6). Besides inducing tumor 
specifi c cell death, HDAC inhibitors were also shown to enhance the immu-
nogenicity of surviving tumor cells as well as to have differential effects on 
various types of immune cells, as reviewed in chapter 3. In this chapter, we 
also reviewed the potential mechanisms of successful combinations of HDAC 
inhibitors with immunotherapy in vivo. From this literature study we con-
cluded that the timing of HDAC inhibitor administration and the type of HDAC 
inhibitor are emerging as critical factors in the outcome of HDAC inhibitor/ 
immunotherapy combinations. For example, several studies have suggested 
that immune activation preceding HDAC inhibitor therapy can result in better 
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immune cell survival and function86-88. Therefore, when testing combinations 
of HDAC inhibitors with anti-GD2 mAb, we chose to initiate anti-GD2 mAb 
therapy before HDAC inhibitor therapy.
anti-gD2 mab plus vorinostat combination therapy for nbl; 
mechanisms and future directions
To improve the outcome of anti-GD2 mAb therapy, we chose to combine 
the HDAC inhibitor Vorinostat with anti-GD2 mAb to treat NBL tumors in 
the transplantable TH-MYCN model (chapter 6). Vorinostat was approved 
in 2007 for the treatment of cutaneous T cell lymphoma89 and is currently 
used in clinical trials in cancer patients, including NBL patients90 (www.
clinicaltrials.gov). We found a synergistic interaction between anti-GD2 mAb 
and the HDAC inhibitor Vorinostat; the combination treatment reduced NBL 
growth in the transplantable TH-MYCN model in a synergistic manner. Next, 
we uncovered novel effects of Vorinostat on tumor cells and immune cells, 
as an explanation for this synergistic anti-NBL effect. 9464D NBL cells were 
highly sensitive to Vorinostat- and other HDAC inhibitor-induced cell death, 
compared to tumor cells of other origins, in vitro. The high sensitivity of NBL 
cells to HDAC inhibitors was previously also reported for human NBL cells83-85. 
In line with the high sensitivity of the NBL cells in vitro, Vorinostat treatment 
alone also markedly reduced NBL tumor growth in vivo, suggesting a direct 
effect of Vorinostat on tumor cell viability (chapter 6). In addition to inducing 
NBL specific cell death, Vorinostat upregulated the expression levels of the 
tumor antigen GD2 on the cell surface of surviving 9464D NBL cells both in 
vitro and in vivo. This is probably due to increased protein levels of the key 
enzyme in the production of GD2, GD2 synthase, following Vorinostat treat-
ment. Exposure of NBL cells to Vorinostat resulted in increased anti-GD2 
mAb mediated antibody dependent cellular cytotoxicity (ADCC) mediated by 
various immune effector cells. Previously, people have also shown that the 
expression levels of cell surface antigen on tumor cells is correlated to levels 
of ADCC91.
Finally, besides the direct effects of Vorinostat on NBL cells, we also found 
interesting novel effects of Vorinostat on NBL infiltrating immune cells in vivo. 
Following Vorinostat, the presence of macrophages expressing high levels of 
Fc-receptors was significantly increased in the NBL tumors. This led to over-
all higher expression of activating FcR within the tumor infiltrating myeloid 
cell population, suggesting increased killing capacity of the tumor infiltrating 
immune cells following Vorinostat treatment92 - 94. Although it seems likely 
that the Vorinostat-induced recruited FcR-high macrophages contributed to 
Michel Kroesen - Binnenwerk V7.indd   170 05-08-15   10:37
171
Summary and Discussion | chapter 7
7
the synergistic effect of anti-GD2 mAb plus Vorinostat combination therapy, 
future studies are needed to determine the exact role of these macrophages 
in vivo. This could be done, for example, by depleting macrophages using 
specifi c mAbs, e.g. a mAb directed to the macrophage marker F4/80.
Concomitantly with the increase in tumor macrophages following Vorinostat 
treatment, we also observed a decrease in cells with a phenotype of immune 
suppressive M-MDSC In addition, we observed that the expression levels 
of genes related to M-MDSC mediated immune suppression were largely 
reduced in the myeloid cell population of tumors treated with Vorinostat 
compared to control. We did not directly test the suppressive capacity of 
these tumor infi ltrating M-MDSC directly ex vivo. This could be done by 
sorting the M-MDSC out of the tumors and subsequently test their immune 
suppressive capacity in suppression assays ex vivo. The isolation of high 
enough numbers of viable myeloid cells from the tumor to perform these 
assays, however, remains challenging.
Overall, our data suggests that the epigenetic drug Vorinostat affects the 
phenotype and function of myeloid cells infi ltrating NBL tumors, resulting in 
more FcR-expressing macrophages and less immune suppressive M-MDSC. 
Overall, these Vorinostat-induced changes may result in a more immune-
permissive TME for tumor directed anti-GD2 mAb therapy in these NBL 
tumors.
future directions for immunotherapy in nbl; 
immunocombination therapy
The data presented in this thesis and data from others, suggest that mani-
fest NBL tumors have evolved to evade anti-tumor immune responses by 
multiple mechanisms. It is important that these immune evasive mecha-
nisms are -as much as possible- counteracted in future immunocombina-
tion therapies. Neutralization or reversal of the immune suppressive TME 
can be achieved in two ways, which can overlap depending on the targeted 
therapy chosen. First, therapies to combine with immunotherapy should 
selectively eliminate tumor cells, while sparing as much as possible immune 
cells and other normal cells. This selective elimination of tumor cells will 
already reduce tumor induced immune suppression, as the mere numbers 
of viable tumor cells will fall dramatically. In addition, selective elimination 
of tumor cells may result in a more accessible tumor for immune effector 
cells. Second, therapies to combine with immunotherapy should eliminate or 
reverse immune suppressive cells in the TME. Our data suggest that tumor 
infi ltrating myeloid cells are a promising target to eliminate or to make them 
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differentiate, in order to relieve local immune suppression in NBL tumors51 
(chapter 4, 5, 6). Myeloid cells possess high plasticity and –depending on 
environmental cues- can become potent anti-tumor immune effector cells64, 
95. Future studies should therefore screen small molecules, designed for the 
selective killing of NBL cells, for their ability to eliminate or convert immune 
suppressive cells into anti-tumor effector immune cells as well, like we have 
observed for the HDAC inhibitor Vorinostat. Besides using small molecules, 
mAb directed towards tumor cells or immune cells can also be used to deliver 
immune activators to the TME in order to reverse local immune suppres-
sion. Immune activating Toll-like receptor (TLR) ligands, such as the TLR9 
ligand CpG-ODN, were shown to convert immune suppressive MDSC into 
macrophages which showed anti-tumor activity96. Current efforts in our lab 
are therefore also aimed to deliver CpG-ODN to the TME by coupling these 
immune stimulants to anti-GD2 mAb (=tumor targeted) or anti-CD11b mAb 
(=myeloid cell targeted) and to test these novel targeted therapies in im-
munocombination regimens using the novel transplantable TH-MYCN model 
of NBL. Ultimately, we anticipate that these and other immunocombination 
therapies will provide a better chance of survival for future NBL patients, 
thereby increasing the hope for these patients and their parents.
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neDerlanDse samenvatting 
Neuroblastoom is een vorm van kanker bij kinderen waarbij de diagnose 
wordt gesteld op een gemiddelde leeftijd van 1 jaar. Afhankelijk van de exacte 
leeftijd bij diagnose, de histologie, de genetische afwijkingen en de lokalisa-
tie van de tumor, worden neuroblastoom patiënten ingedeeld in verschillende 
risicogroepen. Alhoewel patiënten in laag- and intermediaire risicogroepen 
over het algemeen een goede prognose tegemoet kunnen zien, hebben pati-
enten in de hoog risico groep één van de slechtste prognoses van alle kinde-
ren met kanker. De lange termijn overleving voor deze patiëntencategorie is 
slechts 30-50%, een percentage dat nagenoeg onveranderd is gebleven de 
afgelopen tientallen jaren. De behandeling van deze groep van patiënten is 
daarom ook één van de meest intensieve in de kinderoncologie en bestaat uit 
chemotherapie, radiotherapie, autologe beenmergtransplantatie en vitamine 
A zuur behandeling. In de toekomst zullen slimme combinaties van deze en 
andere therapieën nodig zijn om een maximaal effect op de tumor met mi-
nimale bijwerkingen te bewerkstelligen. Met immunotherapie probeert men 
de tumorcellen te doden door gebruik te maken van het immuunsysteem 
van de patiënt zelf. Antilichaamtherapie gericht tegen het neuroblastoom 
specifi eke antigeen ‘GD2’ heeft recent veelbelovende resultaten laten zien in 
de kliniek. Ondanks deze veelbelovende klinische resultaten met anti-GD2 
antilichamen, vertonen nog steeds ongeveer de helft van alle neuroblastoom 
patiënten progressieve ziekte. Onderzoek in patiënten en in muizen heeft 
aangetoond dat de effectiviteit van immunotherapie wordt tegengehouden 
door onderdrukking van het immuunsysteem door de groeiende tumor. Het 
hoofddoel van deze studie was om de interactie tussen het immuunsysteem 
en neuroblastoom tumoren beter te begrijpen met behulp van een muismodel 
van neuroblastoom. Dit zou kunnen leiden tot de ontwikkeling van nieuwe 
en/of verbeterde immunotherapie voor neuroblastoom patienten.
In hoofdstuk 1 introduceren we neuroblastoom, het immuunsysteem en 
immunotherapie in de behandeling van kanker en introduceren we het doel 
en het bereik van dit proefschrift.
In hoofdstuk 2 bespreken we de huidige literatuur met betrekking tot de 
immunobiologie van neuroblastoom tumoren en de ontwikkeling van nieuwe 
immunotherapie voor neuroblastoom patiënten. Hierbij leggen we een een 
speciale nadruk op de preklinische muismodellen voor neuroblastoom. We 
bespreken de toenemende kennis over de mechanismen waarmee neuro-
blastoom tumoren het immuunsysteem kunnen omzeilen en onderdrukken. 
Verder introduceren en defi niëren we de term ‘immunocombinatie therapie’. 
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Kort gezegd mikt immunocombinatie therapie op maximale immuunsti-
mulatie in combinatie met het verwijderen van de onderdrukking van het 
immuunsysteem door de neuroblastoom tumor. Tenslotte geven we een 
overzicht van de meest gebruikt autologe muismodellen voor neuroblastoom 
en bespreken we de voor- en nadelen van deze modellen.
In hoofdstuk 3 bespreken we de huidige literatuur over het effect van een 
groep van tumor gerichte medicijnen, de zogenaamde histon deacetylase 
(HDAC) inhibitoren. We bespreken het effect van deze tumor gericht medi-
cijnen op tumor cellen, maar ook op immuun cellen (witte bloedcellen) en de 
rol van deze medicijnen in immunocombinatie therapie. Verschillende studies 
waarin HDAC inhibitoren met immunotherapie werden gecombineerd hebben 
versterkende effecten op de remming van tumorgroei laten zien in muizen. 
We bespreken deze studies en de mogelijke mechanismen die betrokken 
kunnen zijn bij deze interacties. Uit deze literatuurstudie concludeerden we 
dat het tijdstip van toediening en het type HDAC inhibitor naar voren komen 
als cruciale factoren die bepalend zijn voor de versterkende effecten die 
geobserveerd zijn in therapieën die HDAC inhibitoren en immunotherapie 
combineren.
In hoofdstuk 4 rapporteren we een nieuw transplanteerbaar muismodel 
voor neuroblastoom, het zogenaamde transplanteerbare TH-MYCN model 
en beschrijven de immunobiologie hiervan. De muizen neuroblastoom cel-
len die gebruikt worden in dit model zijn afkomstig van een neuroblastoom 
tumor die ontstond in een zogenaamde TH-MYCN transgene muis, welke na 
verloop van tijd spontane neuroblastoom tumoren ontwikkelt. Deze muizen 
neuroblastoomcellen werden door ons getransplanteerd in gezonde C57Bl/6 
muizen, die dezelfde genetisch achtergrond hebben als de TH-MYCN muis 
waarin deze tumorcellen waren ontstaan. Deze genetische achtergrond is 
erg geschikt voor immunologische modellen, omdat alle immunologische 
‘gereedschappen’ beschikbaar zijn op deze genetische achtergrond. De op-
pervlakte expressie van de muizen neuroblastoom cellen vertoonden veel 
gelijkenis met wat eerder beschreven was voor mensen neuroblastoom 
cellen, inclusief de expressie van het neuroblastoom antigeen GD2 op het 
celoppervlak. In de aanwezigheid van antilichamen gericht tegen GD2 kon-
den verschillende typen immuun cellen de neuroblastoom cellen doden. We 
vonden dat NK cellen, maar niet T en B cellen, de groei van neuroblastoom 
tumoren in muizen afremden, iets wat ook beschreven is in neuroblastoom 
patienten. Daarnaast vonden dat de muizen neuroblastoom tumoren sterk 
geïnfiltreerd werden door immuun cellen van het myeloide type. Met be-
hulp van oppervlakte markers konden deze myeloide cellen verder worden 
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ingedeeld in verschillende subsets. Sommige van deze identifi ceerde mye-
loide subsets zijn eerder beschreven als sterk immuun onderdrukkend. We 
concludeerden uit deze studies dat het nieuwe transplanteerbare TH-MYCN 
neuroblastoommodel een relevant model is om nieuwe immunotherapie voor 
neuroblastoom te ontwikkelen en te begrijpen.
In patienten is de primaire neuroblastoom tumor meestal gelokaliseerd 
in de bijnier. In hoofdstuk 5 breidden we daarom het transplanteerbare 
TH-MYCN model uit naar een zogenaamd orthotopisch model door de muizen 
neuroblastoom cellen direct in de bijnier te injecteren. We vonden dat de 
neuroblastoom tumoren in de bijnier harder groeiden dan de onderhuidse 
neuroblastomen. Na analyse van de infi ltrerende immuun cellen in de 
neuroblastomen, vonden we dat de myeloide cellen die infi ltreerden in de 
bijnier neuroblastomen een lagere expressie van MHCII hadden, hetgeen 
sterk suggestief is voor meer onderdrukking van het immuunsysteem in de 
neuroblastoom tumoren in de bijnier. Tenslotte konden we, met behulp van 
lichtgevende neuroblastoom cellen door expressie van vuurvlieg luciferase, 
de tumorgroei meten door het licht te meten dat werd uitgezonden door 
de neuroblastoom tumoren door de huid. We concludeerden dat dit ortho-
topische TH-MYCN neuroblastoom model tevens een relevant en mogelijk 
nog realistischer model was om immunotherapie voor neuroblastoom te 
bestuderen.
In hoofdstuk 2 introduceerden we onze hypothese dat combinaties van 
tumor gerichte therapie en immunotherapie versterkend zouden kunnen 
werken. In hoofdstuk 6 rapporteren we een dergelijk versterkende inter-
actie in het transplanteerbare TH-MYCN neuroblastoom model. We vonden 
een interactie tussen anti-GD2 antilichaam therapie en de HDAC inhibitor 
Vorinostat. De combinatie van deze therapieën resulteerde in een versterkte 
remming van de groei van de neuroblastoom tumoren. Als onderdeel van 
de verklaring voor deze interactie vonden we nieuwe effecten van de HDAC 
inhibitor Vorinostat op neuroblastoom cellen en immuun cellen. Vorinostat 
zorgde voor een hoge mate van celdood in de muizen neuroblastoom cellen, 
gelijk aan wat eerder was beschreven voor mensen neuroblastoom cellen. 
Daarnaast vonden we dat zowel mensen- als muizen neuroblastoomcellen 
die de HDAC inhibitor therapie overleefden, het tumor antigen GD2 hoger tot 
expressie brachten op het celoppervlak. Dit resulteerde in verhoogde herken-
ning en het doden van de neuroblastoom cellen door verschillende immuun 
cellen in de aanwezigheid van anti-GD2 antilichamen. We vonden dat de 
behandeling met Vorinostat maakte dat de specifi ek de immuun onderdruk-
kende myeloide cellen uit de neuroblastoom tumoren nagenoeg verdwenen. 
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Tenslotte waren er in de neuroblastoom tumoren, na Vorinostat behande-
ling meer zogenaamde macrophagen aanwezig. Deze macrophagen hadden 
hoge expressie van activerende Fc-receptoren op het celoppervlak, welke 
essentieel zijn voor tumor gerichte antilichaamtherapie. We concludeerden 
dat de combinatie van anti-GD2 antilichaamtherapie en Vorinostat elkaar 
versterkende effecten gaf, die verklaard worden door nieuwe gevonden ef-
fecten van Vorinostat op neuroblastoom cellen en op de onderdrukkende 
immuun cellen aanwezig in deze tumoren.
In hoofdstuk 7 geven we een algemeen overzicht en bespreken we de 
resultaten van dit proefschrift, met een speciale nadruk op het immuun 
onderdrukkende milieu in neuroblastoom tumoren. We geven aanwijzingen 
voor toekomstig onderzoek in de anti-GD2 met Vorinostat combinatiethe-
rapie. Tenslotte bespreken we opkomende tumor gerichte therapieën in 
neuroblastoom en geven we aanwijzingen voor toekomstig onderzoek naar 
combinaties van deze therapieën met immunotherapie in de behandeling van 
neuroblastoom tumoren.
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